1. 
TY  - ELEC
ID  - 2006-22766-008
T1  - Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study.
T3  - Psychiatrie & Psychobiologie
A1  - Perez, M
A1  - Tuma, I
A1  - Pytela, O
A1  - Kadlecova, E
A1  - Zemanova, M
A1  - Lenderova, Z
A2  - Friedman, Moller, Nahas, Perez, Risch, Tugal, Tuma
Y1  - 2006//
N2  - The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia. It focuses on an analysis of a sub-group of 20 patients receiving treatment of the donepezil in an extended Czech double-blind placebo controlled study. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Acetylcholinesterase
KW  - *Cognitive Impairment
KW  - *Drug Therapy
KW  - *Enzyme Inhibitors
KW  - *Schizophrenia
M3  - Clinical Psychopharmacology [3340]
JF  - European Psychiatry
VL  - 21
IS  - 8
SP  - 548
EP  - 550
CY  - Netherlands
PB  - Elsevier Science
PB  - Netherlands
SN  - 0924-9338
AD  - Perez, M., Na Dolnim Poli, 12, Opava, Czech Republic, 746 01, prim.psychiatrie@nsphav.cz
AD  - Perez, M.: prim.psychiatrie@nsphav.cz
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). Double-blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psych 2002;51:349-57.
M1  - Moller, H. J. (2005). Risperidone: a review. Expert Opin Pharmacother 2005;6(5):803-18.
M1  - Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., Owens, S. D., et al. (2003). Augmenting atypical anti-psychotics with a cognitive enhancement (donepezil) improves local brain activity in schizophrenia patients: pilot double-blind placebo controlled BOLD fMRI trial. Neurocase, 93, 274-82. http://dx.doi.org/10.1076/neur.9.3.274.15563
M1  - Perez, M. (2004). Cholinergic neurotransmission and cognitive functions in relation to schizophrenia. Czech Psychiatrist 2004;8:489-90.
M1  - Risch, S. G., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., Molloy, M., et al. (2001). A double-blind placebo controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase, 7, 105-10. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Tugal, O., Yazici, K. M., & Yacolu, A. E. (2004). A double-blind, placebo-controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol, 72, 117-23. http://dx.doi.org/10.1017/S1461145703004024
M1  - Tuma, I., Perez, M., Lenderova, Z., Zemanova, M., & Kadlecova, E. (2004). Treatment of cognitive dysfunction in schizophrenia by donepezil: double-blind, placebo controlled trial. Psychiatry 2004;8(2):93-9.
M2  - http://dx.doi.org/10.1016/j.eurpsy.2006.04.008
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc5&NEWS=N&AN=2006-22766-008
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc5&AN=2006-22766-008 

2. 
TY  - ELEC
ID  - 2006-21233-011
T1  - Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder.
A1  - Risch, S. Craig
A1  - Horner, Michael D
A1  - McGurk, Susan R
A1  - Palecko, Simmy
A1  - Markowitz, John S
A1  - Nahas, Ziad
A1  - DeVane, C. Lindsay
A2  - Addington, Allen, Buchanan, Burt, Cummings, Friedman, Janowsky, Miller, Nahas, Risch, Rosse, Tugal
Y1  - 2006//
N2  - Donepezil, 5 mg/d for 6 wk then 10 mg/d for 6 wk, and placebo daily for 12 wk in a double-blind cross-over paradigm, was added to the therapeutic regimen of 13 patients with schizophrenia or schizoaffective disorders, clinically stable on atypical antipsychotic medications. Patients had varying degrees of depressive symptoms, ranging from no depression to clinically significant depression. There was no worsening or induction of depression in individual patients or the group as a whole. In addition there was a statistically significant antidepressant effect in the group as a whole during the donepezil condition and a clinically significant antidepressant effect in the patients with clinically significant depressive symptoms, although there were not enough depressed patients in the group to conclude that donepezil may have antidepressant effects. Thus, in this study, donepezil did not induce or worsen depressive symptoms in schizophrenic and schizoaffective disorder patients. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Cholinesterase Inhibitors
KW  - *Emotional States
KW  - *Major Depression
KW  - *Schizoaffective Disorder
KW  - *Schizophrenia
KW  - Neuroleptic Drugs
M3  - Clinical Psychopharmacology [3340]
M1  - Schizophrenia & Psychotic States [3213]
JF  - International Journal of Neuropsychopharmacology
VL  - 9
IS  - 5
SP  - 603
EP  - 605
CY  - United Kingdom
PB  - Cambridge University Press
PB  - United Kingdom
SN  - 1461-1457
AD  - Risch, S. Craig: UCSF, Department of Psychiatry, 401 Parnassus Avenue, Box F-0984, San Francisco, CA, US, 94143-0984, craigr@lppi.ucsf.edu
AD  - Risch, S. Craig: craigr@lppi.ucsf.edu
M1  - Addington, D., Addington, J., & Maticka-Tindale, E. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6, 201-208. http://dx.doi.org/10.1016/0920-9964(92)90003-N
M1  - Allen, T. B., & McEvoy, J. P. (2002). Galantamine for treatment-resistant schizophrenia. American Journal of Psychiatry, 259, 1244-1245. http://dx.doi.org/10.1176/appi.ajp.159.7.1244
M1  - Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2003). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Burt, T., Sachs, G., & Demopulos, C. (1999). Donepezil in treatment resistant bipolar disorder. Biological Psychiatry, 45, 959-964. http://dx.doi.org/10.1016/S0006-3223(98)00320-5
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry 157, 4-15.2000-13126-001
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parrella, M., & Davis, K. L. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 57, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Janowsky, D. S., & Overstreet, D. H. (1995). The role of acetylcholine in mood disorders. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology : The Fourth Generation of Progress, 4th edn (pp. 671-681). New York: Raven Press.
M1  - Miller, A. L. (2004). Combination treatments for schizophrenia. CNS Spectrums 9, 19-23.2004-18477-003
M1  - Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Xingbao, M. D., Lorbenbaum, M. D., Owens, S. D., McGurk, S., De Vane, C. L., & Risch, S. C. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled fMRI study. Neurocase, 9, 274-282. http://dx.doi.org/10.1076/neur.9.3.274.15563
M1  - Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., Molloy, M., Gilliard, C. E., Christie, S., Markowitz, J. S., DeVane, C. L., et al. (2001). A double-blind placebo controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: fMRI correlates. Neurocase, 7, 105-110. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rosse, R. B., & Deutsch, S. I. (2002). Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clinical Neuropharmacology, 25, 272-275. http://dx.doi.org/10.1097/00002826-200209000-00010
M1  - Tugal, O., Yazici, K. M., Elif Amil Yagiociglu, A., & Gogus, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 7, 117-123. http://dx.doi.org/10.1017/S1461145703004024
M2  - http://dx.doi.org/10.1017/S1461145705006115
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc5&NEWS=N&AN=2006-21233-011
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc5&AN=2006-21233-011 

3. 
TY  - ELEC
ID  - 2006-12131-004
T1  - Donepezil for negative signs in elderly patients with schizophrenia: An add-on, double-blind, crossover, placebo-controlled study.
A1  - Mazeh, D
A1  - Zemishlani, H
A1  - Barak, Y
A1  - Mirecki, I
A1  - Paleacu, D
A2  - Adler, Arnold, Cummings, Davidson, Freedman, Friedman, Gold, Green, Guy, Hoff, Karson, Karson, Kay, Mohs, Palmer, Park, Ripoll, Rogers, Stryjer, Stryjer
Y1  - 2006//
N2  - Objective: Cognitive impairment and negative signs are common in patients with schizophrenia. Up to 35% of elderly patients with schizophrenia fulfill the diagnostic criteria of dementia. Donepezil inhibits cholinesterase, thus enhancing cholinergic neurotransmission. We tested the efficacy of donepezil in elderly patients with chronic schizophrenia and severe cognitive impairment. Method: Following baseline assessment, patients were randomly assigned to receive either donepezil or placebo. The dose was 5 mg daily for the first week and 10 mg for an additional 11 weeks. The procedure was repeated using the crossover compound. The Positive and Negative Symptom Scale (PANSS), Clinical Global Impression Scale (CGI) and Alzheimer Disease Assessment Scale - Cognitive subscale (ADAS-Cog) were used to assess the severity of symptoms, cognitive status and intervention effects. Results: Twenty subjects were enrolled (15 females, five males), mean age 7 0.2 years (SD 6.5) and mean duration of disease 38.5 years (SD 9.3).A modest treatment effect was found for both placebo and donepezil treatment periods. No crossover effect was found. No statistical differences were demonstrated between the two treatment groups (CGI p = 0.37, PANSS p = 0.71, ADAS-Cog p = 0.86). Two patients died during the study period due to unrelated causes and one patient discontinued participation due to increased agitation. Conclusion: Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Impairment
KW  - *Geriatric Patients
KW  - *Positive and Negative Symptoms
KW  - *Schizophrenia
KW  - Dementia
KW  - Drug Therapy
M3  - Clinical Psychopharmacology [3340]
JF  - International Psychogeriatrics
VL  - 18
IS  - 3
SP  - 429
EP  - 436
CY  - United Kingdom
PB  - Cambridge University Press
PB  - United Kingdom
SN  - 1041-6102
AD  - Mazeh, D.: Psychogeriatric Department, Y. Abarbanel Mental Health Center, 15 KKL St, Bat-Yam, Israel, 59100, mazehdor@netvision.net.il
AD  - Mazeh, D.: mazehdor@netvision.net.il
M1  - Adler, L. E., et al. (1998). Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin, 24, 189-202.1998-02576-001
M1  - Arnold, S. E., et al. (1995). Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. American Journal of Psychiatry, 152, 731-737.1995-37046-001
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry, 157, 4-15.2000-13126-001
M1  - Davidson, M., Harvey, P., Welsh, K. A., Powchik, P., Putnam, K. M., & Mohs, R. C. (1996). Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. American Journal of Psychiatry, 153, 1274-1279.1996-00484-004
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in post-mortem brain tissue for decreased number of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 51, 349-337. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Gold, J. M., & Harvey, P. D. (1995). Cognitive deficits in schizophrenia, Psychiatric Clinics of North America, 16, 295-312.1994-01911-001
M1  - Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.1996-00417-002
M1  - Guy, W. (1976). Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology, revised (pp. 218-222). DHEW Publ. No. ADM 76-338. Rockville, MD: National Institute of Mental Health.
M1  - Hoff, A. L., Riordan, H., O'Donnell, D. W., Morris, L., & DeLisi, L. E. (1992). Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry, 149, 898-903.1992-43257-001
M1  - Karson, C. N., Casanova, M. F., Weinman, J. E., & Griffin, W. S. (1993). Choline acetyltransferase in schizophrenia. American Journal of Psychiatry, 150, 454-459.1993-25823-001
M1  - Karson, C. N., Mrak, R. E., Husain, M. M., & Griffin, W. S. (1996). Decreased mesopontine choline acetyltransferance levels in schizophrenia. Molecular and Chemical Neuropathology, 29, 181-191.
M1  - Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.2005-09726-007
M1  - Mohs, R. C., Rosen, W. G., & Davis, K. L. (1983). The Alzheimer's disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacological Bulletin, 19, 448-450.
M1  - Palmer, B. W., Heaton, R. K., & Paulson, I. S. (1997). Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology, 11, 437-446. http://dx.doi.org/10.1037/0894-4105.11.3.437
M1  - Park, S., & Holzman, P. S. (1992). Schizophrenics show spatial working memory deficits. Archives of General Psychiatry, 49, 975-982.1993-17718-001
M1  - Ripoll, N., Bronner, M., & Bourin, M. (2004). Nicotinic receptors and schizophrenia. Current Medical Research Opinion, 20, 1057-1074.
M1  - Rogers, S. L., & Friedhoff, L. T. (1996). The efficacy and safety of donezepil in patients with Alzheimer's disease: results of a US multi-center, randomized, double-blind, placebo-controlled trial, Dementia, 7, 293-303.
M1  - Stryjer, R., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12-17. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Stryjer, R., et al. (2004). Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Human Psychopharmacology, 19, 343-346. http://dx.doi.org/10.1002/hup.595
M2  - http://dx.doi.org/10.1017/S1041610205003017
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc5&NEWS=N&AN=2006-12131-004
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc5&AN=2006-12131-004 

4. 
TY  - ELEC
ID  - 2007-03389-002
T1  - Cognitive dysfuctions in schizophrenia: Potential benefits of cholinesterase inhibitor adjunctive therapy.
T3  - Psychiatric Journal of the University of Ottawa
A1  - Ferreri, Florian
A1  - Agbokou, Catherine
A1  - Gauthier, Serge
A2  - Aasen, Addington, Allen, Allen, Andreasen, Baker, Benton, Bilder, Bora, Buchanan, Buchanan, Burch, Chapman, Chouinard, Conners, Cram, Crook, Dean, Decker, el-Mallakh, Elvevag, Erickson, Feldman, Folstein, Freedman, Freedman, Freedman, Freudenreich, Friedman, Gauthier, Gauthier, Goldberg, Grant, Guy, Hafkenscheid, Harvey, Hyde, Ichikawa, Ihl, Kay, Keefe, Knapp, Kuperberg, Lawton, Lena, Lenzi, Lezak, Lucas-Meunier, Maelicke, Mazeh, McGurk, Mendelsohn, Mesulam, Mohs, Nahas, Nuechterlein, Perry, Peuskens, Polinsky, Powchik, Raedler, Reisberg, Riccio, Robbins, Rogers, Rogers, Rosier, Rutschmann, Samochocki, Sarter, Shapiro, Sharma, Snyder, Spreen, Stroop, Stryjer, Tariot, Terry, Thomsen, Tugal, Vitiello, Watkins, Wechsler, Wechsler, Wyatt
Y1  - 2006//
N2  - Objective: In schizophrenia, cognitive dysfunctions commonly affect attention, memory and executive function, interfere with functional outcome and remain difficult to treat. Previous studies have implicated the cholinergic system in cognitive functioning. In Alzheimer's disease, cholinergic agonists have shown modest clinical benefits on cognitive and behavioural symptoms. Impaired cholinergic activity might also be involved in schizophrenia. Hence the role of cholinesterase inhibitors (ChEI) as adjunctive therapy is under study. We aimed to review the literature and evaluate the overall effectiveness of ChEI adjunctive therapy for the management of cognitive dysfunctions in schizophrenia. Methods: We conducted a computer-based search using PubMed (up to February 15, 2006) and ISI Web of Science (conference proceeding abstracts from January 2003 to December 2005) databases. We used the search terms "schizophrenia," "cognition or memory" and "tacrine or donepezil or rivastigmine or galantamine." Studies included were critically analyzed for allocation, blindness, duration and study design, demographic data, and clinical and neuropsychological outcome assessments. We excluded studies that involved patients with psychiatric disorders other than schizophrenia-spectrum or if they involved animals or molecular investigations. We also excluded conference proceeding abstracts with no explicit neuropsychological battery and/or results. Results: Data on ChEI as adjunctive therapy for the cognitive impairments in schizophrenia are sparse and so far derived from small samples and mostly open uncontrolled studies. ChEI's potential in long-term management has barely been documented and remains to be fully explored. Conclusion: There is insufficient evidence on whether ChEI should be used for the treatment of cognitive dysfunctions in schizophrenia. Nevertheless, further studies with appropriate trial designs and outcome measures in homogenous schizophrenia populations are warranted. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Adjunctive Behavior
KW  - *Behavior Therapy
KW  - *Cholinesterase
KW  - *Cognitive Impairment
KW  - *Schizophrenia
KW  - Contingency Management
M3  - Schizophrenia & Psychotic States [3213]
M1  - Behavior Therapy & Behavior Modification [3312]
JF  - Journal of Psychiatry & Neuroscience
VL  - 31
IS  - 6
SP  - 369
EP  - 376
CY  - Canada
PB  - Canadian Medical Assn
PB  - Canada
SN  - 1180-4882
AD  - Ferreri, Florian: McGill Centre for Studies in Aging, 6825 Blvd. LaSalle, Verdun, PQ, Canada, H4H 1R3, florian.ferreri@mail.ca
AD  - Ferreri, Florian: florian.ferreri@mail.ca
M1  - Aasen, I., Kumari, V., & Sharma, T. (2005). Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. J Clin Psychopharmacol, 25, 311-7. http://dx.doi.org/10.1097/01.jcp.0000169267.36797.76
M1  - Addington, D., Addington, J., Maticka-Tyndale, E., et al. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res, 6, 201-8. http://dx.doi.org/10.1016/0920-9964(92)90003-N
M1  - Allen, T., McEvoy, J., Keefe, R., et al. Galantamine as an adjunctive therapy in the treatment of schizophrenia. Presented at the 11th Congress of the International Psychogeriatric Association; 2003 Aug 17-22; Chicago.
M1  - Allen, T. B., & McEvoy, J. P. (2002). Galantamine for treatment-resistant schizophrenia. Am J Psychiatry, 159, 1244-5. http://dx.doi.org/10.1176/appi.ajp.159.7.1244
M1  - Andreasen, N. (1983). Scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa Press; 1983.
M1  - Baker, F., & Intagliata, J. (1982). Quality of life in the evaluation of community support systems. Eval Program Plann, 5, 69-79. http://dx.doi.org/10.1016/0149-7189(82)90059-3
M1  - Benton, A., & Hamsher, K. (1978). Multilingual Aphasia Examination manual revised. Iowa City: University of Iowa Press; 1978.
M1  - Bilder, R. M., Lipschutz-Broch, L., Reiter, G., et al. (1992). Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992;18:437-48.2005-09766-008
M1  - Bora, E., Veznedaroglu, B., & Kayahan, B. (2005). The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol, 28, 139-41. http://dx.doi.org/10.1097/01.wnf.0000162555.68729.04
M1  - Buchanan, R. W., Davis, M., Goff, D., et al. (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull, 31, 5-19. http://dx.doi.org/10.1093/schbul/sbi020
M1  - Buchanan, R. W., Summerfelt, A., Tek, C., et al. (2003). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Burch, E. A., Jr.., & Andrews, S. R. (1987). Comparison of two cognitive rating scales in medically ill patients. Int J Psychiatry Med 1987;17:193-200.1988-25157-001
M1  - Chapman, S., Fisher, A., Weinstock, M., et al. (1998). The effects of the acetylcholinesterase inhibitor ENA713 and the Ml agonist AF150(S) on apolipoprotein E deficient mice. J Physiol (Paris) 1998;92:299-303.
M1  - Chouinard, S., Poulin, J., Stip, E., et al. (2005). Cognitive performance in patients with schizophrenia after rivastigmine treatment [abstract]. Schizophr Bull 2005;31:478.
M1  - Conners, C. (2000). Conners' Continuous Performance Test II Manual. Toronto: Multi-Health Systems Inc.; 2000.
M1  - Cram, R. M., Anthony, J. C., Bassett, S. S., et al. (1993). Population-based norms for the Mint-Mental State Examination by age and educational level. JAMA 1993;269:2386-91.
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., et al. (2001). Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry, 158, 918-25. http://dx.doi.org/10.1176/appi.ajp.158.987.918
M1  - Dean, B., McLeod, M., Keriakous, D., et al. (2002). Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry, 7, 1083-91. http://dx.doi.org/10.1038/sj.mp.4001199
M1  - Decker, M. W., & McGaugh, J. L. (1991). The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991;7:151-68.
M1  - el-Mallakh, R. S., Kirch, D. G., Shelton, R., et al. (1991). The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatry Clin Neurosci 1991;3:383-6.1992-12743-001
M1  - Elvevag, B., & Goldberg, T. E. (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21.2002-17311-001
M1  - Erickson, S. K., Schwarzkopf, S. B., Palumbo, D., et al. (2005). Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol, 28, 179-84. http://dx.doi.org/10.1097/01.wnf.0000173714.61744.e6
M1  - Feldman, H., Gauthier, S., Chertkow, H., et al. (2006). Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 2006;33 (1):6-26.2006-03753-002
M1  - Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189-98. http://dx.doi.org/10.1016/0022-3956(75)90026-6
M1  - Freedman, R., Adams, C. E., & Leonard, S. (2000). The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 2000;20:299-306.
M1  - Freedman, R., Coon, H., Myles-Worsley, M., et al. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997;94:587-92.
M1  - Freedman, R., Hall, M., Adler, L. E., et al. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Freudenreich, O., Herz, L., Deckersbach, T., et al. (2005). Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl), 181, 358-63. http://dx.doi.org/10.1007/s00213-005-2235-1
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-57. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Gauthier, S. (2005). Drugs for Alzheimer's disease and related dementias. BMJ 2005;330:857-8.
M1  - Gauthier, S. G. (2005). Alzheimer's disease: the benefits of early treatment. Eur J Neurol, 12, 11-6. http://dx.doi.org/10.1111/j.1468-1331.2005.01322.x
M1  - Goldberg, T. E., & Gold, J. M. (1995). Neurocognitive functioning in patients with schizophrenia: an overview. In Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 1245-57.
M1  - Grant, D., & Berg, E. (1948). A behavioral analysis of degree of impairment and ease of shifting to new responses in a Weigl-type card sorting problem. J Exp Psychol Gen, 39, 404-11. http://dx.doi.org/10.1037/h0059831
M1  - Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health and Human Services publication (ADM); 1976: 218-22.
M1  - Hafkenscheid, A. (1993). Reliability of a standardized and expanded Brief Psychiatric Rating Scale: a replication study. Acta Psychiatr Scand, 88, 305-10. http://dx.doi.org/10.1111/j.1600-0447.1993.tb03464.x
M1  - Harvey, P. D., & Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry, 158, 176-84. http://dx.doi.org/10.1176/appi.ajp.158.2.176
M1  - Hyde, T. M., & Crook, J. M. (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 2001;22:53-63.
M1  - Ichikawa, J., Dai, J., O'Laughlin, I. A., et al. (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology, 26, 325-39. http://dx.doi.org/10.1016/S0893-133X(01)00312-8
M1  - Ihl, R., Frolich, L., Dierks, T., et al. (1992). Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Res, 44, 93-106. http://dx.doi.org/10.1016/0165-1781(92)90044-4
M1  - Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.2005-09726-007
M1  - Keefe, R. S., Goldberg, T. E., Harvey, P. D., et al. (2004). The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res, 68, 283-97. http://dx.doi.org/10.1016/j.schres.2003.09.011
M1  - Knapp, M. J., Knopman, D. S., Solomon, P. R., et al. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA, 271, 985-91. http://dx.doi.org/10.1001/jama.271.13.985
M1  - Kuperberg, G., & Heckers, S. (2000). Schizophrenia and cognitive function. Curr Opin Neurobiol, 10, 205-10. http://dx.doi.org/10.1016/S0959-4388(00)00068-4
M1  - Lawton, M. P., & Brody, E. M. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-86.
M1  - Lena, C., & Changeux, J. P. (1993). Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci 1993;16:181-6.
M1  - Lenzi, A., Maltinti, E., Poggi, E., et al. (2003). Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol, 26, 317-21. http://dx.doi.org/10.1097/00002826-200311000-00011
M1  - Lezak, M. D., Howieson, D., & Loring, D. (2004). Neuropsychological assessment. 4th ed. Oxford: Oxford University Press; 2004.
M1  - Lucas-Meunier, E., Fossier, P., Baux, G., et al. (2003). Cholinergic modulation of the cortical neuronal network. Pflugers Arch 2003;446:17-29.
M1  - Maelicke, A., & Albuquerque, E. X. (2000). Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000;393:165-70.
M1  - Mazeh, D., Zemishlani, H., Barak, Y., et al. (2006). Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. http://dx.doi.org/10.1017/S1041610205003017
M1  - McGurk, S. R., Green, M. F., Wirshing, W. C., et al. (2004). Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrnia. Schizophr Res, 68, 225-33. http://dx.doi.org/10.1016/S0920-9964(03)00123-3
M1  - Mendelsohn, E., Rosenthal, M., Bohiri, Y., et al. (2004). Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol, 19, 319-24. http://dx.doi.org/10.1097/00004850-200411000-00001
M1  - Mesulam, M. M., Guillozet, A., Shaw, P., et al. (2002). Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002; 110:627-39.
M1  - Mohs, R. C., Knopman, D., Petersen, R. C., et al. (1997). Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord, 11, S13http://dx.doi.org/10.1097/00002093-199700112-00003
M1  - Nahas, Z., George, M. S., Horner, M. D., et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274-82. http://dx.doi.org/10.1076/neur.9.3.274.15563
M1  - Nuechterlein, K. H., Barch, D. M., Gold, J. M., et al. (2004). Identification of separable cognitive factors in schizophrenia. Schizophr Res, 72, 29-39. http://dx.doi.org/10.1016/j.schres.2004.09.007
M1  - Perry, E. K., & Perry, R. H. (1995). Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn, 28, 240-58. http://dx.doi.org/10.1006/brcg.1995.1255
M1  - Peuskens, J., Demily, C., & Thibaut, F. (2005). Treatment of cognitive dysfunction in schizophrenia. 27, S25-37. http://dx.doi.org/10.1016/j.clinthera.2005.07.015
M1  - Polinsky, R. J. (1998). Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Titer, 20, 634-47. http://dx.doi.org/10.1016/S0149-2918(98)80127-6
M1  - Powchik, P., Davidson, M., Haroutunian, V., et al. (1998). Postmortem studies in schizophrenia. Schizophr Bull 1998;24:325-41.1998-10644-002
M1  - Raedler, T. J., Knable, M. B., Jones, D. W., et al. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry, 160, 118-27. http://dx.doi.org/10.1176/appi.ajp.160.1.118
M1  - Reisberg, B., Ferris, S. H., Franssen, E. H., et al. (1996). Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study. Int Psychogeriatr, 8, 291-311. http://dx.doi.org/10.1017/S1041610296002657
M1  - Riccio, C., Reynolds, C., & Lowe, P. (2001). Clinical applications of continuous performance tests: measuring attention and impulsive responding in children and adults. Chichester (UK): John Wiley & Sons Ltd; 2001.2001-06202-000
M1  - Robbins, T. W. (1997). Arousal systems and attentional processes. Biol Psychol, 45, 57-71. http://dx.doi.org/10.1016/S0301-0511(96)05222-2
M1  - Rogers, S. L., Doody, R. S., Mohs, R. C., et al. (1998). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31.
M1  - Rogers, S. L., Farlow, M. R., Doody, R. S., et al. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology, 50, 136-45. http://dx.doi.org/10.1159/000023160
M1  - Rosier, M., Anand, R., Cicin-Sain, A., et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8.
M1  - Rutschmann, J., Cornblatt, B., & Erlenmeyer-Kimling, L. (1980). Auditory recognition memory in adolescents at risk for schizophrenia: report on a verbal continuous recognition task. Psychiatry Res 1980;3: 151-61.
M1  - Samochocki, M., Hoffle, A., Fehrenbacher, A., et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther, 305, 1024-36. http://dx.doi.org/10.1124/jpet.102.045773
M1  - Sarter, M., Nelson, C. L., & Bruno, J. P. (2005). Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull, 31, 117-38. http://dx.doi.org/10.1093/schbul/sbi006
M1  - Shapiro, A. M., Benedict, R. H., Schretlen, D., et al. (1999). Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol, 13, 348-58. http://dx.doi.org/10.1076/clin.13.3.348.1749
M1  - Sharma, T., & Antonova, L. (2003). Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am, 26, 25-40. http://dx.doi.org/10.1016/S0193-953X(02)00084-9
M1  - Snyder, S., Greenberg, D., & Yamamura, H. I. (1974). Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974;31:58-61.1974-31813-001
M1  - Spreen, O., & Strauss, E. (1991). A compendium of neuropsychological tests. New York: Oxford University Press; 1991.
M1  - Stroop, J. (1935). Studies of interference in serial verbal reaction. J Exp Psychol, 18, 643-62. http://dx.doi.org/10.1037/h0054651
M1  - Stryjer, R., Strous, R. D., Bar, F., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol, 26, 12-7. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Tariot, P. N., Solomon, P. R., Morris, J. C., et al. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.2000-00016-010
M1  - Terry, A. V., Jr.., Buccafusco, J. J., & Jackson, W. J. (1993). Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol Biochem Behav, 45, 925-9. http://dx.doi.org/10.1016/0091-3057(93)90141-F
M1  - Thomsen, T., Kaden, B., Fischer, J. P., et al. (1991). Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991;29:487-92.
M1  - Tugal, O., Yazici, K. M., Anil Yagcioglu, A. E., et al. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol, 7, 117-23. http://dx.doi.org/10.1017/S1461145703004024
M1  - Vitiello, B., Martin, A., Hill, J., et al. (1997). Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology, 16, 15-24. http://dx.doi.org/10.1016/S0893-133X(96)00134-0
M1  - Watkins, P. B., Zimmerman, H. J., Knapp, M. J., et al. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
M1  - Wechsler, D. (1997). Wechsler Adult Intelligence Scale-third edition (WAIS-III). San Antonio (TX): The Psychological Corporation; 1997.
M1  - Wechsler, D. (1987). Wechsler Memory Scale-revised. New York: The Psychological Corporation; 1987.
M1  - World Health Organization. (1993). Battery of cognitive assessment instruments. Geneva: WHO; 1993.
M1  - Wyatt, R. J., Henter, I., Leary, M. C., et al. (1995). An economic evaluation of schizophrenia-1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205.1996-14574-001
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc5&NEWS=N&AN=2007-03389-002
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc5&AN=2007-03389-002 

5. 
TY  - ELEC
ID  - 2004-15499-003
T1  - A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.
A1  - Tugal, Onder
A1  - Yazici, Kazim M
A1  - Yagcioglu, A. Elif Anil
A1  - Gogus, Ahmet
A2  - Addington, Addington, Addington, Addington, Allen, Anil, Bennett, Bilder, Buchanan, Davis, Demir, Drachman, Ertugrul, Fleiss, Francis, Freedman, Friedman, Friedman, Giacobini, Goldberg, Green, Heaton, Hughes, Hyde, Karson, Kay, Kostakoglu, Lohr, MacEwan, Oksay, Ratkowsky, Reitan, Stryjer, Stryjer, Tandon, Tandon, Wechsler, Weinberger, Weiss, Zahn
Y1  - 2004//
N2  - Although there have been several case reports suggesting the beneficial effect of acetylcholinesterase inhibitors in the cognitive deficits seen in schizophrenia, controlled studies have revealed contradictory results. The aim of this study was to investigate if donepezil could improve cognitive functions in schizophrenia. Twelve schizophrenic patients, who were diagnosed according to DSM-IV criteria and who had been on a stable dose of a high-potency typical antipsychotic for a minimum period of 3 months, participated in this 12-wk double-blind, placebo controlled, cross-over study of donepezil adjunctive treatment. Patients were randomly assigned under double-blind conditions to receive 5 mg/d donepezil or placebo for 6 wk, and then were crossed over to the alternate condition for 6 additional weeks. At baseline, 6 and 12 wk, patients were evaluated with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale, the Wechsler Memory Scale - Revised (WMS-R), a test for Verbal Fluency, Trail Making Test, Parts A and B, and Wisconsin Card Sorting Test (WCST). Nicotinic receptor desensitization may cause non-responsiveness to acetylcholine, defects in other neurotransmitter systems account for the cognitive deficits seen in schizophrenic patients. (PsycINFO Database Record (c) 2014 APA, all rights reserved)
KW  - *Acetylcholinesterase
KW  - *Cognitive Impairment
KW  - *Drug Therapy
KW  - *Schizophrenia
KW  - *Treatment Outcomes
KW  - Placebo
M3  - Clinical Psychopharmacology [3340]
M1  - Schizophrenia & Psychotic States [3213]
JF  - International Journal of Neuropsychopharmacology
VL  - 7
IS  - 2
SP  - 117
EP  - 123
CY  - United Kingdom
PB  - Cambridge University Press
PB  - United Kingdom
SN  - 1461-1457
AD  - Yazici, Kazim M.: Hacettepe University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey, 06100, kyazici@hacettepe.edu.tr
AD  - Yazici, Kazim M.: kyazici@hacettepe.edu.tr
M1  - Addington, D., Addington, J., & Maticka-Tindale, E. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6, 201-208. http://dx.doi.org/10.1016/0920-9964(92)90003-N
M1  - Addington, J., & Addington, D. (1999). Neurocognitive and social functioning in schizophrenia. Schizophrenia Bulletin 25, 173-182.1999-10563-010
M1  - Addington, J., & Addington, D. (2000). Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophrenia Research, 44, 47-56. http://dx.doi.org/10.1016/S0920-9964(99)00160-7
M1  - Addington, J., Addington, D., & Gasbarre, L. (2001). Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophrenia Research, 48, 367-368. http://dx.doi.org/10.1016/S0920-9964(00)00103-1
M1  - Allen, T., McEvoy, J. P., Keefe, R., Levin, E., & Wilson, W. (2003). Galantamine improves cognition in patients with schizophrenia. Poster presented at the biennial meeting of the International Congress on Schizophrenia Research, Colorado Springs, Colorado.
M1  - Anil, A. E., Kivircik, B. B., Batur, S., KabakCi, E., Kitis, A., Guven, E., Basar, K., Turgut, T. I., & Arkar, H. (2003). The Turkish Version of the Auditory Consonant Trigram Test as a measure of working memory: a normative study. Clinical Neuropsychologist, 17, 159-169. http://dx.doi.org/10.1076/clin.17.2.159.16510
M1  - Bennett, J. P., Enna, S. J., Bylund, D. B., Gillin, C., Wyatt, R. J., & Snyder, S. H. (1979). Neurotransmitter receptors in frontalcortex in schizophrenia. Archives of General Psychiatry 36, 927-934.1981-01400-001
M1  - Bilder, R. M. (1996). Neuropsychology and neurophysiology in schizophrenia. Current Opinions in Psychiatry 9, 57-62.
M1  - Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Davis, K. L., Mohs, R., Tinklenberg, J., Pfefferbaum, A., Hollister, L., & Kopell, B. (1978). Physostigmine: improvement of long-term memory in normal humans. Science, 201, 272-274. http://dx.doi.org/10.1126/science.351807
M1  - Demir, B., Gogus, A., & Savasir, I. (2000). Cognitive functions in depressed patients [in Turkish]. Turkish Journal of Psychiatry 11, 179-189.
M1  - Drachman, D., Glosser, G., Fleming, P., & Longenecker, G. (1982). Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 32, 944-950.1983-07543-001
M1  - Ertugrul, A., & Ulug, B. (2002). The influence of neurocognitive deficits and symptoms on disability in schizophrenia. Acta Psychiatrica Scandinavia 105, 196-201.
M1  - Fleiss, J. L. (1986). The Design and Analysis of Clinical Experiments (pp. 279-281). New York: John Wiley and Sons.
M1  - Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery, and Psychiatry, 66, 137-147. http://dx.doi.org/10.1136/jnnp.66.2.137
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in post mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parella, M., & Davis, K. L. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for cognitive impairment of schizophrenia. Biological Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Friedman, J. I., Temporini, H., & Davis, K. L. (1999). Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry, 45, 1-16. http://dx.doi.org/10.1016/S0006-3223(98)00287-X
M1  - Giacobini, E. (1998). Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochemistry International, 32, 413-419. http://dx.doi.org/10.1016/S0197-0186(97)00124-1
M1  - Goldberg, T. E., & Gold, J. M. (1995). Neurocognitive functioning in patients with schizophrenia. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 1245-1257). New York: Raven Press.
M1  - Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophrenia Bulletin 26, 119-136.2000-08139-007
M1  - Heaton, R. K. (1981). Wisconsin Card Sorting Manual. Odessa, Florida, Psychological Assessment Resources.
M1  - Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dahlgren, L. A. (1986). Prevalance of smoking among psychiatric outpatients. American Journal of Psychiatry 143, 993-997.1987-01309-001
M1  - Hyde, T. M., & Crook, J. M. (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena. Journal of Chemistry and Neuroanatomy 22, 53-63.
M1  - Karson, C. N., Mrak, R. E., Husain, M. M., & Griffin, W. S. (1996). Decreased mesopontine choline acetyltransferase levels in schizophrenia Correlations with cognitive functions. Molecular Chemistry and Neuropathology 29, 181-191.
M1  - Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.2005-09726-007
M1  - Kostakoglu, E., Batur, S., Tiryaki, A., & Gogus, A. (1999). Reliability and validity of the Turkish version of the positive and negative syndrome scale. Turkish Journal of Psychology 14, 23-32.
M1  - Lohr, J. B., & Flynn, K. (1992). Smoking and schizophrenia. Schizophrenia Research, 8, 93-102. http://dx.doi.org/10.1016/0920-9964(92)90024-Y
M1  - MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatrica Scandinavia 104, 469-472.2002-15544-008
M1  - Oksay, S., Aksaray, G., Kaptanoglu, C., & Bal, C. (2000). Validity and reliability of the Turkish version of Calgary Depression Scale in schizophrenic patients [in Turkish]. Turkish Journal of Psychiatry 11, 278-284.
M1  - Ratkowsky, D. A., Evans, M. A., & Allredge, J. R. (1992). In: Cross-over Experiments: Design, Analysis and Application (pp. 77-120). New York: Marcel Dekker.
M1  - Reitan, R. M., & Wolfson, D. (1985). The Halstead-Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press.
M1  - Stryjer, R., Bar, F., Strous, R. D., Baruch, Y., & Rabey, J. M. (2002). Donepezil management of schizophrenia with associated dementia. Journal of Clinical Psychopharmacology, 22, 226-229. http://dx.doi.org/10.1097/00004714-200204000-00021
M1  - Stryjer, R., Strous, R. D., Bar, F., Werber, E., Shaked, G., Buhiri, Y., Kotler, M., Weizman, A., & Rabey, J. M. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12-17. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Tandon, R. (1999). Cholinergic aspects of schizophrenia. British Journal of Psychiatry 37, 7-11.1999-10613-002
M1  - Tandon, R., DeQuardo, J. R., Goodson, J., Mann, N. A., & Greden, J. F. (1992). Effect of anticholinergics on positive and negative Symptoms in schizophrenia. Psychopharmacology Bulletin 28, 297-302.1993-18781-001
M1  - Wechsler, D. (1987). Wechsler Memory Scale - Revised. New York: The Psychological Corporation.
M1  - Weinberger, D. R., & Gallhofer, B. (1997). Cognitive function in schizophrenia. International Clinical Psychopharmacology, 12, 29-36. http://dx.doi.org/10.1097/00004850-199709004-00006
M1  - Weiss, E. M., Bilder, R. M., & Fleischhacker, W. W. (2002). The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berlin), 162, 11-17. http://dx.doi.org/10.1007/s00213-002-1053-y
M1  - WHO. (1993). WHO/MNH Battery of Cognitive Assessment Instrument Pre-pilot Battery. Geneva: World Health Organization.
M1  - Zahn, T., Pickar, D., & Haier, R. (1994). Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 13, 133-144. http://dx.doi.org/10.1016/0920-9964(94)90094-9
M2  - http://dx.doi.org/10.1017/S1461145703004024
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2004-15499-003
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2004-15499-003 

6. 
TY  - ELEC
ID  - 2005-00417-022
T1  - Adjuvant Therapeutic Effects of Galantamine on Apathy in a Schizophrenia Patient.
T3  - Diseases of the Nervous System
A1  - Arnold, David S
A1  - Rosse, Richard B
A1  - Dickinson, Dwight
A1  - Benham, Rhonda
A1  - Deutsch, Stephen I
A1  - Nelson, Matthew W
A2  - Adler, Albuquerque, Breese, Cummings, Leonard, Marin, Raskind, Rosse, Tariot
Y1  - 2004//
N2  - The limitations of the current medications used to treat schizophrenia have led to a search for adjunctive treatments that may better address the negative symptoms, cognitive deficits, and behavioral problems of the disorder. A promising strategy might be adopted from the current use of acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Acetylcholinesterase inhibitors (e.g., tacrine, donepezil) improve general cognitive functioning and reduce apathy, anxiety, agitation, and other psychiatric symptoms in Alzheimer's patients. Galantamine has a dual mechanism of action that may offer particular benefits for individuals with schizophrenia. Like donepezil, it reversibly inhibits cholinesterase, increasing the quantity and lifetime of acetylcholine within the synaptic cleft. Unlike donepezil, galantamine also acts as a positive allosteric modulator of nicotinic acetylcholine receptor sites and, thereby, enhances signal strength. Diminished expression of the 7, subtype of nicotinic acetylcholine receptor has been reported in several brain regions in schizophrenia, including the hippocampus, frontal cortex, and thalamus. There are data to suggest that early central processing abnormalities, especially difficulties with sensory gating, may exist in patients with schizophrenia and be due, in part, to defective signal transduction by the 7 nicotinic acetylcholine receptor. There are also data showing abnormal regulation of the density of high-affinity nicotinic acetylcholine receptors in schizophrenia. Because of its allosteric properties, galantamine may be able to improve the efficiency of acetylcholine signal transduction by both high- and low-affinity nicotinic acetylcholine receptors. We report a beneficial therapeutic effect of adjuvant galantamine administration on apathy in 1 schizophrenia patient with persistent deficit symptoms. (PsycINFO Database Record (c) 2013 APA, all rights reserved) (journal abstract)
KW  - *Apathy
KW  - *Drug Therapy
KW  - *Schizophrenia
KW  - Acetylcholine
KW  - Cholinergic Receptors
M3  - Schizophrenia & Psychotic States [3213]
M1  - Clinical Psychopharmacology [3340]
JF  - Journal of Clinical Psychiatry
VL  - 65
IS  - 12
SP  - 1723
EP  - 1724
CY  - US
PB  - Physicians Postgraduate Press
PB  - US
SN  - 0160-6689
M1  - Adler, L. E., Olincy, A., Waldo, M., et al. (1998). Schizophrenia, sensory gating, and nicotine receptors. Schizophr Bull 1998; 24: 189-2021998-02576-001
M1  - Albuquerque, E. X., Alkondon, M., Pereira, E. F. R., et al. (1997). Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997; 280: 1117-1136
M1  - Breese, C. R., Lee, M. J., Adams, C. E., et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351-364. http://dx.doi.org/10.1016/S0893-133X(00)00121-4
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4-152000-13126-001
M1  - Leonard, S., Gault, J., Hopkins, J., et al. (2002). Association of promoter variants in the 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry, 59, 1085-1096. http://dx.doi.org/10.1001/archpsyc.59.12.1085
M1  - Marin, R. S., Biedrzycki, R. C., & Firinciogullari, S. (1991). Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res, 38, 143-162. http://dx.doi.org/10.1016/0165-1781(91)90040-V
M1  - Raskind, M. A., Peskind, E. R., Wessel, T., et al., & the Galantamine USA-1 Study Group. (2000). Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-22682000-00016-009
M1  - Rosse, R. B., & Deutsch, S. I. (2002). Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol, 25, 272-275. http://dx.doi.org/10.1097/00002826-200209000-00010
M1  - Tariot, P. N., Solomon, P. R., Morris, J. C., et al., & the Galantamine USA-10 Study Group. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-22762000-00016-010
M2  - http://dx.doi.org/10.4088/JCP.v65n1219e
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2005-00417-022
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2005-00417-022 

7. 
TY  - ELEC
ID  - 2004-21772-005
T1  - Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: A meta-analysis of randomized controlled trials.
T3  - Progress in Neuro-Psychopharmacology
A1  - Tammenmaa, Irina A
A1  - Sailas, Eila
A1  - McGrath, John J
A1  - Soares-Weiser, Karla
A1  - Wahlbeck, Kristian
A2  - Actams, Altaian, Andreassen, Andreassen, Beckham, Bockenheimer, Caroff, Casey, Casey, Clarke, Cunningham Owens, de Montigny, DerSimonian, Domino, Egger, Gelenberg, Gelenberg, George, Gerlach, Glazer, Grimm, Harrison, Izumi, Jackson, Jackson, Jackson, Jeste, Joe, Jus, Klawans, Kocher, Lucius, Mantel, Marshall, Marsalek, Maurer, Miller, Mitchell, Moher, Ojima, Penovich, Perez-Cruet, Peskind, Petticrew, Guy, Guy, Price, Rascol, Schneider, Schooler, Schulz, Schulz, Sibbald, Simpson, Simpson, Sramek, Sterne, Tammenmaa, Tarsy, Wurtman, Yagi
Y1  - 2004//
N2  - The authors evaluated the efficacy of cholinergic drugs in the treatment of neuroleptic-induced tardive dyskinesia (TD) by a systematic review of the literature on the following agents: choline, lecithin, physostigmine, tacrine, 7-methoxyacridine, ipidacrine, galantamine, donepezil, rivastigmine, eptastigmine, metrifonate, arecoline, RS 86, xanomeline, cevimeline, deanol, and meclofenoxate. All relevant randomized controlled trials, without any language or year limitations, were obtained from the Cochrane Schizophrenia Group's Register of Trials. Trials were classified according to their methodological quality. For binary and continuous data, relative risks (RR) and weighted or standardized mean differences (SMD) were calculated, respectively. Eleven trials with a total of 261 randomized patients were included in the meta-analysis. Cholinergic drugs showed a minor trend for improvement of tardive dyskinesia symptoms, but results were not statistically significant (RR 0.84, 95% confidence interval (CI) 0.68 to 1.04, p=0.11). Despite an extensive search of the literature, eligible data for the meta-analysis were few and no results reached statistical significance. In conclusion, we found no evidence to support administration of the old cholinergic agents lecithin, deanol, and meclofenoxate to patients with tardive dyskinesia. In addition, two trials were found on novel cholinergic Alzheimer drugs in tardive dyskinesia, one of which was ongoing. Further investigation of the clinical effects of novel cholinergic agents in tardive dyskinesia is warranted. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Cholinergic Drugs
KW  - *Drug Therapy
KW  - *Neuroleptic Drugs
KW  - *Side Effects (Drug)
KW  - *Tardive Dyskinesia
M3  - Medical Treatment of Physical Illness [3363]
JF  - Progress in Neuro-Psychopharmacology & Biological Psychiatry
VL  - 28
IS  - 7
SP  - 1099
EP  - 1107
CY  - Netherlands
PB  - Elsevier Science
PB  - Netherlands
SN  - 0278-5846
AD  - Wahlbeck, Kristian: STAKES National Research and Development Centre for Welfare and Health, P.O. Box 220, Helsinki, Finland, FIN-00531, kristian.wahlbeck@stakes.fi
AD  - Wahlbeck, Kristian: kristian.wahlbeck@stakes.fi
M1  - Actams, C. E., Coutinho, E., Duggan, L., Gilbody, S., Leucht, S., & Wahlbeck, K. 2002. The Cochrane Library, Issue 4. Oxford, UK: Update Software.
M1  - Altaian, D. G., & Bland, J. M. 1996. Detecting skewness from summary information. BMJ 313, 1200.
M1  - Andreassen, O. A., & Jorgensen, H. A. 2000. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61, 525-541.
M1  - Andreassen, O. A., Meshul, C. K., Moore, C., & Jorgensen, H. A. (2001). Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Psychopharmacology, 157, 11-19. http://dx.doi.org/10.1007/s002130100767
M1  - Beckham, B. J. 1981. Lecithin therapy for tardive dyskinesia, Dissertation. North Texas State University, Denton, TX.
M1  - Bockenheimer, S., & Lucius, G. (1976). Zur Therapie mit Dimethylaminoathanol (Deanol) bei neuroleptikainduzierten extrapyramidalen Hyper-kinesen. Arch. Psychiatr. Nervenkr., 222, 69-75. http://dx.doi.org/10.1007/BF00369796
M1  - Caroff, S. N., Campbell, E. C., Havey, J., Sullivan, K. A., Mann, S. C., & Gallop, R. 2001. Treatment of tardive dyskinesia with donepezil: a pilot study. J. Clin. Psychiatry 62, 772-775.2001-05581-003
M1  - Casey, D. E. 2000. Tardive dyskinesia: pamophysiology and animal models. J. Clin. Psychiatry 61(Suppl. 4), 5-9.2000-15367-001
M1  - Casey, D. E., & Denney, D. 1975. Deanol in the treatment of tardive dyskinesia. Am. J. Psychiatry 132, 864-867.1976-01065-001
M1  - Clarke, M., & Oxman, A. D. (Eds.). (2002). Cochrane Reviewers' Handbook 4.1.5 [updated April 2002] The Cochrane Library, Issues 2. Oxford: Update Software.
M1  - Cunningham Owens, D. G. 1999. Standardised rating scales for tardive dyskinesia. A Guide to the Extrapyramidal Side-Effects of Anti-psychotic Drugs. Cambridge: Cambridge Univ. Press, pp. 293-296.
M1  - de Montigny, C., Chouinard, G., & Annable, L. (1979). Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology, 65, 219-223. http://dx.doi.org/10.1007/BF00492207
M1  - DerSimonian, R., & Laird, N. 1986. Meta-analysis in clinical trials. Control. Clin. Trials?, 177-188.
M1  - Domino, E. F., May, W. W., Demetriou, S., Mathews, B., Tait, S., & Kovacic, B. (1985). Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy. Biol. Psychiatry, 20, 1189-1196. http://dx.doi.org/10.1016/0006-3223(85)90177-5
M1  - Egger, M., Smith, G. D., Schneider, M., & Minder, C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634.
M1  - Gelenberg, A. J., Dorer, D. J., Wojcik, J. D., Falk, W. E., Brotman, A. W., & Leahy, L. 1990. A crossover study of lecithin treatment of tardive dyskinesia. J. Clin. Psychiatry 51, 149-153.1990-26289-001
M1  - Gelenberg, A. J., Wojcik, J., Falk, W. E., Bellinghausen, B., & Joseph, A. B. (1989). CDP-Choline for the treatment of tardive dyskinesia: a small negative series. Comp. Psychiatry, 30, 1-4. http://dx.doi.org/10.1016/0010-440X(89)90111-9
M1  - George, J., Pridmore, S., & Aldous, D. (1981). Double blind controlled trial of deanol in tardive dyskinesia. Aust. N. Z. J. Psychiatry, 15, 68-71. http://dx.doi.org/10.3109/00048678109159413
M1  - Gerlach, J., Reisby, N., & Randrup, A. (1974). Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia, 34, 21-35. http://dx.doi.org/10.1007/BF00421217
M1  - Glazer, W. M. 2000. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry 61(Suppl. 4), 15-20.2000-15367-003
M1  - Grimm, J. W., Chapman, M. A., Zahm, D. S., & See, R. E. 2001. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse 39, 51-57.
M1  - Harrison, P. J. (1999). The neuropathological effects of antipsychotic drugs. Schizophr. Res., 40, 87-99. http://dx.doi.org/10.1016/S0920-9964(99)00065-1
M1  - Izumi, K., Tominaga, H., Koja, T., Nomoto, M., Shimizu, T., Sonoda, H., Imamura, K., Igata, A., & Fukuda, T. 1986. Meclofenoxate therapy in tardive dyskinesia: a preliminary report. Biol. Psychiatry 21, 151-160.
M1  - Jackson, I. V. 1978. Cholinergic enhancement in tardive dyskinesia. Curr. Ther. Res. Clin. Exp. 24, 725-733.
M1  - Jackson, I. V., Davis, L. G., Cohen, R. K., & Nuttall, E. A. 1981. Lecithin administration in tardive dyskinesia: clinical and biomedical correlates. Biol. Psychiatry 16, 85-90.1981-33336-001
M1  - Jackson, I. V., Nuttall, E. A., Ibe, I. O., & Perez-Cruet, J. 1979. Treatment of tardive dyskinesia with lecithin. Am. J. Psychiatry 136, 1458-1460.
M1  - Jeste, D. V. 2000. Tardive dyskinesia in older patients. J. Clin. Psychiatry 61 (Suppl. 4), 27-32.2000-15367-005
M1  - Joe, S. H., Suh, K. Y., & Lee, B. Y. 1985. Effect of lecithin on tardive dyskinesia. Korea Univ. Med. J. 22, 197-206.
M1  - Jus, A., Villeneuve, A., Gautier, J., Jus, K., Villeneuve, C., Pires, P., & Villeneuve, R. (1978). Deanol, lithium and placebo in the treatment of tardive dyskinesia: a double-blind crossover study. Neuropsychobiology, 4, 140-149. http://dx.doi.org/10.1159/000117629
M1  - Klawans, H. L., & Rubovits, R. (1974). Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J. Neurol. Neurosurg. Psychiatry, 27, 941-947. http://dx.doi.org/10.1136/jnnp.37.8.941
M1  - Kocher, R., Hobi, V., Linder, M., & Studer, K. 1980. Zur Therapie mit Dimethylaminoathanol (Deanol) bei neuroleptikainduzierten Spatdyskinesien Schweiz. Arch. Neurol. Neurochir. Psychiatr. 126, 103-109.
M1  - Lucius, G. 1978. Uber die therapeutische Wirksamkeit von Dimethylaminoaethanol bei neuroleptikainduzierten Spathyperkinesen. Dissertation. Der Albert-Ludwigs-Universitat Freiburg im Breisgau, Freiburg im Breisgau.
M1  - Mantel, N., & Haenszel, W. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719-748.
M1  - Marshall, M., Lockwood, A., Bradley, C., Actams, C., Joy, C., & Fenton, M. 2000. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br. J. Psychiatry 176, 249-252.
M1  - Marsalek, M., Filip, V., Petrovsky, M., Klar, L., Filipova, M., & Klaschka, J. 1997. 7-MEOTA in the treatment of tardive dyskinesia. Double-blind placebo controlled study. Homeost. Health Dis. 38, 7.
M1  - Maurer, I., & Volz, H. 2001. Cell-mediated side effects of psychopharmacological treatment. Arzneim.-Forsch. 51, 785-792.
M1  - Miller, R., & Chouinard, G. (1993). Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa-induced dyskinesia, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry, 34, 713-738. http://dx.doi.org/10.1016/0006-3223(93)90044-E
M1  - Mitchell, I. J., Cooper, A. C., Griffiths, M. R., & Cooper, A. J. 2002. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 109, 89-99.
M1  - Moher, D., Schulz, K. F., & Altaian, D. 2001. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285, 1987-1991.
M1  - Ojima, Y., Tsubaki, M., Yagi, G., Kamishima, K., & Miura, S. 1991. Experimental design and analysis for determination of improvement rating by video imaging-a double-blind placebo-controlled study for meclofenoxate hydrocloride (Lucidril) in tardive dyskinesia. Rinsho Hyoka (Clin. Eval.) 19, 267-276.
M1  - Penovich, P., Morgan, I. P., Kerzner, B., Karch, F., & Goldblatt, D. 1978. Double-blind evaluation of deanol in tardive dyskinesia. JAMA 239, 1997-1998.
M1  - Perez-Cruet, J., Menendez, I., Alvarez-Ghersi, J., Falcon, J. R., Valderrabano, O., Castro-Urrutia, E. G., Ifarraguerri, C., & Perez, L. L. 1981. Double-blind study of lecithin in the treatment of persistent tardive dyskinesia. Bol. Assoc. Med. P. R. 73, 531-537.
M1  - Peskind, E. R. 1998. Pharmacologie approaches to cognitive deficits in Alzheimer's disease. J. Clin. Psychiatry 59(Suppl. 9), 22-27.1998-10834-004
M1  - Petticrew, M. 2001. Systematic reviews from astronomy to zoology: myths and misconceptions. BMJ 322, 98-101.
M1  - Pharmacology Research Branch, National Institute of Mental Health. 1976a. Abnormal Involuntary Movement Scale (AIMS). In: Guy, W. (Ed.), ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM), vol. 76-338. Rockville, MD: National Institute of Mental Health, pp. 534-537.
M1  - Pharmacology Research Branch, National Institute of Mental Health. 1976b. Clinical Global Impression (CGI). In: Guy, W. (Ed.), ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM), vol. 76-338. Rockville, MD: National Institute of Mental Health, pp. 217-222.
M1  - Price, L. A. 1982. Lecithin treatment for tardive dyskinesia: a clinical evaluation. Dissertation. North Texas State University, Denton, TX.
M1  - Rascol, O., & Fahre, N. (2001). Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin. Neuropharmacol., 24, 313-323. http://dx.doi.org/10.1097/00002826-200111000-00002
M1  - Review Manager (RevMan) [Computer program], 2000. Version 4.1.1 for Windows. The Cochrane Collaboration, Oxford.
M1  - Schneider, L. S. 1998. New therapeutic approaches to cognitive impairment. J. Clin. Psychiatry 59(Suppl. 11), 8-13.1998-10958-002
M1  - Schooler, N. R., & Kane, J. M. 1982. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486-487.
M1  - Schulz, K. F., & Grimes, D. A. 2002a. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 359, 515-519.
M1  - Schulz, K. F., & Grimes, D. A. 2002b. Allocation concealment in randomised trials: defending against deciphering. Lancet 359, 614-618.
M1  - Sibbald, B., & Roberts, C. 1998. Understanding controlled trials: crossover trials. BMJ 316, 17-19.
M1  - Simpson, G. M., Lee, J. H., Zoubok, B., & Gardos, G. 1979. A rating scale for tardive dyskinesia. Psychopharmacology (Berl.) 64, 171-179.
M1  - Simpson, G. M., Voitashevsky, A., Young, M. A., & Lee, J. H. (1977). Deanol in the treatment of tardive dyskinesia. Psychopharmacology, 52, 257-261. http://dx.doi.org/10.1007/BF00426709
M1  - Sramek, J. J., & Cutler, N. R. 1999. Recent developments in the drug treatment of Alzheimer's disease. Drags Aging 14, 359-373.
M1  - Sterne, J. A., Egger, M., & Smith, G. D. 2001. Investigating and dealing with publication and other biases in meta-analysis. BMJ 323, 101-105.
M1  - Tammenmaa, I. A., McGrath, J. J., Sailas, E., & Soares-Weiser, K. 2002. Cholinergic medication for neuroleptic-induced tardive dyskinesia (Cochrane Review). The Cochrane Library, Issue 3. Oxford: Update Software.
M1  - Tarsy, D., & Bralower, M. 1977. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch. Neurol. 34, 756-758.
M1  - Wurtman, R. J., & Growdon, J. H. 1978. Dietary enhancement of CNS neurotransmitters. Hosp. Pract. 13, 71-77.
M1  - Yagi, G., Kamishima, K., & Miura, S. 1990. Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia-a double-blind placebo-controlled study. Rinsho Hyoka (Clin. Eval.) 18, 455-479.
M2  - http://dx.doi.org/10.1016/j.pnpbp.2004.05.045
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2004-21772-005
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2004-21772-005 

8. 
TY  - ELEC
ID  - 2005-11622-018
T1  - Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial.
T3  - Psychopharmacologia
A1  - Freudenreich, Oliver
A1  - Herz, Lawrence
A1  - Deckersbach, Thilo
A1  - Evins, A. Eden
A1  - Henderson, David C
A1  - Cather, Corinne
A1  - Goff, Donald C
A2  - Addington, Adler, Allen, Andreasen, Andreasen, Arciniegas, Arendt, Barnes, Benedict, Benton, Blair, Caroff, Dalack, Dean, Dunn, el-Mallakh, Folstein, Freedman, Freedman, Friedman, Friedman, Furey, Goff, Goff, Green, Griffin, Guy, Hasselmo, Holt, Kay, Levine, Maelicke, McEvoy, Mohs, Perry, Powchik, Raedler, Reichman, Simpson, Spreen, Sullivan, Takada, Tandon, Tandon, Tual, Wechsler, White, Wynn
Y1  - 2005//
N2  - Rationale: Schizophrenia is a disorder with cognitive deficits that could stem from cholinergic dysfunction. Objectives: Our aim was to examine if donepezil administered to stable, medicated outpatients with schizophrenia improves cognition and psychopathology. Methods: We conducted a double-blind placebo-controlled trial of donepezil up to 10 mg/day added for 8 weeks to ongoing antipsychotic treatment in 36 typical community-treated schizophrenia patients not selected for cognitive impairment. Results: Donepezil did not improve measures of cognition or psychopathology. It was well tolerated. Conclusion: Consistent with other studies, addition of donepezil to stable patients with schizophrenia did not improve cognition or measures of psychopathology. This result does not support the hypothesis that residual symptoms and cognitive problems result from a cholinergic deficit that can be remedied by an acetylcholinesterase inhibitor. A donepezil add-on strategy might make sense in selected schizophrenia cases where a pathological process is known to affect cholinergic neurons (e.g., history of head injury or comorbid dementia). (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Drug Augmentation
KW  - *Drug Therapy
KW  - *Neuroleptic Drugs
KW  - *Schizophrenia
KW  - Cognitive Impairment
M3  - Clinical Psychopharmacology [3340]
JF  - Psychopharmacology
VL  - 181
IS  - 2
SP  - 358
EP  - 363
CY  - Germany
PB  - Springer
PB  - Germany
SN  - 0033-3158
AD  - Freudenreich, Oliver: MGH Schizophrenia Program, Freedom Trail Clinic, 25 Staniford Street, 2nd Floor, Boston, MA, US, 02114, ofreud@massmed.org
AD  - Freudenreich, Oliver: ofreud@massmed.org
M1  - AD 2000 Collaborative Group. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): randomised double-blind trial. Lancet, 363, 2105-2115. http://dx.doi.org/10.1016/S0140-6736(04)16499-4
M1  - Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenia. Schizophr Res, 3, 247-251. http://dx.doi.org/10.1016/0920-9964(90)90005-R
M1  - Adler, L. E., Hoffer, L. D., Wiser, A., & Freedman, R. (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-18611994-25605-001
M1  - Allen, T., McEvoy, J. P., Keefe, R., Levin, E., & Wilson, W. (2003) Galantamine as an adjunctive therapy in the treatment of schizophrenia. In: 11th Congress of the International Psychogeriatric Association (IPA), Chicago, 17-22
M1  - American Psychiatric Association Committee on Nomenclature and Statistics. (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
M1  - Andreasen, N. C. (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784-7881982-29376-001
M1  - Andreasen, N. C. (1983) Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City
M1  - Arciniegas, D. B. (2003) The cholinergic hypothesis of cognitiv impairment caused by traumatic brain injury. Curr Psychiatr Rep 5: 391-399
M1  - Arendt, T., Bigl, V., Arendt, A., & Tennstedt, A. (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol (Berl) 61: 101-108
M1  - Barnes, T. R. E. (1989). A rating scale for drug-induced akathisia. Br J Psychiatry, 154, 672-676. http://dx.doi.org/10.1192/bjp.154.5.672
M1  - Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998). The Hopkins verbal learning test-revised. Clin Neuropsychol, 12, 43-55. http://dx.doi.org/10.1076/clin.12.1.43.1726
M1  - Benton, A., & Hamsher, K. (1978) Multilingual aphasia examination (manual revised). University of Iowa, Iowa City
M1  - Blair, J., & Spreen, D. (1989). Predicting premorbid IQ: a revision of the national adult reading test. Clin Neuropsychol, 3, 129-136. http://dx.doi.org/10.1080/13854048908403285
M1  - Caroff, S. N., Campbell, E. C., Havey, J., Sullivan, K. A., Mann, S. C., & Gallop, R. (2001) Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 62: 772-7752001-05581-003
M1  - Dalack, G. W., Healey, D. J., & Meador-Woodruff, J. H. (1998) Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 155: 1490-15011998-11156-001
M1  - Dean, B., McLeod, M., Keriakous, D., McKenzie, J., & Scarr, E. (2002). Decreased muscarinicl receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry, 7, 1083-1091. http://dx.doi.org/10.1038/sj.mp.4001199
M1  - Dunn, N. R., Pearce, G. L., & Shakir, S. A. W. (2000). Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol, 14, 406-408. http://dx.doi.org/10.1177/026988110001400410
M1  - el-Mallakh, R. S., Kirch, D. G., Shelton, R., Fan, K. J., Pezeshkpour, G., Kanhouwa, S., Wyatt, R. J., & Kleinman, J. E. (1991) The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatry Clin Neurosci 3: 383-3861992-12743-001
M1  - Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189-198. http://dx.doi.org/10.1016/0022-3956(75)90026-6
M1  - Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M. C., Reimherr, F., Wender, P., Yaw, J., Young, D. A., Breese, C. R., Adams, C., Patterson, D., Adler, L. E., Kruglyak, L., Leonhard, S., & Byerley, W. (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sei U S A 94: 587-592
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology, 174, 45-53. http://dx.doi.org/10.1007/s00213-004-1794-x
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parrella, M., & Davis, K. L. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Furey, M. L., Pietrini, P., & Haxby, J. V. (2000). Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science, 290, 2315-2319. http://dx.doi.org/10.1126/science.290.5500.2315
M1  - Goff, D. C., Amico, E., Dreyfuss, D., & Ciraulo, D. A. (1994) A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psychiatry 151: 429-4321994-30743-001
M1  - Goff, D. C., Henderson, D. C., & Amico, E. (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-11941993-10682-001
M1  - Green, M. F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-3301996-00417-002
M1  - Griffin, S. L., van Reekum, R., & Masanic, C. (2003). A review of Cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. J Neuropsychiatry Clin Neurosci, 15, 17-26. http://dx.doi.org/10.1176/appi.neuropsych.15.1.17
M1  - Guy, W. (1976) ECDEU Assessment manual for psychopharmacology -revised (DHEW Publ No ADM 76-338). U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs
M1  - Hasselmo, M. E., & Bower, J. M. (1993). Acetylcholine and memory. Trends Neurosci, 16, 218-222. http://dx.doi.org/10.1016/0166-2236(93)90159-J
M1  - Holt, D. J., Herman, M. M., Hyde, T. M., Kleinman, J. E., Sinton, C. M., German, D. C., Hersh, L. B., Graybiel, A. M., & Saper, C. B. (1999) Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 94: 21-31
M1  - Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-2762005-09726-007
M1  - Levine, J., & Schooler, N. R. (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psycho-pharmacol Bull 22: 343-381
M1  - Maelicke, A., & Albuquerque, E. X. (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393: 165-170
M1  - McEvoy, J. P., & Allen, T. B. (2003). Substance abuse (including nicotine) in schizophrenic patients. Curr Opin Psychiatry, 16, 199-205. http://dx.doi.org/10.1097/00001504-200303000-00010
M1  - Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & "312" Study Group. (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481-4882001-18197-006
M1  - Perry, K. W., Nisenbaum, L. K., George, C. A., Shannon, H. E., Felder, C. C., & Bymaster, F. P. (2001) The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 49: 716-725
M1  - Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, D. P., Perl, D. P., Harvey, P. D., & Davis, K. L. (1998) Postmortem studies in schizophrenia. Schizophr Bull 24: 325-3411998-10644-002
M1  - Raedler, T. J., Knable, M. B., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K. S., Egan, M. F., Coppola, R., & Weinberger, D. R. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry, 160, 118-127. http://dx.doi.org/10.1176/appi.ajp.160.1.118
M1  - Reichman, W. E., Coyne, A. C., Amirneni, S., Molino, B., & Egan, S. (1996) Negative symptoms in Alzheimer's disease. Am J Psychiatry 153: 424-4261996-00417-019
M1  - Simpson, G. M., & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212: 11-19
M1  - Spreen, O., & Strauss, E. (1991) A compendium of neuropsychological tests. Oxford University Press, New York
M1  - Sullivan, R. J., Allen, J. S., Otto, C., Tiobech, J., & Nero, K. (2000). Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. Br J Psychiatry, 177, 174-178. http://dx.doi.org/10.1192/bjp.177.2.174
M1  - Takada, Y., Yonezawa, A., Kume, T., Katsuki, H., Kaneko, S., Sugimoto, H., & Akaike, A. (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306: 772-777
M1  - Tandon, R. (1999) Cholinergic aspects of schizophrenia. Br J Psychiatry 174(Suppl 37): 7-111999-10613-002
M1  - Tandon, R., & Greden, J. F. (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46: 745-7531990-01574-001
M1  - Tual, N., Yazc, K. M., Yacolu, A. E., & Gogus, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol, 7, 117-123. http://dx.doi.org/10.1017/S1461145703004024
M1  - Wechsler, D. (1997) Wechsler Adult Intelligence Scale, 3rd edn. (WAIS-III). The Psychological Corporation, San Antonio, TX
M1  - White, K. E., & Cummings, J. L. (1996). Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry, 37, 188-195. http://dx.doi.org/10.1016/S0010-440X(96)90035-8
M1  - Wynn, Z. J., & Cummings, J. L. (2004). Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord, 17, 100-108. http://dx.doi.org/10.1159/000074281
M2  - http://dx.doi.org/10.1007/s00213-005-2235-1
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2005-11622-018
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2005-11622-018 

9. 
TY  - ELEC
ID  - 2005-09329-006
T1  - Efficacy and Tolerability of Low-Dose Donepezil in Schizophrenia.
A1  - Erickson, Steven K
A1  - Schwarzkopf, Steven B
A1  - Palumbo, Donna
A1  - Badgley-Fleeman, Jennifer
A1  - Smirnow, Alexis M
A1  - Light, Gregory A
A2  - Adler, Aghajanian, Arnold, Brauder, Breese, Bryson, Buchanan, Buchanan, Caroff, Crook, Cummings, Dursun, First, Freedman, Freedman, Friedman, Friedman, Garrido, Green, Green, Haroutunian, Holt, Jann, Karson, Kay, King, Levin, Lindstrom, Macewan, Moore, Mortimer, Nahas, Potkin, Rogers, Sevy, Shioiri, Silverstein, Smith, Stevens, Stip, Stryjer, Tuominen, White, Wyatt, Zekry
Y1  - 2005//
N2  - There have been many advancements in the pharmacologic treatment of schizophrenia; however, negative symptoms and cognitive impairment remain an intractable part of this illness. Donepezil is an anticholinesterase inhibitor with cognitive enhancing effects approved for the treatment of Alzheimer disease that has shown some benefit in the treatment of schizophrenia. In this study, 15 inpatients at a state hospital with a history of schizophrenia were administered donepezil in a randomized, double-blind, crossover design. Neurocognitive testing and psychiatric ratings were completed at baseline and at regular intervals for 18 weeks. Results indicated that donepezil treatment was associated with modest improvements in psychiatric symptoms and improved verbal learning. These results suggest that donepezil may be helpful as adjunctive therapy for the treatment of psychiatric symptoms and cognitive impairment in a subgroup of schizophrenic patients. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Drug Therapy
KW  - Cognitive Impairment
KW  - Positive and Negative Symptoms
KW  - Schizophrenia
M3  - Clinical Psychopharmacology [3340]
JF  - Clinical Neuropharmacology
VL  - 28
IS  - 4
SP  - 179
EP  - 184
CY  - US
PB  - Lippincott Williams & Wilkins
PB  - US
SN  - 0362-5664
AD  - Erickson, Steven K.: University of Rochester Medical Center, Department of Psychiatry, 300 Crittenden Boulevard, Box PSYCH, Rochester, NY, US, 14642, steven_erickson@urmc.rochester.edu
AD  - Erickson, Steven K.: steven_erickson@urmc.rochester.edu
M1  - Adler, L., Hoffer, L., Wiser, A., et al. (1993). Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993; 150: 1856-1861.1994-25605-001
M1  - Aghajanian, G., & Marek, G. (2000). Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev., 31, 302-312. http://dx.doi.org/10.1016/S0165-0173(99)00046-6
M1  - Arnold, H., Nelson, C., Sarter, M., et al. (2003). Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats. Psychopharmacology (Berl). 2003; 165: 346-358.2003-04444-004
M1  - Brauder, L., Cramblett, M., Paxton, D., et al. (2001). Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl), 159, 31-37. http://dx.doi.org/10.1007/s002130100894
M1  - Breese, C., Lee, M., Adams, C., et al. (2000). Abnormal regulation of high affinity nicotine receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351-364. http://dx.doi.org/10.1016/S0893-133X(00)00121-4
M1  - Bryson, H., & Benfield, P. (1997). Donepezil. Drugs Aging. 1997; 10: 234-239.
M1  - Buchanan, R., Francis, A., Arango, C., et al. (2004). Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry, 161, 322-331. http://dx.doi.org/10.1176/appi.ajp.161.2.322
M1  - Buchanan, R., Summerfelt, A., Tek, C., et al. (2003). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res., 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Caroff, S., Campbell, E., Havey, J., et al. (2001). Treatment of tardive dyskinesia with donepezil: a pilot study. J Psychiatry. 2001; 62: 772-775.2001-05581-003
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., et al. (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry, 48, 381-388. http://dx.doi.org/10.1016/S0006-3223(00)00918-5
M1  - Cummings, J., Gorman, D., & Shapira, J. (1993). Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry, 33, 536-541. http://dx.doi.org/10.1016/0006-3223(93)90009-3
M1  - Dursun, S., & Kutcher, S. (1999). Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research. Med Hypotheses. 1999; 52: 101-109.
M1  - First, M., Spitzer, R., Gibbon, M., et al. (1995). Structured clinical interview for DSM IV Axis I disorders-patient edition (SCID-I/P). New York: Biometrics Research Department, New York Psychiatric. Institute; 1995.
M1  - Freedman, R., Adams, C. E., & Leonard, S. (2000). The alpha-7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat. 2000; 20: 299-306.
M1  - Freedman, R., Hall, M., Adler, L. E., et al. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Garrido, G., Furuie, C., Buchpiguel, C., et al. (2002). Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry, 73, 508-516. http://dx.doi.org/10.1136/jnnp.73.5.508
M1  - Green, M. (1997). Schizophrenia from a neurocognitive perspective: probing the impenetrable darkness. Boston: Pearson Allyn & Bacon; 1997.
M1  - Green, M. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996; 153: 321-330.1996-00417-002
M1  - Haroutunian, V., Davidson, M., Kanof, P., et al. (1994). Cortical cholinergic markers in schizophrenia. Schizophr Res., 12, 137-144. http://dx.doi.org/10.1016/0920-9964(94)90071-X
M1  - Holt, D. J., Herman, M. M., Hyde, T. M., et al. (1999). Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience. 1999; 94: 21-31.
M1  - Jann, M., Shirley, K., & Small, G. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002; 41: 719-739.
M1  - Karson, C., Mrak, R., Husain, M., et al. (1996). Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol. 1996; 29: 181-191.
M1  - Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.2005-09726-007
M1  - King, D. J. (1990). The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry, 157, 799-811. http://dx.doi.org/10.1192/bjp.157.6.799
M1  - Levin, E., Wilson, W., Rose, J., et al. (1996). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15, 429-436. http://dx.doi.org/10.1016/S0893-133X(96)00018-8
M1  - Lindstrom, J. (1997). Nicotine acetylcholine receptors in health and disease. Mol Neurobiol. 1997; 15: 193-222.
M1  - Macewan, G. W., Ehmann, T. S., Khanbhai, I., et al. (2001). Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatr Scand. 2001; 104: 469-472.2002-15544-008
M1  - Moore, H., Fadel, J., Sarter, M., et al. (1999). Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience. 1999; 88: 811-822.
M1  - Mortimer, A. M. (1997). Cognitive function in schizophrenia-do neuroleptics make a difference?. Pharmacol Biochem Behav., 56, 789-795. http://dx.doi.org/10.1016/S0091-3057(96)00425-X
M1  - Nahas, A., George, M. S., Markowitz, J. S., et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274-282. http://dx.doi.org/10.1076/neur.9.3.274.15563
M1  - Potkin, S., Basile, Y., Jin, Y., et al. (2003). Dl receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry, 8, 109-113. http://dx.doi.org/10.1038/sj.mp.4001191
M1  - Rogers, S., & Friedhoff, L. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996; 7: 293-303.
M1  - Sevy, S., & Davidson, M. (1995). The cost of cognitive impairment in schizophrenia. Schizophr Res., 17, 1-3. http://dx.doi.org/10.1016/0920-9964(95)00025-H
M1  - Shioiri, T., Hamakawa, H., Kato, T., et al. (1996). Proton magnetic resonance spec-troscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophr Res., 22, 19-26. http://dx.doi.org/10.1016/0920-9964(96)00017-5
M1  - Silverstein, S., Schenkel, L., Valone, C., et al. (1998). Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia. Psychiatr Q., 69, 169-191. http://dx.doi.org/10.1023/A:1022197109569
M1  - Smith, R., Singh, A., Infante, M., et al. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology, 27, 479-493. http://dx.doi.org/10.1016/S0893-133X(02)00324-X
M1  - Stevens, K. E., Meltzer, J., & Rose, G. M. (1995). Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats. Psychopharmacology (Berl), 119, 163-170. http://dx.doi.org/10.1007/BF02246157
M1  - Stip, E., Chouinard, S., & Boulay, L. (2005). On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psvchiatry, 29, 219-232. http://dx.doi.org/10.1016/j.pnpbp.2004.11.004
M1  - Stryjer, R., Strous, R. D., Bar, F., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropsychopharmacol., 26, 12-17. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Tuominen, H., Tiihonen, J., & Wahlbeck, K. (2005). Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res., 72, 225-234. http://dx.doi.org/10.1016/j.schres.2004.05.005
M1  - White, K., & Cummings, J. (1996). Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry, 37, 188-195. http://dx.doi.org/10.1016/S0010-440X(96)90035-8
M1  - Wyatt, R., Henter, I., Leary, M., et al. (1991). An economic evaluation of schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1991; 30: 196-205.1996-14574-001
M1  - Zekry, D., Duyckaerts, C., Belmin, J., et al. (2001). The vascular lesions in vascular and mixed dementia: the weight of functional neuroanatomy. Neurobiol Aging, 24, 213-219. http://dx.doi.org/10.1016/S0197-4580(02)00066-0
M2  - http://dx.doi.org/10.1097/01.wnf.0000173714.61744.e6
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2005-09329-006
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2005-09329-006 

10. 
TY  - ELEC
ID  - 2004-17041-007
T1  - Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study.
A1  - Stryjer, Rafael
A1  - Strous, Rael
A1  - Bar, Faina
A1  - Shaked, Ginette
A1  - Shiloh, Roni
A1  - Rozencwaig, Silvio
A1  - Grupper, Daniel
A1  - Buchman, Nili
A1  - Kotler, Moshe
A1  - Rabey, J. Martin
A1  - Weizman, Abraham
A2  - Aarsland, Addington, Babic, Bergman, Borda, Buchanan, Buckley, Carlsson, Crook, Cummings, Dean, Felder, Freedman, Friedman, Guy, Howard, Hyde, Ichikawa, Ichikawa, Karson, Kay, Leonard, Mori, Raedler, Risch, Rogers, Shiloh, Shirazi-Southall, Simpson, Stryjer, Stryjer, Tandon, Tandon, Werber, White
Y1  - 2004//
N2  - Increasing evidence suggests that the cholinergic system is involved in the pathogenesis of schizophrenia. Donepezil, a central cholinesterase inhibitor, improves psychotic symptomatology in demented patients, however, evidence for its role in the management of active psychosis in schizophrenia remains limited. An 18-week double blind cross-over study was conducted in which eight patients were randomly assigned to either donepezil (5 mg/day for the first 4 weeks and 10 mg/day for the following 4 weeks) or placebo as augmentation treatment to clozapine. After this initial phase, there was a 2-week washout period of the study medication after which the same regimen was crossed over at the same dose and for the same period (8 weeks). No significant difference was noted in the total positive and negative symptom scale scores when donepezil was compared with placebo (16.7% + 12.97% vs 3.20% + 13.94% respectively, p = 0.18). However, three patients improved (> 15%) in the total PANSS scores (37.03%, 16.6% and 25.33%) during the donepezil treatment phase, while only one patient improved (20.87%) during the placebo phase. No differences were noted in the Calgary depression scale (p = 0.305), Simpson Angus scale (p = 0.374), clinical global impression-improvement scale (p = 0.23) and clinical global impression-severity of illness scores (p = 0.116). Although this preliminary study failed to demonstrate a clear effect of donepezil augmentation in clozapine treated chronic schizophrenia patients, it seems that the subtle positive effect of donepezil observed in some of our patients should encourage further investigation in a larger sample of this patient subpopulation. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Acetylcholine
KW  - *Cholinergic Receptors
KW  - *Clozapine
KW  - *Psychosis
KW  - *Schizophrenia
M3  - Clinical Psychopharmacology [3340]
M1  - Schizophrenia & Psychotic States [3213]
JF  - Human Psychopharmacology: Clinical and Experimental
VL  - 19
IS  - 5
SP  - 343
EP  - 346
CY  - US
PB  - John Wiley & Sons
PB  - US
SN  - 0885-6222
AD  - Stryjer, Rafael: Beer Yaakov Mental Health Center, Beer Yaakov, Israel, lacan_r@netvision.net.il
AD  - Stryjer, Rafael: lacan_r@netvision.net.il
M1  - Aarsland, D., Laake, K., Larsen, J. P., & Janvin, C. (2002). Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neural Neurosurg Psychiatry, 72, 708-712. http://dx.doi.org/10.1136/jnnp.72.6.708
M1  - Addington, D., Addington, J., & Maticka-Tyndale, E. 1993. Assessing depression in schizophrenia. The Calgary Depression Scale. Br J Psychiatry Suppl; (22): 39-44.1994-23949-001
M1  - Babic, T., & Zurak, N. 1999. Convulsions induced by donepezil. J Neural Neurosurg Psychiatry 66: 410.
M1  - Bergman, J., & Lerner, V. (2002). Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol, 25, 107-110. http://dx.doi.org/10.1097/00002826-200203000-00009
M1  - Borda, T., Perez Rivera, R., Joensen, L., Gomez, R. M., & Sterin-Borda, L. 2002. Antibodies against cerebral Ml cholinergic muscarinic receptors from schizophrenic patients: molecular interaction. J Immunol 168: 3667-3674.
M1  - Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Buckley, P., Miller, A., Olsen, J., Carver, D., Miller, D. D., & Csernansky, J. 2001. When symptoms persists: clozapine augmentation strategies. Schizophr Bull 27: 615-628.2002-10453-007
M1  - Carlsson, A. (1988). The current status of dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1, 179-186. http://dx.doi.org/10.1016/0893-133X(88)90012-7
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry, 48, 381-388. http://dx.doi.org/10.1016/S0006-3223(00)00918-5
M1  - Cummings, J. L. 2000. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 157: 1.2000-13126-001
M1  - Dean, B., McLeod, M., Keriakous, D., McKenzie, J., & Scarr, E. (2002). Decreased muscarinic(1) receptor in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry, 7, 1083-1091. http://dx.doi.org/10.1038/sj.mp.4001199
M1  - Felder, C. C., Porter, A. C., Skillman, T. L., et al. (2002). Elucidating the role of muscarinic receptors in psychosis. Life Sci, 68, 2605-2613. http://dx.doi.org/10.1016/S0024-3205(01)01059-1
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Guy, W. 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health: Rockville MD; 218-222.
M1  - Howard, A. K., Thornton, A. E., Altman, S., & Honer, W. G. (2002). Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol, 16, 267-270. http://dx.doi.org/10.1177/026988110201600313
M1  - Hyde, T. M., & Crook, J. M. 2001. Cholinergic systems and schiziphrenia: primary pathology or epiphenomena. J Chem Neuroanatomy 22: 53-63.
M1  - Ichikawa, J., Chung, Y. C., Li, Z., Dai, J., & Meltzer, H. Y. (2002). Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res, 958, 176-184. http://dx.doi.org/10.1016/S0006-8993(02)03692-2
M1  - Ichikawa, J., Dai, J., O'Laughlin, I. A., Fowler, W. L., & Meltzer, H. Y. (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology, 26, 325-339. http://dx.doi.org/10.1016/S0893-133X(01)00312-8
M1  - Karson, C. N., Mrak, R. E., Husain, M. M., & Griffin, W. S. 1996. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 29: 181-191.
M1  - Kay, S., Fiszbein, A., & Opler, L. A. 1987. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13: 261-276.2005-09726-007
M1  - Leonard, S., Adams, C., Breese, C. R., et al. 1996. Nicotinic receptor function in schizophrenia. Schizophr Bull 22: 431-445.1996-06147-004
M1  - Mori, S. 2002. Responses to donepezil in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci 977: 493-500.
M1  - Raedler, T. J., Knable, M. B., Jones, D. W., et al. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry, 160, 118-127. http://dx.doi.org/10.1176/appi.ajp.160.1.118
M1  - Risch, S. C., McGurk, S., Homer, M. D., et al. (2001). A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase, 7, 105-110. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of US multicentre open-label study. Eur Neuropsychopharmacol, 10, 195-203. http://dx.doi.org/10.1016/S0924-977X(00)00067-5
M1  - Shiloh, R., Zemishlany, Z., Aizenberg, D., et al. (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double blind placebo-controlled study. Br J Psychiatry, 171, 569-573. http://dx.doi.org/10.1192/bjp.171.6.569
M1  - Shirazi-Southall, S., Rodriguez, D. E., & Nomikos, G. G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology, 26, 583-594. http://dx.doi.org/10.1016/S0893-133X(01)00400-6
M1  - Simpson, G. M., & Angus, J. W. S. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 46(Suppl. 212): 11.
M1  - Stryjer, R., Bar, F., Straus, R., Baruch, Y., & Rabey, J. M. 2002. Donepezil management in schizophrenia with associated dementia. J Clin Psychopharmacol 22: 226-229.
M1  - Stryjer, R., Straus, R., Bar, F., et al. 2003. Beneficial effect of donepezil augmentation in the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 26: 7-12.
M1  - Tandon, R., Shipley, J. E., Greden, J. F., Mann, N. A., Eisner, W. H., & Goodson, J. A. (1991). Muscarinic cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms. Schizophr Res, 4, 23-30. http://dx.doi.org/10.1016/0920-9964(91)90006-D
M1  - Tandon, R. 1999. Cholinergic aspects of schizophrenia. Br J Psychiatry 37: 7-11.1999-10613-002
M1  - Werber, E. A., & Rabey, J. M. 2001. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108: 1319-1325.
M1  - White, K., & Cummings, J. L. (1996). Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry, 37, 188-195. http://dx.doi.org/10.1016/S0010-440X(96)90035-8
M2  - http://dx.doi.org/10.1002/hup.595
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2004-17041-007
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2004-17041-007 

11. 
TY  - ELEC
ID  - 2009-01416-021
T1  - Donepezil management of schizophrenia with associated dementia.
A1  - Stryjer, Rafael
A1  - Bar, Faina
A1  - Strous, Rael
A1  - Baruch, Yehuda
A1  - Rabey, Jose Martin
A2  - Cummings, Dwork, Folstein, Giacobini, Guy, Holt, Katzman, Katzman, Kudo, Maany, Magnuson, Moore, Purohit, Ring, Rogers, Rogers, Sarter, Tandon
Y1  - 2002//
N2  - Comorbid schizophrenia and dementia is a common clinical phenomenon. Although pharmacologic management of these separate conditions is improving, successful treatment of the coexisting illness remains incomplete. Donepezil, a cholinesterase inhibitor, has been shown to be beneficial in the management of symptoms of memory and cognitive loss in patients with mild to moderately severe Alzheimer's disease. In this case reports on the use of donepezil in comorbid schizophrenia and dementia, we describe the beneficial effect of donepezil, with regard to cognition and behavior, in three chronic schizophrenic patients with dementia who had already achieved relative mental state stability after several months of ongoing antipsychotic treatment. Our three case reports of schizophrenic patients with associated dementia demonstrate dramatic improvement with the administration of donepezil within a short time even after several months of relative mental stability with antipsychotic treatment. These hypothesized associations may further suggest an important contribution of cholinergic systems to the etiopathologic findings of schizophrenia. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Cognition
KW  - *Comorbidity
KW  - *Dementia
KW  - *Drug Therapy
KW  - *Schizophrenia
KW  - Behavior
KW  - Cholinesterase Inhibitors
M3  - Health & Mental Health Treatment & Prevention [3300]
JF  - Journal of Clinical Psychopharmacology
VL  - 22
IS  - 2
SP  - 1
EP  - 6
CY  - US
PB  - Lippincott Williams & Wilkins
PB  - US
SN  - 0271-0749
AD  - Strous, Rael, rael@photonet.com
AD  - Strous, Rael: rael@photonet.com
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157:4-15.2000-13126-001
M1  - Dwork, A. J., Susser, E. S., Keilp, J., et al. (1998). Senile degeneration and cognitive impairment in chronic schizophrenia. Am J Psychiatry 1998; 155:1536-43.1998-11156-007
M1  - Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini Mental State. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res, 12, 189-98. http://dx.doi.org/10.1016/0022-3956(75)90026-6
M1  - Giacobini, E. (1996). New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors? Prog Brain Res 1996; 109:311-23.
M1  - Guy, W. (1976). Clinical Global Impression Scale. In: EDCEU Assessment Manual. Washington, DC: US Department of Health, Education and Welfare, 1976:218-22.
M1  - Holt, D. J., Herman, M. M., Hyde, T. M., et al. (1999). Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999; 94:21-31.
M1  - Katzman, R., Terry, R., DeTeresa, R., et al. (1988). Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23:138-44.
M1  - Katzman, R. (1991). Advances in Alzheimer disease. FASEB J 1991; 5:278-86.
M1  - Kudo, S., & Ishizaki, T. (1999). Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37435-56.
M1  - Maany, I. (1996). Adverse interaction of tacrine and haloperidol [letter]. Am J Psychiatry 1996; 153:1504.1996-00488-022
M1  - Magnuson, T. M., Keller, B. K., & Burke, W. J. (1998). Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am J Psychiatry 1998; 155:1458-9.1998-12596-024
M1  - Moore, H., Fadel, J., Sarter, M., et al. (1999). Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience 1999; 88:811-22.
M1  - Purohit, D. P., Perl, D. P., Haroutunian, V., et al. (1998). Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry, 55, 205-11. http://dx.doi.org/10.1001/archpsyc.55.3.205
M1  - Ring, B. J., Catlow, J., Lindsay, T. J., et al. (1996). Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276:658-66.
M1  - Rogers, S. L., & Friedhoff, L. T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, randomized, double-blind, placebo-controlled trial. The donepezil study group. Dementia 1996; 7:293-303.
M1  - Rogers, S. L. (1998). A 24 week, double blind, placebo-controlled trail of donepezil in patients with Alzheimer disease. Neurology, 50, 136-45. http://dx.doi.org/10.1159/000023160
M1  - Sarter, M., Bruno, J. P., & Turchi, J. (1999). Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann NY Acad Sci 1999; 877:368-82.1999-02761-016
M1  - Tandon, R. (1999). Cholinergic aspects of schizophrenia. Br J Psychiatry Suppl 1999; 37:7-11.1999-10613-002
M2  - http://dx.doi.org/10.1097/00004714-200204000-00021
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2009-01416-021
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2009-01416-021 

12. 
TY  - ELEC
ID  - 2005-15279-002
T1  - Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice.
A1  - Csernansky, John G
A1  - Martin, Maureen
A1  - Shah, Renu
A1  - Bertchume, Amy
A1  - Colvin, Jenny
A1  - Dong, Hongxin
A2  - Adler, Aigner, Allen, Andine, Ballard, Bardgett, Barnes, Benes, Buchanan, Buffalo, Colgin, Coyle, Dall'Igna, Dean, Everitt, Fenton, Freedman, Friedman, Friedman, Gao, Giovannini, Goff, Gold, Hasegawa, Higgins, Hutson, Hyde, Jian-ping, Kim, Kim, Knopman, Lenzi, Luisada, Lydie, Martin, Mesulam, Moghaddam, Newcomer, Ochoa, Ohno, Olney, Pepeu, Raskind, Rogers, Rogers, Rogers, Rupniak, Samochocki, Samochocki, Schubert, Schwarcz, Shannon, Stewart, Stryjer, Stryjer, Tugal, Walker, Wang
Y1  - 2005//
N2  - Enhancing cholinergic function has been suggested as a possible strategy for ameliorating the cognitive deficits of schizophrenia. The purpose of this study was to examine the effects of acetylcholinesterase (AChE) inhibitors in mice treated with the noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, MK-801, which has been suggested as an animal model of the cognitive deficits of schizophrenia. Three separate experiments were conducted to test the effects of physostigmine, donepezil, or galantamine on deficits in learning and memory induced by MK-801. In each experiment, MK-801 (0.05 or 0.10 mg/kg) or saline was administered i.p. 20 min prior to behavioral testing over a total of 12 days. At 30 min prior to administration of MK-801 or saline, one of three doses of the AChE inhibitor (ie physostigmine--0.03, 0.10, or 0.30 mg/kg; donepezil--0.10, 0.30, or 1.00 mg/kg; or galantamine--0.25, 0.50, or 1.00 mg/kg) or saline was administered s.c. Behavioral testing was performed in all experimental animals using the following sequence: (1) spatial reversal learning, (2) locomotion, (3) fear conditioning, and (4) shock sensitivity. Both doses of MK-801 produced impairments in spatial reversal learning and in contextual and cued memory, as well as hyperlocomotion. Physostigmine and donepezil, but not galantamine, ameliorated MK-801-induced deficits in spatial reversal learning and in contextual and cued memory in a dose-dependent manner. Also, physostigmine, but not donepezil or galantamine, reversed MK-801-induced hyperlocomotion. Galantamine, but not physostigmine or donepezil, altered shock sensitivity. These results suggest that AChE inhibitors may differ in their capacity to ameliorate learning and memory deficits produced by MK-801 in mice, which may have relevance for the cognitive effects of cholinomimetic drugs in patients with schizophrenia. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Acetylcholinesterase
KW  - *Animal Learning
KW  - *Cholinesterase Inhibitors
KW  - *Memory
KW  - *N-Methyl-D-Aspartate
KW  - Animal Locomotion
KW  - Animal Models
KW  - Galanthamine
KW  - Mice
KW  - Physostigmine
KW  - Schizophrenia
M3  - Psychopharmacology [2580]
M1  - Schizophrenia & Psychotic States [3213]
JF  - Neuropsychopharmacology
VL  - 30
IS  - 12
SP  - 2135
EP  - 2143
CY  - United Kingdom
PB  - Nature Publishing Group
PB  - United Kingdom
SN  - 0893-133X
AD  - Csernansky, John G.: Department of Psychiatry, Washington University School of Medicine, (Box 8134), 660 S. Euclid, St Louis, MO, US, 63110, jgc@conte.wustl.edu
AD  - Csernansky, John G.: jgc@conte.wustl.edu
M1  - Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T., Egan, M., Pickar, D., et al. (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156: 1646-1649.1999-11995-025
M1  - Aigner, T. G., & Mishkin, M. (1986). The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neurol Biol, 45, 81-87. http://dx.doi.org/10.1016/S0163-1047(86)80008-5
M1  - Allen, R. M., & Young, S. J. (1978). Phencyclidine-induced psychosis. Am J Psychatry 135: 1081-1084.1979-24177-001
M1  - Andine, P., Widermark, N., Axelsson, R., Nyberg, G., Olofsson, U., Martensson, E., et al. (1999). Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharm Exp Ther 290: 1393-1408.1999-11101-010
M1  - Ballard, T. M., & McAllister, K. H. (1999). The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats. Psychopharmacology, 146, 10-18. http://dx.doi.org/10.1007/s002130051082
M1  - Bardgett, M. E., Boeckman, R., Krochmal, D., Fernando, H., Ahrens, R., & Csernansky, J. G. (2003). NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57B1/6 mice. Brain Res Bull 60: 131-142.
M1  - Barnes, C. A., Meltzer, J., Houston, F., Orr, G., McGann, K., & Wenk, G. L. (2000). Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99: 17-23.
M1  - Benes, F. M. (1999). Evidence for altered trisynaptic circutry in schizophrenic hippocampus. Biol Psychiatry, 46, 589-599. http://dx.doi.org/10.1016/S0006-3223(99)00136-5
M1  - Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2002). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Res, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Buffalo, E. A., Gillam, M. P., Allen, R. R., & Paule, M. G. (1994). Acute behavioral effects of MK-801 in rhesus monkeys: assessment using an operant test battery. Pharma Biochem Beh, 48, 935-940. http://dx.doi.org/10.1016/0091-3057(94)90203-8
M1  - Colgin, L. L., Kubota, D., & Lynch, G. (2003). Cholinergic plasticity in the hippocampus. PNAS 100: 2872-2877.
M1  - Coyle, J. T., & Tsai, G. (2004). NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Intl Rev Neurobiol 59: 491-515.
M1  - Dall'Igna, O. P., Da Silva, A. L., Dietrich, M. O., Hoffman, A., de Oliveira, R. V., Souze, D. O., et al. (2003). Chronic treatment with caffeine blunts the hyperlocomotor but not the cognitive effects of the N-methyl-D-asparate receptor antagonist MK-801 in mice. Psycho-pharmacology 166: 258-263.
M1  - Dean, B., Bymaster, F. P., & Scarr, E. (2003). Muscarinic receptors in schizophrenia. Curr Mol Med 3: 419-426.
M1  - Everitt, B. J., & Robbins, T. W. (1997). Central cholinergic systems and cognition. Annu Rev Psychol, 48, 649-684. http://dx.doi.org/10.1146/annurev.psych.48.1.649
M1  - Fenton, W., Stover, E. L., & Insel, T. R. (2003). Breaking the log-jam in treatment development for cognition in schizophrenia. Psycho-pharmacology 169: 365-366.
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology, 174, 45-53. http://dx.doi.org/10.1007/s00213-004-1794-x
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatement to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry, 157, 1141-1149. http://dx.doi.org/10.1176/appi.ajp.157.7.1141
M1  - Giovannini, M. G., Mutolo, D., Bianchi, L., Michelassi, A., & Pepeu, G. (1994). NMDA receptor antagonists decrease GABA outflow from the septum and increse acetylcholine outflow from the hippocampus: a microdialysis study. J Neurosci 14: 1358-1365.
M1  - Goff, D. C., & Coyle, J. T. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry, 158, 1367-1377. http://dx.doi.org/10.1176/appi.ajp.158.9.1367
M1  - Gold, P. E. (2004). Coordination of multiple memory systems. Neurobiol Learn Mem, 82, 230-242. http://dx.doi.org/10.1016/j.nlm.2004.07.003
M1  - Hasegawa, M., Kinoshita, M., Amano, M., Hasegawa, T., Kameyama, T., & Nabeshima, T. (1993). MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis. Neurosci Lett 150: 53-56.
M1  - Higgins, G. A., Enderlin, M., Fimbel, R., Haman, M., Grottick, A. J., Soriano, M., et al. (2002). Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesions or transient cerebral ischaemia. Eur J Neurosci, 15, 1827-1840. http://dx.doi.org/10.1046/j.1460-9568.2002.02018.x
M1  - Hutson, P. H., & Hogg, J. E. (1996). Effects of and interaction between antagonists for different sites on the NMDA receptor complex on hippocampal and striatal acetylcholine efflux in vivo. Eur J Pharmacol 295: 45-52.
M1  - Hyde, T. M., & Crook, J. M. (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 22: 53-63.
M1  - Jian-ping, J., Jian-min, J., Wei-dong, Z., Min, X., Chang-biao, C., Xin, Y., et al. (2004). Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Chin Med J 117: 1161-1164.
M1  - Kim, J. S., & Levin, E. D. (1996). Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: effects on spatial working memory in rats. Brain Res, 725, 231-240. http://dx.doi.org/10.1016/S0006-8993(96)00213-2
M1  - Kim, S. H., Price, M. T., Olney, J. W., & Farber, N. B. (1999). Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and 2-adrenergic agonists. Mol Psychiatry 4: 344-352.
M1  - Knopman, D., & Morris, J. C. (1997). An update on primary drug therapies for Alzheimer's disease. Arch Neurol 54: 1406-1409.1998-00262-006
M1  - Lenzi, A., Maltinti, E., Poggi, E., Fabrizio, L., & Coli, E. (2003). Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol, 26, 317-321. http://dx.doi.org/10.1097/00002826-200311000-00011
M1  - Luisada, P. V., & Brown, B. L. (1976). Clinical management of the phencyclidine psychosis. Clin Toxicol, 9, 539-545. http://dx.doi.org/10.3109/15563657608988155
M1  - Lydie, R., & Baghdoyan, H. A. (2002). Ketamine and MK-801 decreases acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep. Sleep 25: 617-622.2002-08039-003
M1  - Martin, L. F., Kem, W. R., & Freedman, R. (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology, 174, 54-64. http://dx.doi.org/10.1007/s00213-003-1750-1
M1  - Mesulam, M. M., & Geula, C. (1988). Acetylcholinestase-rich pyramidal neurons in the human neocortex and hippocampus: absence at birth, development during the life span, and dissolution in Alzheimer's disease. Ann Neurol 24: 765-773.
M1  - Moghaddam, B., & Jackson, M. E. (2003). Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003: 131-137.2004-00072-011
M1  - Newcomer, J. W., & Krystal, J. H. (2001). NMDA receptor regulation of memory and behavior in humans. Hippocampus, 11, 529-542. http://dx.doi.org/10.1002/hipo.1069
M1  - Ochoa, E. L. M., & Clark, E. (2004). Galantamine as an adjuvant treatment for negative symptoms in schizophrenia: a pilot study. Abstract Viewer/Itinerary Planner. Society for Neuroscience: Washington, DC. Program No. 351.8.
M1  - Ohno, M., Kishi, A., & Watanabe, S. (1996). Effect of cholinergic activation by physostigmine on working memory failure caused in rats by pharmacological manipulation of hippocampal glutamatergic and 5-HTergic neurotransmission. Neurosci Lett 217: 21-24.
M1  - Olney, J. W., & Farber, N. B. (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.1996-14564-001
M1  - Pepeu, G., & Giovannini, M. G. (2004). Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem, 11, 21-27. http://dx.doi.org/10.1101/lm.68104
M1  - Raskind, S. L., Peskind, E. R., Wessel, T., & Yuan, W. (2000). Galantamine in AD: a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 54: 2261-2268.2000-00016-009
M1  - Rogers, J. L., & Kesner, R. P. (2003). Cholinergic modulation of the hippocampus during encoding and retrieval. Neurobiol Learn Memory, 80, 332-342. http://dx.doi.org/10.1016/S1074-7427(03)00063-7
M1  - Rogers, J. L., & Kesner, R. P. (2004). Cholinergic modulation of the hippocampus during encoding and retrieval of tone/shock-induced fear conditioning. Learning Memory, 11, 102-107. http://dx.doi.org/10.1101/lm.64604
M1  - Rogers, S. L., Friedhoff, L. T., & the Donepezil Study Group. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized double-blind, placebo-controlled trial. Dementia 7: 293-303.
M1  - Rupniak, N. M., Tye, S. J., & Field, M. J. (1997). Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psycho-pharmacology, 131, 406-410. http://dx.doi.org/10.1007/s002130050310
M1  - Samochocki, M., Hoffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharm Exp Ther, 305, 1024-1036. http://dx.doi.org/10.1124/jpet.102.045773
M1  - Samochocki, M., Zerlin, M., Jostock, R., Kormelink, P. J. G., & Luyten, W. H. M. L. (2000). Galantamine is an allosterically potentiating ligand of the human 4 nAChR. Acta Neurol Scand 176: 68-73.
M1  - Schubert, M. H., Young, K. A., & Hicks, P. B. (2004). Cognitive improvement in schizophrenia and schizoaffective disorder by augmentation of risperidone with galantamine. Abstract Viewer/Itinerary Planner. Society for Neuroscience: Washington, DC. Program No. 351.10.
M1  - Schwarcz, R., Rassoulpour, A., Wu, H. Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001). Increased cortical kynurenate content in schizophrenia. Biol Psychiatry, 50, 521-530. http://dx.doi.org/10.1016/S0006-3223(01)01078-2
M1  - Shannon, H. E., Rasmussen, K., Bymaster, F. P., Hart, J. C., Peters, S. C., Swedberg, M. D. B., et al. (2000). Xanomeline, an M1/M4 preferring muscarinic receptor agonist, produces antipsychotic-like activitiy in rats and mice. Schizophrenia Res, 42, 249-259. http://dx.doi.org/10.1016/S0920-9964(99)00138-3
M1  - Stewart, M., & Fox, S. E. (1990). Do septal neurons pace the hippocampal theta rhythm? Trends Neurosci 13: 163-168.
M1  - Stryjer, R., Strous, R., Bar, F., Shaked, G., Shiloh, R., Rozencwaig, S., et al. (2004). Donepezil augmentation of colzaine monotherapy in schizophrenia patients: a double blind cross-over study. Hum Psychopharmacol, 5, 343-346. http://dx.doi.org/10.1002/hup.595
M1  - Stryjer, R., Strous, R. D., Bar, F., Werber, F., Shaked, G., Buhiri, Y., et al. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol, 26, 12-17. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Tugal, O., Yazici, K. M., Yagcioglu, A. E., & Gogus, A. (2004). A double blind, placebo controlled, cross over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int f Neuropsychopharmacol, 7, 117-123. http://dx.doi.org/10.1017/S1461145703004024
M1  - Walker, D. L., & Gold, P. E. (1992). Impairment of spontaneous alternation performance by an NMDA antagonist: attenuation with non-NMDA treatments. Behav Neural Biol, 58, 61-69. http://dx.doi.org/10.1016/0163-1047(92)90952-Z
M1  - Wang, T., & Tang, X. C. (1998). Reversal of scopolamine-induced deficits in radial arm maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349: 137-142.
M2  - http://dx.doi.org/10.1038/sj.npp.1300761
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2005-15279-002
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2005-15279-002 

13. 
TY  - ELEC
ID  - 2005-11019-005
T1  - Does Cholinergic Facilitation Enhance Cognitive Functions in Schizophrenia?
A1  - Kumari, Veena
A1  - Sharma, Tonmoy
A2  - Aasen, Acri, Addington, Adler, Adler, Aggleton, Arnt, Birks, Breese, Buchanan, Caroff, Clarke, Curzon, Damasio, Darvesh, Decker, Della Casa, Doody, Duncan, el-Mallakh, Ettinger, Ettinger, Evans, Everett, Faraday, Freedman, Freedman, Freedman, Friedman, Friedman, Friedman, George, Giacobini, Gold, Goldberg, Gray, Green, Green, Griffith, Harvey, Harvey, Hughes, Jaffe, Jann, Keefe, Keefe, Krall, Kumari, Kumari, Kumari, Kumari, Kumari, Kumari, Kumari, Kumari, Kumari, Lenzi, Levin, Levin, Levin, MacEwan, Maelicke, Mandel, Martin, McAlonan, Meltzer, Mesulam, Moller, Nahas, Nestor, Page, Polinsky, Potkin, Powchik, Rezvani, Risch, Rund, Sawaguchi, Saykin, Schrattenholz, Sharma, Sharma, Sharma, Sharma, Sharma, Spielewoy, Strauss, Stryjer, Stryjer, Swerdlow, Tariot, Terry, Terry, Tual, Velligan, Vennerica, Vitiello, Warburton, Watanabe, Weikert, Williams, Woodward, Zachariah
Y1  - 2005//
N2  - Individuals with schizophrenia show multifaceted cognitive impairment, which is found to predict the functional, outcome of this disorder more strongly than its negative or positive symptoms. This has led cognitive impairment now to become a prime target for pharmacological interventions in schizophrenia. Facilitation of central cholinergic activity, which is currently the main therapeutic approach to treat cognitive decline in Alzheimer's disease, has been suggested to form one of the several potential treatment strategies for cognitive improvement in schizophrenia. Exploration of the cognitive effects of acelylcholinesterase inhibitors such as donepezil, rivastigmine and galantamine in schizophrenia has only recently begun. Some but not all studies have shown acetylcholinesterase inhibitors to produce significant improvement in one or more cognitive functions in patients with schizophrenia or schizoaffective disorder. The data available so far on cognitive effects of acetylcholinesterase inhibitors in schizophrenia can be considered promising but unable to conclusively inform about their full potential because most of the published studies are limited by factors such as a lack of blinding of patients and raters, between-subject rather than within-subject designs, poor characterisation of cognitive impairment, limited exploration of cognitive effects and use of a single (and not necessarily effective) dose, all of which can influence study outcome. In addition, actions at nicotinic cholinergic receptions may be required since nicotine has also been found to produce improvements on measures of sensory gating, attention and working memory in schizophrenia patients. We emphasize the need for further empirical studies to determine full therapeutic potential of acetylcholinesterase inhibitors and nicotinic agonists in treating cognitive deficits in schizophrenia with a view to optimize treatment options for individual patients based on their cognitive profile. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Cholinergic Receptors
KW  - *Cognitive Ability
KW  - *Cognitive Impairment
KW  - *Drug Therapy
KW  - *Schizophrenia
M3  - Schizophrenia & Psychotic States [3213]
M1  - Clinical Psychopharmacology [3340]
JF  - Clinical Neuropsychiatry: Journal of Treatment Evaluation
VL  - 2
IS  - 2
SP  - 116
EP  - 122
CY  - Italy
PB  - Giovanni Fioriti Editore
PB  - Italy
SN  - 1724-4935
AD  - Kumari, Veena: Psychology - Institute of Psychiatry, PO78, De Crespigny Park, London, United Kingdom, SE5 8AF, v.kumari@iop.kcl.ac.uk
AD  - Kumari, Veena: v.kumari@iop.kcl.ac.uk
M1  - Aasen, I., Kumari, V., & Sharma, T. (in press). Effects of rivastigmine on attention in schizophrenia. Journal of Clinical Psychopharmacology.
M1  - Acri, J. B., Morse, D. E., Popke, E. J., & Grunberg, N. E. (1994). Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology, 1142, 369-274. http://dx.doi.org/10.1007/BF02244861
M1  - Addington, J., & Addington, D. (1999). Neurocognitive and social functioning in schizophrenia. Schizophrenia Bulletin 25, 1, 173-182.1999-10563-010
M1  - Adler, L. E., Hoffer, L. D., Wise, A., & Freedman, R. (1993). Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 150, 12, 1856-1861.1994-25605-001
M1  - Adler, L. E., Hoffer, L. J., Griffith, J., Waldo, M. C., & Freedman, R. (1992). Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biological Psychiatry, 327, 607-616. http://dx.doi.org/10.1016/0006-3223(92)90073-9
M1  - Aggleton, J. P., Keith, A. B., Rawlins, J. N., Hunt, P. R., & Sahgal, A. (1992). Removal of the hippocampus and transection of the fornix produce comparable deficits on delayed non-matching to position by rats. Behav Brain Research, 521, 61-71. http://dx.doi.org/10.1016/S0166-4328(05)80325-0
M1  - Arnt, J., & Skarsfeldt, T. (1998). Do novel antipsychotics have similar pharmacological characteristics? A review. Neuropsychopharmacology, 18, 63-101. http://dx.doi.org/10.1016/S0893-133X(97)00112-7
M1  - Birks, J., Grimley, E. J., Iakovidou, V., & Tsolaki, M. (2002). Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews (4), CD001191.
M1  - Breese, C. R., Marks, M. J., Logel, J., Adams, C. E., Sullivan, B., Collins, A. C., & Leonard, S. (1997). Effect of smoking history on [3H]nicotine binding in human postmortem brain. Journal of Pharmacology and Experimental Therapeutics 282, 7-13.
M1  - Buchanan, W., Summerfelt, A., Tek, C., & Gold, J. (2003). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Caroff, S. N., Campbell, E. C., Havey, J., Sullivan, K. A., Mann, S. C., & Gallop, R. (2001). Treatment of tardive dyskinesia with donepezil: a pilot study. Journal of Clinical Psychiatry 62, 10, 772-775.2001-05581-003
M1  - Clarke, P. B. (1993). Nicotinic receptors in mammalian brain: localization and relation to cholinergic innervation. Progress in Brain Research 98, 77-83.
M1  - Curzon, P., Kim, D. J., & Decker, M. W. (1994). Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Biochemistry and Behaviour, 494, 877-882. http://dx.doi.org/10.1016/0091-3057(94)90237-2
M1  - Damasio, A. R., Graff-Radford, N. R., Eslinger, P. J., Eslinger, P. J., Damasio, H., & Kassell, N. (1985). Amnesia following basal forebrain lesions. Archives of Neurology 42, 263-2711986-06738-001
M1  - Darvesh, S., MacKnight, C., & Rockwood, K. (2001). Butyrylcholinesterase and cognitive function. International Psychogeriatrics, 134, 461-464. http://dx.doi.org/10.1017/S1041610201007876
M1  - Decker, M. W., & McGaugh, J. L. (1991). The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 2, 151-168.
M1  - Della Casa, V., Hofer, I., Weiner, I., & Feldon, J. (1998). The effects of smoking on acoustic prepulse inhibition in healthy men and women. Psychopharmacology, 1374, 362-368. http://dx.doi.org/10.1007/s002130050631
M1  - Doody, R. S. (2003). Current treatments for Alzheimer's disease: cholinesterase inhibitors. Journal of Clinical Psychiatry 64, suppl 9, 11-17.2003-08063-003
M1  - Duncan, E., Madonick, S., Chakravorty, S., Parwani, A., Szilagyi, S., Efferen, T., Gonzenbach, S., Angrist, B., & Rotrosen, I. (2001). Effects of smoking on acoustic startle and prepulse inhibition in humans. Psychopharmacology, 1562-3, 266-272. http://dx.doi.org/10.1007/s002130100719
M1  - el-Mallakh, R. S., Kirch, D. G., Shelton, R., Fan, K. J., Pezeshkpour, G., Kanhouwa, S., Wyatt, R. J., & Kleinman, J. E. (1991). The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. Journal of Neuropsychiatry and Clinical Neuroscience 3, 4, 383-386.1992-12743-001
M1  - Ettinger, U., Kumari, V., Zachariah, E., Galea, A., Crawford, T. J., Corr, P. J., Taylor, D., Das, M., & Sharma, T. (2003). Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology 28, 2199-2208.2003-10680-015
M1  - Ettinger, U., & Kumari, V. (2003). Pharmacological studies of smooth pursuit and antisaccade eye movements in schizophrenia: Current status and directions for future research. Current Neuropharmacology, 1, 285-300. http://dx.doi.org/10.2174/1570159033477017
M1  - Evans, J. D., Heaton, R. K., Paulsen, J. S., Palmer, B. W., Patterson, T., & Jeste, D. V. (2003). The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biological Psychiatry, 535, 422-430. http://dx.doi.org/10.1016/S0006-3223(02)01476-2
M1  - Everett, J., Lavoie, K., Gagnon, J. F., & Gosselin, N. (2001). Performance of patients with schizophrenia on the Wisconsin Card Sorting Test (WCST). Journal of Psychiatry and Neuroscience 26, 2, 123-130.2001-00768-004
M1  - Faraday, M. M., O'Donoghue, V. A., & Grunberg, M. E. (1999). Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. Pharmacology Biochemistry and Behaviour, 22, 273-284. http://dx.doi.org/10.1016/S0091-3057(98)00159-2
M1  - Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M. C., Reimherr, F., Wender, P., Yaw, J., Young, D. A., Breese, C. R., Adams, C., Patterson, D., Adler, L. E., Kruglyak, L., Leonard, S., & Byerley, W. (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences USA 94, 587-592.
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Freedman, R., Leonard, S., Gault, J. M., Hopkins, J., Cloninger, C. R., Kaufmann, C. A., Tsuang, M. T., Faraone, S. V., Malaspina, D., Svrakic, D. M., Sanders, A., & Gejman, P. (2001). Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the a7-nicotinic acetylcholine receptor subunit gene (CHRNA7). American Journal of Medical Genetics 105, 20-22.
M1  - Friedman, J. I. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology, 174, 45-53. http://dx.doi.org/10.1007/s00213-004-1794-x
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parrella, M., & Davis, K. L. (2002). A double-bund placebo-controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Friedman, J. I., Temporini, H., & Davis, K. L. (1999). Pharmacological strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry, 45, 1-16. http://dx.doi.org/10.1016/S0006-3223(98)00287-X
M1  - George, T. P., Termine, A., Dudas, M. M., Seyal, A. A., Ludhi, T., Bannon, K., Vessicchio, J. C., Madonick, S. H., & Sacco, K. A. (2003). Differential modulation of the acoustic startle response by cigarette smoking in schizophrenics versus healthy controls. American College of Neuropsychopharmacology, San Juan, Puerto Rico.
M1  - Giacobini, E. (2003). Cholinergic function and Alzheimer's disease. International Journal of Geriatric Psychiatry, 18, S1http://dx.doi.org/10.1002/gps.935
M1  - Gold, J. M., Hermann, B. P., Randolph, C., Wyler, A. R., Goldberg, T. E., & Weinberger, D. R. (1994). Schizophrenia and temporal lobe epilepsy: a neuropsychological analysis. Archives of General Psychiatry 51, 265-272.1994-33548-001
M1  - Goldberg, T. E., & Gold, J. M. (1995). Neurocognitive deficits in Schizophrenia. In: Hirsh SR, Weinberger D (eds) Schizophrenia. Blackwell, Oxford.
M1  - Gray, J. A., Mitchell, S. N., Joseph, M. H., Grigoryan, G. A., Dawe, S., & Hodges, H. (1994). Neurochemical mechanisms mediating the behavioural and cognitive effects of nicotine. Drug Development Research (Special Issue: Therapeutics, Part 1) 31, 3-17.
M1  - Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321-3301996-00417-002
M1  - Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits in functional outcome in schizophrenia: are we measuring the "right stuff'? Schizophrenia Bulletin 26, 1, 119-136.2000-08139-007
M1  - Griffith, J. M., O'Neill, J. E., Petty, F., Garver, D., Young, D., & Freedman, R. (1998). Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biological Psychiatry, 442, 98-106. http://dx.doi.org/10.1016/S0006-3223(97)00362-4
M1  - Harvey, P. D., Green, M. F., Keefe, R. S., & Velligan, D. I. (2004). Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry 65, 3, 361-372.2004-13151-012
M1  - Harvey, P. D., & Keefe, R. S. E. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158, 176-184. http://dx.doi.org/10.1176/appi.ajp.158.2.176
M1  - Hughes, C., Kumari, V., Soni, W., Binneman, B., Drozd, S., O'Neil, S., Mathew, V., & Sharma, T. (2003). Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophrenia Research, 59, 137-146. http://dx.doi.org/10.1016/S0920-9964(01)00393-0
M1  - Jaffe, J. H. (1985). Drug addiction and drugs abuse. In, Oilman AC, Goodman LS, Rail TW, Murad F (Eds), The pharamacological basis of therapeutics. Macmillan, New York.
M1  - Jann, M. W. (2000). Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20, 1, 1-12.
M1  - Keefe, R. S., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., Tollefson, G. D., Sanger, T. M., & Lieberman, J. A. (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry, 1616, 985-995. http://dx.doi.org/10.1176/appi.ajp.161.6.985
M1  - Keefe, R. S., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 25, 201-222.1999-05588-003
M1  - Krall, W. J., Sramek, J. J., & Cutler, N. R. (1999). Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease. The Annals of Pharmacotherapy 33, 441-50
M1  - Kumari, V., Aasen, I., & Sharma, T. (2004). Neural correlates of rivastigmine treatment in schizophrenia: an fMRI study. Schizophrenia Research, 671s, 213http://dx.doi.org/10.1016/S0920-9964(03)00047-1
M1  - Kumari, V., Antonova, E., Zachariah, E., Galea, A., Aasen, I., Ettinger, U., Mitterschiffthaler, M. T., & Sharma, T. (in press). Structural brain correlates of prepulse inhibition of the acoustic startle response in healthy humans. NeuroImage.
M1  - Kumari, V., Checkley, S. A., & Gray, J. A. (1996). Effect of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers. Psychopharmacology, 1281, 54-60. http://dx.doi.org/10.1007/s002130050109
M1  - Kumari, V., Cotter, P. A., Checkley, S. A., & Gray, J. A. (1997). Effect of acute subcutaneous nicotine on prepulse inhibition of the acoustic startle reflex in healthy male non-smokers. Psychopharmacology, 1324, 389-395. http://dx.doi.org/10.1007/s002130050360
M1  - Kumari, V., Gray, J. A., Geyer, M. A., Mitterschiffthaler, M., Ffytche, D., Vythelingum, G. N., Soni, W., Simmons, A., Williams, S. C. R., & Sharma, T. (2003). Neural correlates of prepulse inhibition in normal and schizophrenic subjects: A functional MRI Study. Psychiatry Research: Neuroimaging, 122, 99-113. http://dx.doi.org/10.1016/S0925-4927(02)00123-3
M1  - Kumari, V., & Postma, P. (in press). Nicotine use in schizophrenia: the self-medication hypotheses. Neuroscience and Biobehavioural Reviews.
M1  - Kumari, V., Soni, W., & Sharma, T. (2001). Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Human Psychopharmacology: Clinical & Experimental, 16, 321-326. http://dx.doi.org/10.1002/hup.286
M1  - Kumari, V., Zachariah, E., Galea, A., Jones, H., Das, M., Mehrotra, R., Taylor, D., & Sharma, T. (2003). Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study. Journal of Psychopharmacology, 17, 89-95. http://dx.doi.org/10.1177/0269881103017001710
M1  - Kumari, V., Zachariah, E., Mehrotra, R., Taylor, D., & Sharma, T. (2001). Effects of procyclidine on prepulse inhibition of the acoustic startle response in healthy human volunteers. Psychopharmacology, 154, 221-229. http://dx.doi.org/10.1007/s002130000656
M1  - Lenzi, A., Maltinti, E., Poggi, E., Fabrizio, L., & Coli, E. (2003). Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clinical Neuropharmacology, 266, 317-321. http://dx.doi.org/10.1097/00002826-200311000-00011
M1  - Levin, E. D., & Rezvani, A. H. (2000). Development of nicotinic drug therapy for cognitive disorders. European Journal of Pharmacology 393, 141-146.
M1  - Levin, E. D., & Rezvani, A. H. (2002). Nicotinic treatment for cognitive dysfunction. Current Drug Targets: CNS and Neurological Disorders 1, 4, 423-31
M1  - Levin, E. D., & Simon, B. B. (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology, 138, 217-230. http://dx.doi.org/10.1007/s002130050667
M1  - MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica 104, 469-472.2002-15544-008
M1  - Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001). Allosteric sensitization of nicotinic receptors by galanthamine, a new treatment strategy for Alzheimer's disease. Biological Psychiatry, 49, 279-288. http://dx.doi.org/10.1016/S0006-3223(00)01109-4
M1  - Mandel, R. J., Chen, A. D., Connor, D. J., & Thal, L. J. (1989). Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. Journal of Pharmacology and Experimental Therapeutics 251, 2, 612-619.
M1  - Martin, L. F., Kem, W. R., & Freedman, R. (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology, 741, 54-64. http://dx.doi.org/10.1007/s00213-003-1750-1
M1  - McAlonan, G. M., Dawson, G. R., Wilkinson, L. O., Robbins, T. W., & Everitt, B. J. (1995). The effects of AMPA-induced lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on spatial delayed non-matching to sample and spatial learning in the water maze. European Journal of Neuroscience, 5, 1034-1049. http://dx.doi.org/10.1111/j.1460-9568.1995.tb01091.x
M1  - Meltzer, H. Y., & McGurk, S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 2, 233-255.1999-05588-005
M1  - Mesulam, M., Guillozet, A., Shaw, P., & Quinn, B. (2002). Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiology of Disease 9, 1, 88-93.
M1  - Moller, H.-J. (2000). Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodologcal issues and clinical consequences. World Journal of Biological Psychiatry 1, 75-91.
M1  - Nahas, Z., George, M. S., Homer, M. D., Markowitz, J. S., Li, X., Lorberbaum, J. P., Owens, S. D., McGurk, S., DeVane, L., & Risen, S. C. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274-282. http://dx.doi.org/10.1076/neur.9.3.274.15563
M1  - Nestor, P. G., Faux, S. F., McCarley, R. W., Shenton, M. E., & Sands, S. F. (1990). Measurement of visual sustained attention in schizophrenia using signal detection analysis and a newly developed computerized CPT task. Schizophrenia Research, 35, 329-32. http://dx.doi.org/10.1016/0920-9964(90)90018-3
M1  - Page, K. J., Everitt, B. J., Robbins, T. W., Marston, H. M., & Wilkinson, L. S. (1991). Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA-and ibotenic acid-induced excitotoxic lesions of the basal fore-brain in rats: differential dependence on cholinergic neuronal loss. Neuroscience 43, 2-3, 457-472.
M1  - Polinsky, R. J. (1998). Clinical pharmacology of rivastigmine: anew-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical Therapeutics, 20, 634-647. http://dx.doi.org/10.1016/S0149-2918(98)80127-6
M1  - Potkin, S. G., Anand, R., Fleming, K., Alva, G., Keator, D., Carreon, D., Messina, J., Wu, J. C., Hartman, R., & Fallon, J. H. (2001). Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. International Journal of Neuropsychopharmacology, 43, 223-230. http://dx.doi.org/10.1017/S1461145701002528
M1  - Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, D. P., Perl, D. P., Harvey, P. D., & Davis, K. L. (1998). Postmortem studies in schizophrenia. Schizophrenia Bulletin 24, 3, 325-341.1998-10644-002
M1  - Rezvani, A. H., & Levin, E. D. (2001). Cognitive effects of nicotine. Biological Psychiatry, 49, 258-267. http://dx.doi.org/10.1016/S0006-3223(00)01094-5
M1  - Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., Molloy, M., Gilliard, C., Christie, S., Markowitz, J. S., DeVane, C. L., Mintzer, J., & George, M. S. (2001). A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase, 72, 105-110. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rund, B. R. (1998). A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophrenia Bulletin 24, 425-435.1998-10644-009
M1  - Sawaguchi, T., & Goldman-Rakic, P. S. (1994). The role of Dl-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. Journal of Neurophysiology 71, 515-528.1994-32855-001
M1  - Saykin, A. J., Shtasel, D. L., Gur, R. E., Rester, D. B., Mozley, L. H., Stafiniak, P., & Gur, R. C. (1994). Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 51, 2, 124-131.1994-25655-001
M1  - Schrattenholz, A., Pereira, E. F. R., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996). Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands. Molecular Pharmacology 46, 1-6.
M1  - Sharma, T., & Antonova, L. (2003). Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatric Clinic of North America, 261, 25-40. http://dx.doi.org/10.1016/S0193-953X(02)00084-9
M1  - Sharma, T., & Harvey, P. (2000). Cognitive enhancement as a treatment strategy in schizophrenia. In: Sharma T, Harvey P (Eds), Cognition in schizophrenia: Impairments, importance and treatment strategies. Oxford University Press, Oxford, UK.
M1  - Sharma, T., Hughes, C., & Kumari, V. (2004). A placebo-controlled double-blind investigation of cognitive effects of rivastigmine in schizophrenia. Schizophrenia Research 67, 1s, 208.
M1  - Sharma, T., Hughes, C., Soni, W., & Kumari, V. (2003). Cognitive effects of olanzapine and clozapine treatment hi chronic schizophrenia. Psychopharmacology, 169, 398-403. http://dx.doi.org/10.1007/s00213-003-1506-y
M1  - Sharma, T. (1999). Cognitive effects of conventional and atypical antipsychotics in schizophrenia. British Journal of Psychiatry, 38, S44-51. http://dx.doi.org/10.1192/bjp.174.5.395
M1  - Spielewoy, C., & Markou, A. (2004). Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: relevance to smoking in schizophrenia patients. Behaviour Genetics, 343, 343-354. http://dx.doi.org/10.1023/B:BEGE.0000017878.75206.fd
M1  - Strauss, M. E., Reynolds, K. S., Jayaram, G., & Tune, L. E. (1990). Effects of anticholinergic medication on memory in schizophrenia. Schizophrenia Research, 3, 127-129. http://dx.doi.org/10.1016/0920-9964(90)90045-9
M1  - Stryjer, R., Bar, F., Strous, R. D., Baruch, Y., & Rabey, J. M. (2002). Donepezil management of schizophrenia with associated dementia. Journal of Clinical Psychopharmacology, 22, 226-229. http://dx.doi.org/10.1097/00004714-200204000-00021
M1  - Stryjer, R., Strous, R. D., Bar, F., Werber, E., Shaked, G., Buhiri, Y., Kotler, M., Weizman, A., & Rabey, J. M. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12-17. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Swerdlow, N. R., Geyer, M. A., & Braff, D. L. (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology, 1562-3, 194-215. http://dx.doi.org/10.1007/s002130100799
M1  - Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galanthamine USA-10 Study Group. (2000). A 5-month, randomized, placebo-controlled trial of galanthamine in AD. Neurology 54, 2269-2276.2000-00016-010
M1  - Terry, A. V., Jr.., & Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. Journal of Pharmacology and Experimental Therapeutics, 3063, 821-827. http://dx.doi.org/10.1124/jpet.102.041616
M1  - Terry, A. V., Buccafusco, J. J., & Jackson, W. J. (1993). Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacology Biochemistry., & Behaviour, 45, 925-929. http://dx.doi.org/10.1016/0091-3057(93)90141-F
M1  - Tual, N., Yazici, K. M., Anil Yagcioglu, A. E., & Gogus, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 72, 117-123. http://dx.doi.org/10.1017/S1461145703004024
M1  - Velligan, D. I., Mahurin, R. K., Diamond, P. L., Hazleton, B. C., Stacey, L. E., & Miller, A. L. (1997). The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research, 25, 21-31. http://dx.doi.org/10.1016/S0920-9964(97)00010-8
M1  - Vennerica, A., Shanks, M. F., Staff, R. T., Pestell, S. J., Forbes, K. E., Gemmell, H. G., & Murray, A. D. (2002). Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport, 131, 83-87. http://dx.doi.org/10.1097/00001756-200201210-00020
M1  - Vitiello, B., Martin, A., Hill, J., Mack, C., Molchan, S., Martinez, R., Murphy, D. L., & Sunderland, T. (1997). Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology, 16, 15-24. http://dx.doi.org/10.1016/S0893-133X(96)00134-0
M1  - Warburton, D. M. (1990). Nicotine as a cognitive enhancer. In: Yamashita I (Ed), Clinical Neuropharmacology. Raven Press, New York.
M1  - Watanabe, S., Nishikawa, T., Takashima, M., & Toru, M. (1983). Increased muscarinic cholinergic receptors in prefrontal cortices of mediated schizophrenia. Life Sciences 33, 2187-2196.
M1  - Weikert, T. W., & Goldberg, T. E. (2000). The course of cognitive impairment in patients with schizophrenia. In: Sharma T, Harvey P (Eds), Cognition in schizophrenia: Impairments, importance and treatment strategies. Oxford University Press, Oxford, UK.
M1  - Williams, B. R., Nazarians, A., & Gill, M. A. (2003). A review of rivastigmine: a reversible cholinesterase inhibitor. Clinical Therapeutics, 256, 1634-1653. http://dx.doi.org/10.1016/S0149-2918(03)80160-1
M1  - Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia, Neuropsychopharmacology, 23, 1-16. http://dx.doi.org/10.1017/S146114570500516X
M1  - Zachariah, E., Kumari, V., Galea, A., Das, M., Mehrotra, R., Taylor, D., Ruprah, M., & Sharma, T. (2002). Effects of oral procyclidine administration on cognitive functions in healthy subjects: Implications for schizophrenia, Journal of Clinical Psychopharmacology 22, 2, 224-226. http://dx.doi.org/10.1097/00004714-200204000-00020
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2005-11019-005
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2005-11019-005 

14. 
TY  - ELEC
ID  - 2004-16942-007
T1  - Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
T2  - Special Issue: MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia.
T3  - Psychopharmacologia
A1  - Friedman, Joseph I
A2  - Adler, Aggleton, Aigner, Allen, Anagnostaras, Andersen, Arendash, Bartus, Benwell, Blozovski, Bodick, Bolden, Breese, Briggs, Brito, Buchanan, Bymaster, Callahan, Caulfield, Crook, Crook, Davidson, Davis, Dean, Dean, Dunnett, Eichenbaum, El-Mallack, Fadda, Fenster, Flynn, Frazier, Freedman, Freedman, Friedman, Gerber, Goldberg, Hagan, Harvey, Hughes, Ichikawa, Iga, Knapp, Levey, Luntz-Leybman, Maelicke, Maelicke, Mandel, McAlonan, McEvoy, Meek, Meltzer, Messer, Muir, Nahas, Nielsen, Olincy, Page, Perry, Polinsky, Powchik, Raedler, Reitstetter, Riley, Robbins, Rogers, Rogers, Rosler, Rupniak, Samochocki, Santucci, Saykin, Schotte, Schrattenholz, Schwarz, Shannon, Sitaram, Smith, Stanhope, Stevens, Stryjer, Tamlyn, Tariot, Tecle, Thomsen, Wanibuchi, Watanabe, Watkins, Wei, Wienrich, Winkler, Wood, Woolf, Zarei
Y1  - 2004//
N2  - Rationale: Alterations in the central cholinergic system of patients with schizophrenia such as reduced numbers of muscarinic and nicotinic receptors in the cortex and hippocampus may contribute to the cognitive impairment of schizophrenia. Therefore, pharmacological treatments that enhance central cholinergic function may be useful as cognitive enhancers in schizophrenia. Methods: Searches were conducted for articles which investigated alterations of central cholinergic systems in patients with schizophrenia. Additional searches were conducted for animal and human trials of potential cognitive enhancing compounds that target the cholinergic system and any preliminary trials conducted with schizophrenic patients. Results: Currently available treatments which are potentially suitable for this purpose include acetylcholinesterase inhibitors, muscarinic agonists, nicotinic agonists, and allosteric potentiators of nicotinic receptor function. Although some open label studies demonstrate modest cognitive improvements of schizophrenic patients treated with donepezil, data from a blinded, placebo controlled study demonstrate no effect. Data from a controlled trial of galantamine, a combined acetylcholinesterase inhibitor and allosteric potentiator of the nicotinic receptor, indicates that this may be an effective alternative. In addition, some preclinical data indicates that selective MI muscarinic agonists under development may have potential as cognitive enhancers and antipsychotic treatments for schizophrenic patients. Conclusions: A cholinergic approach to ameliorating the cognitive dysfunction of schizophrenia appears viable. There is some preliminary data to support the efficacy of combined acetylcholinesterase inhibitors and allosteric potentiators of the nicotinic receptor, whereas future trials are awaited for more specific muscarinic agonists currently under development. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Cholinergic Receptors
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Impairment
KW  - *Drug Therapy
KW  - *Schizophrenia
KW  - Cholinergic Drugs
KW  - Pharmacology
M3  - Clinical Psychopharmacology [3340]
JF  - Psychopharmacology
VL  - 174
IS  - 1
SP  - 45
EP  - 53
CY  - Germany
PB  - Springer
PB  - Germany
SN  - 0033-3158
AD  - Friedman, Joseph I.: Department of Psychiatry, The Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230, New York, NY, US, 10029, jfriedmanI@rcn.com
AD  - Friedman, Joseph I.: jfriedman1@rcn.com
M1  - Adler, L. E., Hoffer, L. D., Wiser, A., & Freedman, R. (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-18611994-25605-001
M1  - Aggleton, J., Keith, A., Rawlins, J., Hunt, P., & Sahgal, A. (1992). Removal of the hippocampus and transection of the fornix produce comparable deficits on delyed non-match to position by rats. Behav Brain Res, 52, 61-71. http://dx.doi.org/10.1016/S0166-4328(05)80325-0
M1  - Aigner, T., & Mishkin, M. (1986). The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol, 45, 81-87. http://dx.doi.org/10.1016/S0163-1047(86)80008-5
M1  - Allen, T., McEvoy, J. P., Keefe, R., Levin, E., & Wilson, W. (2003) Galantamine as an adjunctive therapy in the treatment of schizophrenia. Presented at 11th Congress of the International Psychogeriatric Association (IPA), Chicago, Ill., August 17-22
M1  - Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., & Silva, A. J. (2003). Selective cognitive dysfunction in acetylcholine MI muscarinic receptor mutant mice. Nat Neurosci, 6, 51-58. http://dx.doi.org/10.1038/nn992
M1  - Andersen, M. B., Fink-Jensen, A., Peacock, L., Gerlach, J., Bymaster, F., Lundbaek, J. A., & Werge, T. (2003) The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28: 1168-11752003-05485-018
M1  - Arendash, G. W., Sengstock, G. J., Sanberg, P. R., & Kem, W. R. (1995). Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res, 674, 252-259. http://dx.doi.org/10.1016/0006-8993(94)01449-R
M1  - Bartus, R., & Uehara, Y. (1979). Physostigmine and recent memory: effects in young and aged nonhuman primates. Science, 206, 1085-1087. http://dx.doi.org/10.1126/science.227061
M1  - Benwell, M. E., Balfour, D. J., & Birrell, C. E. (1995) Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol 114: 454-460
M1  - Blozovski, D., Cudennec, A., & Garrigou, D. (1977). Deficits in passive avoidance learning following atropine in the developing rat. Psychopharmacology, 54, 139-144. http://dx.doi.org/10.1007/BF00426769
M1  - Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z., & Paul, S. M. (1997) Effects of xanomaline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54: 465-473
M1  - Bolden, C., Cusack, B., & Richelson, E. (1992) Antagonism by anti-muscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260: 576-5801992-26362-001
M1  - Breese, C. R., Lee, M. J., Adams, C. E., Sullivan, B., Logel, J., Gillen, K. M., Marks, M. J., Collins, A. C., & Leonard, S. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351-364. http://dx.doi.org/10.1016/S0893-133X(00)00121-4
M1  - Briggs, C. A., Anderson, D. J., Brioni, J. D., Buccafusco, J. J., Buckley, M. J., Campbell, J. E., Decker, M. W., Donnelly-Roberts, D., Elliott, R. L., Gopalakrishnan, M., Holladay, M. W., Hui, Y. H., Jackson, W. J., Kim, D. J., Marsh, K. C., O'Neill, A., Prendergast, M. A., Ryther, K. B., Sullivan, J. P., & Arneric, S. P. (1997) Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57: 231-241
M1  - Brito, G., Davis, B., Stopp, L., & Stanton, M. (1983) Memory and the septohippocampal cholinergic system in the rat. Psychopharmacology 81: 315-320
M1  - Buchanan, R. W., Summerfelt, A., Tek, C., & Gold, J. (2003). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res, 59, 29-33. http://dx.doi.org/10.1016/S0920-9964(01)00387-5
M1  - Bymaster, F. P., Wong, D. T., Mitch, C. H., Ward, J. S., Calligaro, D. O., Schoepp, D. D., Shannon, H. E., Sheardown, M. J., Olesen, P. H., Suzdak, P. D., et al. (1994). Neurochemical effects of the M1 muscarinic agonist xanomeline. J Pharmacol Exp Ther 269: 282-289
M1  - Callahan, M., Kinsora, J., Harbaugh, R., Reeder, T., & Davis, R. (1993). Continuous icv infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging, 14, 147-151. http://dx.doi.org/10.1016/0197-4580(93)90090-X
M1  - Caulfield, M. P. Muscarinic receptors-characterization, coupling and function (1993). Pharmacol Ther 58: 319-379
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry, 48, 381-388. http://dx.doi.org/10.1016/S0006-3223(00)00918-5
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2001). Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry, 158, 918-925. http://dx.doi.org/10.1176/appi.ajp.158.987.918
M1  - Davidson, M., Harvey, P. D., Welsh, K. A., Powchik, P., & Putnam KM<Mohs, R. C. (1996) Cognitive functioning in late-life schizophrenia: A comparison of elderly schizophrenic patients with Alzheimer's disease. Am J Psychiatry 153: 1274-12791996-00484-004
M1  - Davis, K. L., Mohs, R., Tinklenberg, J., Pfefferbaum, A., Hollister, L., & Kopell, B. (1978). Physostigmine: improvement of long-term memory in normal humans. Science, 201, 272-274. http://dx.doi.org/10.1126/science.351807
M1  - Dean, B., Crook, J. M., Opeskin, K., Hill, C., Keks, N., & Copolov, D. L. (1996) The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1: 54-58
M1  - Dean, B., McLeod, M., Keriakous, D., McKenzie, J., & Scarr, E. (2002). Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry, 7, 1083-1091. http://dx.doi.org/10.1038/sj.mp.4001199
M1  - Dunnett, S. (1985). Comparative effects of cholinergic drugs and lesions of the nucleus basalis or fimbria-fornix on delayed-matching in rats. Psychopharmacology, 87, 357-363. http://dx.doi.org/10.1007/BF00432721
M1  - Eichenbaum, H., Otto, T., & Cohen, N. (1994) Two functional components of the hippocampal memory system. Behav Brain Sci 17: 449-5181995-16378-001
M1  - El-Mallack, R., Kirch, D., Shelton, R., Fan, K., Pezeshkpour, G., Kanhouwa, S., et al. (1991) The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatr Clin Neurosci 3: 383-386
M1  - Fadda, F., Melis, F., & Stancampiano, R. (1996) Increased hippocampal acetylcholine release during a working memory task. Eur J Pharmacol 307: R1-R2
M1  - Fenster, C. P., Whitworth, T. L., Sheffield, E. B., Quick, M. W., & Lester, R. A. (1999) Upregulation of Surgace alpha4beta2 nicotine receptors in initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 19: 4804-48181999-05650-001
M1  - Flynn, D. D., Ferrari-DiLeo, G., Mash, D. C., & Levey, A. I. (1995) Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64: 1888-1891
M1  - Frazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998) Acetylcholine activates an -bungaro-toxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18: 1187-1195
M1  - Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M. C., Reimherr, F., Wender, P., Yaw, J., Young, D. A., Breese, C. R., Adams, C., Patterson, D., Adler, L. E., Kruglyak, L., Leonard, S., & Byerley, W. (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci 94: 587-592
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parrella, M., & Davis, K. L. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Gerber, D. J., Sotnikova, T. D., Gainetdinov, R. R., Huang, S. Y., Caron, M. G., & Tonegawa, S. (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 98: 15312-15317
M1  - Goldberg, T., Weinberger, D., Pliskin, N., Berman, K., & Podd, M. (1989). Recall memory deficit in schizophrenia: a possible manifestation of prefrontal dysfunction. Schizophr Res, 2, 251-257. http://dx.doi.org/10.1016/0920-9964(89)90001-7
M1  - Hagan, J. J., Jansen, J. H., & Broekkamp, C. L. (1987) Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine. Psycho-pharmacology 93: 470-476
M1  - Harvey, P. D., & Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry, 158, 176-184. http://dx.doi.org/10.1176/appi.ajp.158.2.176
M1  - Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dahlgren, L. A. (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993-9971987-01309-001
M1  - Ichikawa, J., Dai, J., O'Laughlin, A., Fowler, W. L., & Meltzer, H. Y. (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology, 26, 325-339. http://dx.doi.org/10.1016/S0893-133X(01)00312-8
M1  - Iga, Y., Arisawa, H., Ogane, N., Saito, Y., Tomizuka, T., Nakagawa-Yagi, Y., Masunaga, H., Yasuda, H., & Miyata, N. (1998) (+)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 78: 373-380
M1  - Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., & Gracon, S. I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA, 271, 985-991. http://dx.doi.org/10.1001/jama.271.13.985
M1  - Levey, A. I., Kitt, C. A., Simonds, W. F., Price, D. L., & Brann, M. R. (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11: 3218-3226
M1  - Luntz-Leybman, V., Bickford, P. C., & Freedman, R. (1992). Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res, 587, 130-136. http://dx.doi.org/10.1016/0006-8993(92)91437-J
M1  - Maelicke, A., & Albuquerque, E. X. (1996) New approach to drug therapy in Alzheimer's disease. Drug Discovery Today 1: 53-59
M1  - Maelicke, A., Schrattenholz, A., Storch, A., Schroder, B., Gutrod, O., Methfessel, C., Weber, K. H., Pereira, E. E., Alkondon, M., & Albuquerque, E. X. (1995) Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. J Recept Signal Transduct Res 15: 333-353
M1  - Mandel, R., Chen, A., Connor, D., & Thal, L. (1989) Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther 251: 612-619
M1  - McAlonan, G., Wilkinson, L., Robbins, T., & Everitt, B. (1995). The effects of AMPA-induced lesions of the septohippocampal cholinergic projection on aversive conditioning to explicit and contextual cues and spatial learning in the water maze. Eur J Neurosci, 7, 281-292. http://dx.doi.org/10.1111/j.1460-9568.1995.tb01064.x
M1  - McEvoy et al. (2003)
M1  - Meek, W., Chuch, R., Wenk, G., & Olton, D. (1987) Nucleus basalis magnocellularis and medial septal area lesions differentially impair temporal memory. J Neurosci 7: 3505-3511
M1  - Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246
M1  - Messer, W. S., Jr.., Rajeswaran, W. G., Cao, Y., Zhang, H. J., el-Assadi, A. A., Dockery, C., Liske, J., O'Brien, J., Williams, F. E., Huang, X. P., Wroblewski, M. E., Nagy, P. I., & Peseckis, S. M. (2000) Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Pharm Acta Helv 74: 135-140
M1  - Muir, J., Dunnett, S., Robbins, T., & Everitt, B. (1992) Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal cortical lesions and intracortical grafts on a multiple choice serial reaction time task. Exp Brain Res 89: 611-622
M1  - Nahas, Z., George, M. S., Horner, M. D., Markowitz, J. S., Li, X., Lorber-baum, J. P., Owens, S. D., McGurk, S., De Vane, L., & Risch, S. C. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase, 9, 274-282. http://dx.doi.org/10.1076/neur.9.3.274.15563
M1  - Nielsen, J., Mena, A., Williams, I., Nocerini, M., & Liston, D. (1989) Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacri-dine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 173: 53-64
M1  - Olincy, A., Ross, R. G., Young, D. A., Roath, M., & Freedman, R. (1998). Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology, 18, 175-185. http://dx.doi.org/10.1016/S0893-133X(97)00095-X
M1  - Page, K., Everitt, B., Robbins, T., Marston, H., & Wilkinson, L. (1991) Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: diffrential dependence on cholinergic neuronal loss. Neuroscience 43: 457-472
M1  - Perry, K. W., Nisenbaum, L. K., George, C. A., Shannon, H. E., Felder, C. C., & Bymaster, F. P. (2001) The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 49: 716-725
M1  - Polinsky, R. J. (1998). Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther, 20, 634-647. http://dx.doi.org/10.1016/S0149-2918(98)80127-6
M1  - Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, D. P., Perl, D. P., Harvey, P. D., & Davis, K. L. (1998) Postmortem studies in schizophrenia. Schizophr Bull 24: 325-3411998-10644-002
M1  - Raedler, T. J., Knable, M. B., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K. S., Egan, M. F., Coppola, R., & Weinberger, D. R. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry, 160, 118-127. http://dx.doi.org/10.1176/appi.ajp.160.1.118
M1  - Reitstetter, R., Lukas, R. J., & Gruener, R. (1999) Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther 289: 656-660
M1  - Riley, B. P., Makoff, A. M., Mogudi-Carter, M., Jenkins, T. J., Williamson, R., Collier, D. A., & Murray, R. M. (2000) High marker-density analyses of the 7-nicotine cholinergic receptor subunit (CHRNA7) gene region on chromosome 15q13-q14 and 5' RACE cloning of fragments specific to CHRNA7 or its partial duplication. Schizophr Res 41: 93
M1  - Robbins, T., Everitt, B., Marston, H., Wilkinson, J., Jones, G., & Page, K. (1989). Comparative effects of ibotenic acid and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res, 35, 221-240. http://dx.doi.org/10.1016/S0166-4328(89)80143-3
M1  - Rogers, S. L., Doody, R. S., Mohs, R. C., & Friedhoff, L. T. (1998a) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Int Med 158: 1021-1031
M1  - Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology, 50, 136-145. http://dx.doi.org/10.1159/000023160
M1  - Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dai-Bianco, P., Stahelin, H. B., Hartman, R., & Gharabawi, M. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318: 633-638
M1  - Rupniak, N., Spencer, T., & Field, M. (1997). Enhanced performance of spatial and visual memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology, 131, 406-410. http://dx.doi.org/10.1007/s002130050310
M1  - Samochocki, M., Hoffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E. F., Lubbert, H., Albuquerque, E. X., & Maelicke, A. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther, 305, 1024-1036. http://dx.doi.org/10.1124/jpet.102.045773
M1  - Santucci, A. C., Haroutunian, V., & Davis, K. L. (1991) Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin Neuropharmacol 14: 81-8
M1  - Saykin, A., Shtasel, D., Gur, R., Kester, D., Mozley, L., Stafiniak, P., et al. (1994) Neuropsycholoigcal deficits in neuroleptic native patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-1311994-25655-001
M1  - Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., Van Compel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73
M1  - Schrattenholz, A., Pereira, E. F. R., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996) Agonist responses of neuronal nicotinic are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49: 1-6
M1  - Schwarz, R. D., Callahan, M. J., Coughenour, L. L., Dickerson, M. R., Kinsora, J. J., Lipinski, W. J., Raby, C. A., Spencer, C. J., & Tecle, H. (1999) Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther 291: 812-221999-01538-002
M1  - Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Greenwood, B., Mitch, C. H., Sawyer, B. D., Ward, J. S., Wong, D. T., Olesen, P. H., Sheardown, M. J., et al. (1994) Xanomeline: a novel muscarinic receptor agonist with functional selectivity for m1 receptors. J Pharmacol Exp Ther 269: 271-281
M1  - Sitaram, N., Weingarten, H., & Gillin, J. (1978). Human serial learning: enhancement with arecholine and choline and impairment with scopolamine. Science, 201, 274-276. http://dx.doi.org/10.1126/science.351808
M1  - Smith, R. C., Singh, A., Infante, M., Khandat, A., & Kloos, A. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology, 27, 479-497. http://dx.doi.org/10.1016/S0893-133X(02)00324-X
M1  - Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L., Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S., Sheardown, M. J., Syed, R., Upton, R. L., Wadsworth, G., Weiss, S. M., & Wyatt, A. (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299: 782-792
M1  - Stevens, K. E., Kern, W. R., Mahnir, V. M., & Freedman, R. (1998). Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology, 136, 320-327. http://dx.doi.org/10.1007/s002130050573
M1  - Stryjer, R., Strous, R. D., Bar, F., Werber, E., Shaked, G., Buhiri, Y., Kotler, M., Weizman, A., & Rabey, J. M. (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol, 26, 12-17. http://dx.doi.org/10.1097/00002826-200301000-00004
M1  - Tamlyn, D., McKenna, P. J., Mortimer, A., Lund, C., Hammond, S., & Beddeley, A. (1992). Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychol Med, 12, 564-571. http://dx.doi.org/10.1017/S0033291700032773
M1  - Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., & Ding, C. (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-22762000-00016-010
M1  - Tecle, H., Schwarz, R. D., Barrett, S. D., Callahan, M. J., Caprathe, B. W., Davis, R. E., Doyle, P., Emmerling, M., Lauffer, D. J., Mirzadegan, T., Moreland, D. W., Lipiniski, W., Nelson, C., Raby, C., Spencer, C., Spiegel, K., Thomas, A. J., & Jaen, J. C. (2000) CI-1017, a functionally Ml-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharm Acta Helv 74: 141-148
M1  - Thomsen, T., Kaden, B., Fischer, J. P., Bickel, U., Barz, H., Gusztony, G., Cervos-Navarro, J., & Kewitz, H. (1991) Inhibition of acetylcholin-esterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 29: 487-492
M1  - Wanibuchi, F., Nishida, T., Yamashita, H., Hidaka, K., Koshiya, K., Tsukamoto, S., & Usuda, S. (1994) Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 265: 151-158
M1  - Watanabe, S., Nishikawa, T., Takashima, M., & Toru, M. (1983) Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 33: 2187-2196
M1  - Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I., & Lewis, K. W. (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271: 992-998
M1  - Wei, J., Walton, E. A., Milici, A., & Buccafusco, J. J. (1994) m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neurochem 63: 815-821
M1  - Wienrich, M., Meier, D., Ensinger, H. A., Gaida, W., Raschig, A., Walland, A., & Hammer, R. (2001). Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci, 68, 2593-2600. http://dx.doi.org/10.1016/S0024-3205(01)01057-8
M1  - Winkler, J., Suhr, S., Gage, F., Thai, L., & Fisher, L. (1995). Essential role of neocortical acetylcholine in spatial memory. Nature, 375, 484-487. http://dx.doi.org/10.1038/375484a0
M1  - Wood, M. D., Murkitt, K. L., Ho, M., Watson, J. M., Brown, F., Hunter, A. J., & Middlemiss, D. N. (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol 126: 1620-1624
M1  - Woolf, N., & Butcher, L. (1989) Cholinergic systems: synopsis of anatomy and overview of physiology and pathology. In: The biological substrates of Alzheimer's disease. Academic Press, New York, pp 73-86
M1  - Zarei, M., Radcliffe, K. A., Chen, D., Patrick, J. W., & Dani, J. A. (1999) Distribution of nicotinic acetylcholine receptor 7 and 2 submits on cultured hippocampal neurons. Neuroscience 88: 755-764
M2  - http://dx.doi.org/10.1007/s00213-004-1794-x
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2004-16942-007
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2004-16942-007 

15. 
TY  - ELEC
ID  - 2003-99731-009
T1  - Augmenting atypical antipsychotics with a cognitive enhancer (Donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study.
A1  - Nahas, Ziad
A1  - George, Mark S
A1  - Horner, Michael D
A1  - Markowitz, John S
A1  - Li, Xingbao
A1  - Lorberbaum, Jeffrey P
A1  - Owens, Susan D
A1  - McGurk, Susan
A1  - DeVane, Lindsay
A1  - Risch, S. Craig
A2  - Andreasen, Benton, Breir, Crespo-Facorro, Cummings, Curtis, Curtis, Dolan, Dye, Fletcher, Friston, Friston, Gaillard, Gold, Goldman, Green, Green, Green, Gur, Honey, Ingvar, Kay, Kim, Kraeplin, Lehman, MacEwan, McCarthy, McGuire, Meller, Meltzer, Meltzer, Middelton, Mozley, Phelps, Pihlajamaki, Purdon, Risch, Rollema, Ruff, Sawagushi, Saykin, Schlosser, Small, Spence, Spence, Stefanski, Stryjer, Swanson, Weinberger, Weinberger, Woodard, Zhang
Y1  - 2003//
N2  - Cognitive impairments are cardinal features of schizophrenia and predictors of poor vocational and social outcome. Imaging studies with verbal fluency tasks (VFT) lead some to suggest that in schizophrenia, the combination of a failure to deactivate the left temporal lobe and a hypoactive frontal lobe reflects a functional disconnectivity between the left prefrontal cortex and temporal lobe. Others have theorized that an abnormal cingulate gyrus modulates such fronto-temporal connectivity. Thus addition of a cognitive enhancing medication to current antipsychotic therapy might improve functionality of networks necessary in working memory and internal concept generation. To test this hypothesis, we serially measured brain activity in 6 subjects on stable atypical antipsychotics performing a VFT, using BOLD fMRI. Measurements were made at baseline and again after groups were randomized to receive 12 weeks of donepezil (an acetylcholinesterase inhibitor) and placebo in a blind cross-over design. Donepezil addition provided a functional normalization with an increase in left frontal lobe and cingulate activity when compared to placebo and from baseline scans. This pilot study supports the cingulate's role in modulating cognition and neuronal connectivity in schizophrenia. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Chemical Brain Stimulation
KW  - *Cognitive Impairment
KW  - *Drug Therapy
KW  - *Neuroleptic Drugs
KW  - *Schizophrenia
KW  - Brain
KW  - Magnetic Resonance Imaging
KW  - Neurochemistry
KW  - Verbal Fluency
M3  - Clinical Psychopharmacology [3340]
JF  - Neurocase
VL  - 9
IS  - 3
SP  - 274
EP  - 282
CY  - United Kingdom
PB  - Taylor & Francis
PB  - United Kingdom
SN  - 1355-4794
AD  - Nahas, Ziad: Ctr for Advanced Imaging Research, Inst of Psychiatry and Behavioral Sciences, Medical U South Carolina,, PO Box 25086167, President Street, Room 502 North, Charleston, SC, US, 29425, nahasz@musc.edu
AD  - Nahas, Ziad: nahasz@musc.edu
M1  - Andreasen, N. C., Paradiso, S., & O'Leary, D. S. (1998). "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry? Schizophrenia Bulletin 1998; 24(2): 203-18.1998-02576-002
M1  - Benton, A. L., Hamsher, K., & Sivan, A. B. (1994). Multilingual aphasia examination, 3rd edn. Iowa City: AJA Associates, 1994.
M1  - Breir, A., Schreiber, J. L., Dyer, J., et al. (1991). National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Archives of General Psychiatry 1991; 48: 239-46.1991-21436-001
M1  - Crespo-Facorro, B., Paradiso, S., Andreasen, N. C., O'Leary, D. S., Watkins, G. L., Boles, L. L., & Hichwa, R. D. (1999). Recalling word lists reveals "cognitive dysmetria" in schizophrenia: A positron emission tomography study. American Journal of Psychiatry 1999; 156(3): 386-92.1999-10569-006
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: A new class of psychotropic compounds. American Journal of Psychiatry 2000; 157: 4-15.2000-13126-001
M1  - Curtis, V. A., Bullmore, E. T., Brammer, M. J., Wright, I. C., Chir, B., Williams, S. C. R., Morris, R. G., Shanna, T. S., Murray, R. M., & McGuire, P. K. (1998). Attenuated frontal activation during a verbal fluency task in patients with schizophrenia. American Journal of Psychiatry 1998: 155: 1056-63.1998-10381-010
M1  - Curtis, V. A., Bullmore, E. T., Morris, R. G., Brammer, M. J., Williams, S. C., Simmons, A., Sharma, T., Murray, R. M., & McGuire, P. K. (1999). Attenuated frontal activation in schizophrenia may be task dependent. Schizophrenia Research, 371, 35-44. http://dx.doi.org/10.1016/S0920-9964(98)00141-8
M1  - Dolan, R. J., Fletcher, P., Frith, C. D., et al. (1996). Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature, 378, 180-2. http://dx.doi.org/10.1038/378180a0
M1  - Dye, S. M., Spence, S. A., Bench, C. J., Hirsch, S. R., Stefan, M. D., Sharma, T., & Grasby, P. M. (1999). No evidence for left superior temporal dysfunction in asymptomatic schizophrenia and bipolar disorder. PET study of verbal fluency. Britislh Journal of Psychiatry 1999; 175: 367-74.
M1  - Fletcher, P., McKenna, P. J., Friston, K. J., Frith, C. D., & Dolan, R. J. (1999). Abnormal cingulate modulation of fronto-temporal connectivity in schizophrenia. Neuroimage 1999; 9(3): 337-42.
M1  - Friston, K. J., Frith, C. D., & Liddle, P. F. (1991). Investigating a network model of word generation with positron emission tomography. Proceedings of the Royal Society of London Series B Biological Sciences 1991; 244: 101-6.
M1  - Friston, K. J., Herold, S., & Fletcher, P. (1995). Abnormal fronto-temporal interaction in schizophrenia. In: Watson SJ, editor. Biology of schizophrenia and affective diseases. New York, NY: Raven, 1995: 449-81.
M1  - Gaillard, W. D., Hertz-Pannier, L., Mott, S. H., Barnett, A. S., LeBihan, D., & Theodore, W. H. (2000). Functional anatomy of cognitive development: fMRI of verbal fluency in children and adults. Neurology 2000; 54(1): 180-5.2000-13163-012
M1  - Gold, J. M., & Harvey, P. D. (1995). Cognitive deficits in schizophrenia. Psychiatric Clinic of North America 1995; 16: 295-312.1994-01911-001
M1  - Goldman, R. S., Axelrod, B. N., Tandon, R., Ribeiro, S. C., Craig, K., & Berent, S. (1993). Neuropsychological prediction of treatment efficacy and one year outcome in schizophrenia. Psychopathology 1993: 26: 122-6.1994-22604-001
M1  - Green, M. F., Marshall, B. D., Jr.., Wirshing, W. C., Ames, D., Marder, S. R., McGurk, S., Kern, R. S., & Mintz, J. (1997). Does risperidone improve verbal working memory in trealment-resistant schizophrenia? American Journal of Psychiatry 1997; 154(6): 799-804.1997-04662-010
M1  - Green, M. F., & Nueehterlein, K. H. (1999). Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin 1999; 25(2): 309-19.1999-05588-009
M1  - Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 1996; 153: 321-30.1996-00417-002
M1  - Gur, R. E., Mozley, P. D., & Resnick, S. M. (1995). Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia related to clinical features. Archives of General Psychiatry 1995; 52: 657-67.1996-01536-001
M1  - Honey, G. D., Bullmore, E. T., Soni, W., Varatheesan, M., Willimas, S. C., & Sharma, T. (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1999: 96(23): 1342-7.
M1  - Ingvar, D. H. (1983). Serial aspects of language and speech related to prefrontal cortical activity. A selective review. Human Neurobiology 1983; 2(3): 177-89.
M1  - Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry Supplements 1989: 7: 59-67.1990-13714-001
M1  - Kim, J. J., Mohamed, S., Andreasen, N. C., O'Leary, D. S., Watkins, G. L., Boles Ponto, L. L., & Hichwa, R. D. (2000). Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. American Journal of Psychiatry, 157, 542-8. http://dx.doi.org/10.1176/appi.ajp.157.4.542
M1  - Kraeplin, E. (1971). Dementia praecox and paraphrenia (facsimile of 1919 edition. Barclay RM, trans.). Huntington, NY: Robert Kreiger, 1971.
M1  - Lehman, A. (1995). Vocational rehabilitation in schizophrenia. Schizophrenia Bulletin 1995; 21: 645-56.1996-04394-010
M1  - MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatrica Scandinavia 2001; 104(6): 469-72.2002-15544-008
M1  - McCarthy, R. A., & Warrington, E. J. (1990). Auditory word comprehension. In: McCarthry RA, Warrington EJ, editors. Cognitive neuropsychology - A clinical introduction. San Diego, CA: Academic Press, 1990: 122-51.1990-98988-000
M1  - McGuire, P. K., Shah, G. M., & Murrary, R. M. (1993). Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. Lancet 1993; 342(8873): 703-6.
M1  - Meller, J. D., Adachi, N., Takei, N., Cluckie, A., Toone, B. K., & Lishman, W. A. (1998). SPET study of verbal fluency in schizophrenia and epilepsy. British Journal of Psychiatry, 173, 69-74. http://dx.doi.org/10.1192/bjp.173.1.69
M1  - Meltzer, H. Y., & McGurk, S. (1999). The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999; 25(2): 233-55.1999-05588-005
M1  - Meltzer, H. Y. (1996). Pre-clinical pharmacology of atypical drugs. A selective review. British Journal of Psychiatry 1996: 168(Suppl 29): 23-31.1996-04857-003
M1  - Middelton, F. A., & Strick, P. L. (1991). Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science 1991: 27: 119-44.
M1  - Mozley, L. H., Gur, R. C., Gur, R. E., et al. (1996). Relationships between verbal memory performance and the cerebral distribution of fluorodeoxyglucose in patients with schizophrenia. Biological Psychiatry, 40, 443-51. http://dx.doi.org/10.1016/0006-3223(95)00421-1
M1  - Phelps, E. A., Hyder, F., Blamire, A. M., & Shulman, R. G. (1997). FMRI of the prefrontal cortex during overt verbal fluency. NeuroReport, 82, 561-5. http://dx.doi.org/10.1097/00001756-199701200-00036
M1  - Pihlajamaki, M., Tanila, H., Hanninen, T., Kononen, M., Laakso, M., Partanen, K., Soininen, H., & Aronen, H. J. (2000). Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study. Annals of Neurology, 474, 470-6. http://dx.doi.org/10.1002/1531-8249(200004)47:4<470::AID-ANA10>3.0.CO;2-M
M1  - Purdon, S. E. (2000). Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. Journal of Psychiatry and Neuroscience 2000; 25(2): 108-16.2000-15220-001
M1  - Risch, S. C., McGurk, S., Homer, M. D., Nahas, Z., Owens, S. D., Molloy, M., Gilliard, C., Christie, S., Markowitz, J. S., De Vane, C. L., Mintzer, J., & George, M. S. (2001). A double-blind placebo-controlled case study of the use of donepezil lo improve cognition in a schizoaffective disorder patient: Functional MRI correlates. Neurocase, 72, 105-10. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rollema, H., Yi, L., Schmidt, A. W., & Zorn, S. H. (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HTlc receptors. European Journal of Pharmacology 1997; 338: R3-R5.
M1  - Ruff, R. M., Crouch, J. A., Troster, A. I., Marshall, L. F., Buchsbaum, M. S., Lottenberg, S., & Somers, L. M. (1994). Selected cases of poor outcome following a minor brain trauma: Comparing neuropsychological and positron emission tomography assessment. Brain Injury, 84, 297-308. http://dx.doi.org/10.3109/02699059409150981
M1  - Sawagushi, T., & Goldman-Rackic, P. S. (1994). The role of Dl-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of Rhesus monkeys performing an oculomotor delayed-response task. Journal of Neurophysiology 1994: 71: 515-28.1994-32855-001
M1  - Saykin, A. L., Shtasel, D. I., Gur, R. E., Kester, D. B., Moxley, L. H., Stafaniak, P., et al. (1994). Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 1994; 51(2): 124-31.1994-25655-001
M1  - Schlosser, R., Hutchinson, M., Joseffer, S., Rusinek, H., Saarimaki, A., Stevenson, J., et al. (1998). Functional magnetic resonance imaging of human brain activity in a verbal fluency task. Journal of Neurology, Neurosurgery and Psychiatry, 644, 492-8. http://dx.doi.org/10.1136/jnnp.64.4.492
M1  - Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2000; 97(11): 6037-42.
M1  - Spence, S. A., Hirsch, S. R., Brooks, D. J., & Grasby, P. M. (1998). Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. British Journal of Psychiatry, 172, 316-23. http://dx.doi.org/10.1192/bjp.172.4.316
M1  - Spence, S. A., Liddle, P. F., Stefan, M. D., Hellwell, J. S. E., Sharma, T., Friston, K. J., Hirsch, S. R., Frith, C. D., Murray, R. M., Deakin, J. F. W., & Grasby, P. M. (2000). Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. British Journal of Psychiatry 2000; 176: 52-60.
M1  - Stefanski, R., & Goldberg, S. R. (1997). Serotonin 5-HT2 receptor antagonists-potential in the treatment of psychiatric disorders. Drag Therapy 1997; 5: 388-409.
M1  - Stryjer, R., Bar, F., Strous, R. D., Baruch, Y., & Rabey, J. M. (2002). Donepezil management of schizophrenia with associated dementia. Journal of Clinical Psychopharmacology, 222, 226-9. http://dx.doi.org/10.1097/00004714-200204000-00021
M1  - Swanson, C. L., Jr.., Mozley, L. H., & Gur, R. E. (1997). Positron emission tomography studies of cerebral metabolism and blood flow in schizophrenia. In: Kirshan KRR, Doraiswamy PM, editors. Brain imaging in clinical psychiatry. New York: Marcel Dekker, 1997: 401-24.
M1  - Weinberger, D. R., Berman, K. F., & Daniel, D. G. (1991). Prefrontal cortex dysfunction in schizophrenia. In: Levin HS, Eisenberg HM, Benton AL, editors. Frontal lobe function and dysfunction. New York: Oxford University Press, 1991: 275-87.1992-97203-014
M1  - Weinberger, D. R., & Berman, K. F. (1996). Prefrontal function in schizophrenia: Confounds and controversies. Philosophical Transactions of the Royal Society of London Series B Biological Sciences 1996; 351(1346): 1495-503.
M1  - Woodard, J. L., Grafton, S. T., Votaw, J. R., Green, R. C., Dobraski, M. E., & Hoffman, J. M. (1998). Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease. Neuropsychology, 124, 491-504. http://dx.doi.org/10.1037/0894-4105.12.4.491
M1  - Zhang, W., & Bymaster, F. P. (1999). Effects of olanzapine and other antipsychotics in receptor occupancy and antagonism of dopamine Dl, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology, 141, 267-78. http://dx.doi.org/10.1007/s002130050834
M2  - http://dx.doi.org/10.1076/neur.9.3.274.15563
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2003-99731-009
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2003-99731-009 

16. 
TY  - ELEC
ID  - 2003-08289-018
T1  - Donepezil for the treatment of a schizophrenia patient with frontal lobotomy.
A1  - Mazeh, Doron
A1  - Mirecki, Ilona
A1  - Paleacu, Diana
A1  - Barak, Yoram
A2  - Cummings, Friedman, Risch, Rogers, Stryjer
Y1  - 2003//
N2  - Donepezil is a relatively new compound that inhibits acetylcholinesterase, thus enhancing cholinergic neurotransmission. It is widely used in patients suffering from Alzheimer disease, producing an improvement in cognition. In this report, we present the effect of donepezil on an 71-year-old man suffering from residual schizophrenia with frontal lobotomy and profound negative signs. Donepezil was started with 5 mg/d and increased to 10 mg/d after 4 weeks in which he was free of side effects. After 2 months, improvement in his communication skills became noticeable. The fluidity and productivity of his verbal process improved so he was able to explain himself with structured sentences. To our knowledge, this is the first report of treatment of negative signs of schizophrenia with donepezil alone. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Acetylcholinesterase
KW  - *Drug Therapy
KW  - *Neurosurgery
KW  - *Schizophrenia
M3  - Clinical Psychopharmacology [3340]
M1  - Schizophrenia & Psychotic States [3213]
JF  - Journal of Clinical Psychopharmacology
VL  - 23
IS  - 5
SP  - 522
CY  - US
PB  - Lippincott Williams & Wilkins
PB  - US
SN  - 0271-0749
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a. new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15.2000-13126-001
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry., 51, 349-357. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Risch, S. C., McGurk, S., Horner, M. D., et al. (2001). A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase., 7, 105-110. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rogers, S. L., & Friedhoff, L. T. (1996). The efficacy and safety of donezepil in patients with Alzheimer's disease: results of a US multi-center, randomized, double-blind, placebo-controlled trial. Dementia. 1996:7:293
M1  - Stryjer, R., Bar, F., Strous, R. D., et al. (2002). Donepezil management of schizophrenia with associated dementia. J Clin Psychopharmacol., 22, 226-229. http://dx.doi.org/10.1097/00004714-200204000-00021
M2  - http://dx.doi.org/10.1097/01.jcp.0000088913.24613.9f
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2003-08289-018
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2003-08289-018 

17. 
TY  - ELEC
ID  - 2003-02305-017
T1  - 'Awakenings' in demented patients.
A1  - Hori, Koji
A1  - Oda, Tatsuro
A1  - Tominaga, Itaru
A1  - Inada, Toshiya
A2  - Cummings, Davis, Duckworth, Janowsky, Larsen, Weiden
Y1  - 2003//
N2  - Reports on 2 demented AD patients who developed depressive episodes after improvement of their delusions with donepezil. Both patients were women (aged 73 and 74 yrs) experiencing forgetfulness who had developed delusions of theft. Donepezil improved or cured the delusions in the two Ss, but subsequently both developed severe depressive symptoms. The improvement in psychotic symptoms may have enabled the patients to realize their current circumstances, which may have triggered the depression. These episodes resemble the 'awakening' observed in a study of schizophrenic patients whose psychotic symptoms markedly improved after administration of risperidone, but who then also developed depression. This may be what Oliver Sacks has called 'awakening,' not only to a new mental state but also to a novel set of challenges. If there is a common underlying pathophysiological mechanism in patients who develop depressive states after improvement of psychotic symptoms, it will be necessary to better help patients adapt to the emotional upheaval that comes with symptom improvement, not only in schizophrenia but also in dementia. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Alzheimer's Disease
KW  - *Cholinesterase Inhibitors
KW  - *Drug Therapy
KW  - *Major Depression
KW  - *Psychiatric Symptoms
KW  - Delusions
KW  - Neuroleptic Drugs
KW  - Schizophrenia
M3  - Clinical Psychopharmacology [3340]
JF  - Psychiatry and Clinical Neurosciences
VL  - 57
IS  - 2
SP  - 237
CY  - United Kingdom
PB  - Blackwell Publishing
PB  - United Kingdom
SN  - 1323-1316
AD  - Hori, Koji: National Shimofusa Hosp, 578 Heta, Midoriku, Chiba-shi, Chiba, Japan, 266-0007, hori@simofusa.hosp.go.jp
AD  - Hori, Koji: hori@simofusa.hosp.go.jp
M1  - Cummings, J. L., & Kaufer, D. (1996). Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisted. Neurology 1996; 47: 876-883.1997-02450-002
M1  - Davis, K. L., Hollander, E., Davidson, M., et al. (1987). Induction of depression with oxotremorine in patients with Alzheimer's disease. Am. J. Psychiatry 1987; 144: 468-471.1987-29003-001
M1  - Duckworth, K., Nair, V., Patel, J. K., et al. (1997). Lost time, found hope and sorrow: The seach for self, connection, and purpose during 'awakenings' on the new antipsychotics. Harvard Res. Psychiatry 1997; 5: 227-233.
M1  - Janowsky, D. S., El-Yousef, M., & Davis, L. M. (1973). Acetylcholine and depression. Psychosom. Med. 1973; 36: 248-257.1974-32901-001
M1  - Larsen, P., & Ashleigh, E. (1996). Response to risperidone: A two edged sword? J. Calif. Alliance Mentally Ill 1996; 7: 10-11.
M1  - Weiden, P., Aquila, R., & Standard, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry 1996; 57: 53-60.1997-03214-006
M2  - http://dx.doi.org/10.1046/j.1440-1819.2003.01108.x
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2003-02305-017
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2003-02305-017 

18. 
TY  - ELEC
ID  - 2003-01762-004
T1  - Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
A1  - Stryjer, Rafael
A1  - Strous, Rael D
A1  - Bar, Faina
A1  - Werber, Edith
A1  - Shaked, Ginette
A1  - Buhiri, Yosef
A1  - Kotler, Moshe
A1  - Weizman, Abraham
A1  - Rabey, Jose M
A2  - Anthony, Burch, Crook, Cummings, Davidson, Folstein, Freedman, Friedman, Friedman, Goldberg, Guy, Harvey, Heaton, Hoff, Holt, Karson, Kay, King, Leonard, Magnuson, Moore, Mortimer, Murphy, Owens, Park, Powchick, Ring, Risch, Rogers, Rogers, Saykin, Siegal, Stevens, Stryjer, Tandon, White
Y1  - 2003//
N2  - Comorbid schizophrenia and dementia is a common clinical phenomenon; however, management of the coexisting illnesses remains incomplete. Donepezil, a cholinesterase inhibitor, may be beneficial for the management of symptoms of Alzheimer's disease (AD). There are apparently no published controlled studies reporting the use of cholinesterase inhibitors in the management of schizophrenia in patients with associated dementia. In this study, six patients with chronic schizophrenia and comorbid dementia were administered donepezil, 5 mg, in single-blind fashion as augmentation to their standard antipsychotic medication for a 4-week period. Patients were evaluated with the Mini Mental State Examination (MMSE); Alzheimer's Disease Assessment Scale, Cognitive subscale; Positive and Negative Symptom Scale (PANSS); and the Clinical Global Impression (CGI) scales. A significant improvement was noted in MMSE scores and for CGI scores. In addition, three patients demonstrated improvement on the PANSS. Donepezil appears to be an effective treatment for the management of symptoms of dementia accompanying patients with comorbid schizophrenia and dementia. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Comorbidity
KW  - *Dementia
KW  - *Drug Therapy
KW  - *Schizophrenia
KW  - Drug Interactions
KW  - Neuroleptic Drugs
KW  - Treatment Outcomes
M3  - Health & Mental Health Treatment & Prevention [3300]
JF  - Clinical Neuropharmacology
VL  - 26
IS  - 1
SP  - 12
EP  - 17
CY  - US
PB  - Lippincott Williams & Wilkins
PB  - US
SN  - 0362-5664
AD  - Strous, Rael D.: Beer Yakov Mental Health Ctr, P.O. Box 1, Beer Yakov, Israel, 70350, raels@post.tau.ac.il
AD  - Strous, Rael D.: raels@post.tau.ac.il
M1  - Anthony, J. C., LeReche, L., Niaz, U., et al. (1982). Limits of the mini-mental state as a screening test for dementia and delirium among hospital patients. Psychol Med, 12, 397-408. http://dx.doi.org/10.1017/S0033291700046730
M1  - Burch, E. A., Jr.., & Andrews, S. R. (1987). Comparison of two cognitive rating scales in medically ill patients. Int J Psychiatry Med 1987; 17: 193-200.1988-25157-001
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., et al. (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry, 48, 381-8. http://dx.doi.org/10.1016/S0006-3223(00)00918-5
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 1: 157.2000-13126-001
M1  - Davidson, M., Harvey, P., Welsh, K. A., et al. (1996). Cognitive functioning in late life schizophrenia: a comparison of elderly schizophrenics patients and patients with Alzheimer's disease. Am J Psychiatry 1996; 153: 1274-9.1996-00484-004
M1  - Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res, 12, 189http://dx.doi.org/10.1016/0022-3956(75)90026-6
M1  - Freedman, R., Hall, M., Adler, L. E., et al. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., et al. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51, 349-57. http://dx.doi.org/10.1016/S0006-3223(01)01342-7
M1  - Friedman, J. I., Temporini, H., & Davis, K. L. (1999). Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry, 45, 1-16. http://dx.doi.org/10.1016/S0006-3223(98)00287-X
M1  - Goldberg, T. E., Weinberger, D. R., Berman, K. E., et al. (1987). Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin card-sorting test. Arch Gen Psychiatry 1987; 44: 1008-14.1988-10810-001
M1  - Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976: 218-22.
M1  - Harvey, P. D., Lombardi, J., Kincaid, M. M., et al. (1995). Cognitive functioning in chronically hospitalized schizophrenic patients: age related changes and age disorientation as a predictor of impairment. Schizophr Res, 17, 15-24. http://dx.doi.org/10.1016/0920-9964(95)00026-I
M1  - Heaton, R., Paulsen, J. S., McAdams, L. A., et al. (1994). Neuropsychologic deficits in schizophrenics: relationship to age, chronicity and dementia. Arch Gen Psychiatry 1994; 51: 469-76.1994-41323-001
M1  - Hoff, A. L., Riordan, H., O'Donnell, D. W., et al. (1992). Neuropsychologic functioning of first-episode schizophreniform patients. Am J Psychiatry 1992; 149: 898-903.1992-43257-001
M1  - Holt, D. J., Herman, M. M., Hyde, T. M., et al. (1999). Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999; 94: 21-31.
M1  - Karson, C. N., Mrak, R. E., Husain, M. M., et al. (1996). Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 1996; 29: 181-91.
M1  - Kay, S., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale for schizophrenia. Schizophr Bull 1987; 13: 261-76.2005-09726-007
M1  - King, D. J. (1990). The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry, 157, 799-811. http://dx.doi.org/10.1192/bjp.157.6.799
M1  - Leonard, S., Adams, C., Breese, C. R., et al. (1996). Nicotinic receptor function in schizophrenia. Schizophr Bull 1996; 22: 431-45.1996-06147-004
M1  - Magnuson, T. M., Keller, B. K., & Burke, W. J. (1998). Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am J Psychiatry 1998; 155: 1458-9.1998-12596-024
M1  - Moore, H., Fadel, J., Sarter, M., et al. (1999). Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Neuroscience 1999; 88: 811-22.
M1  - Mortimer, A. M. (1997). Cognitive function in schizophrenia: do neuroleptics make a difference. Pharmacol Biochem Behav, 56, 789-95. http://dx.doi.org/10.1016/S0091-3057(96)00425-X
M1  - Murphy, G. M., Jr.., Lim, K. O., Wieneke, M., et al. (1998). No neuropathologic evidence for an increased frequency of Alzheimer disease among elderly schizophrenics. Biol Psychiatry, 43, 205-9. http://dx.doi.org/10.1016/S0006-3223(97)00031-0
M1  - Owens, D. G., & Johnstone, E. C. (1980). The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. Br J Psychiatry, 136, 384-93. http://dx.doi.org/10.1192/bjp.136.4.384
M1  - Park, S., & Holzman, P. S. (1992). Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992; 49: 975-82.1993-17718-001
M1  - Powchick, P., Davidson, M., Haroutunian, V., et al. (1998). Postmortem studies in schizophrenia. Schizophr Bull 1998; 24: 325-41.1998-10644-002
M1  - Ring, B. J., Catlow, J., Lindsay, T. J., et al. (1996). Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658-66.
M1  - Risch, S. C., McGurk, S., Horner, M. D., et al. (2001). A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase, 7, 105-10. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rogers, S. L., Doody, R. S., Pratt, R. D., et al. (2000). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of US multicenter open-label study. Eur Neuropsychopharmacol, 10, 195-203. http://dx.doi.org/10.1016/S0924-977X(00)00067-5
M1  - Rogers, S. L. (1998). A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer disease. Neurology, 50, 136-45. http://dx.doi.org/10.1159/000023160
M1  - Saykin, A. L., Shtasel, D. I., Gur, R. E., et al. (1994). Neuropsychologic deficits in neuroleptic naive patients with first episode schizophrenia. Arch Gen Psychiatry 1994; 51: 124-31.1994-25655-001
M1  - Siegal, G. J., Arganoff, B. W., Albers, R. W., et al. (1999). Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th Ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
M1  - Stevens, M., Crow, T. J., Bowman, M. J., et al. (1978). Age disorientation in schizophrenia: a constant prevalence of 25% in a chronic mental hospital population?. Br J Psychiatry, 133, 130-6. http://dx.doi.org/10.1192/bjp.133.2.130
M1  - Stryjer, R., Bar, F., Strous, R., et al. (2002). Donepezil management in schizophrenia with associated dementia. J Clin Psychopharmacol 2002; 22: 226-9.
M1  - Tandon, R. (1999). Cholinergic aspects of schizophrenia. Br J Psychiatry 1999; 37 (suppl): 7-11.1999-10613-002
M1  - White, K., & Cummings, J. L. (1996). Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry, 37, 188-95. http://dx.doi.org/10.1016/S0010-440X(96)90035-8
M2  - http://dx.doi.org/10.1097/00002826-200301000-00004
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2003-01762-004
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2003-01762-004 

19. 
TY  - ELEC
ID  - 2002-11695-007
T1  - An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.
A1  - Buchanan, Robert W
A1  - Summerfelt, Ann
A1  - Tek, Cenk
A1  - Gold, James
A2  - Adler, Blyler, Broocks, Cohen, Cummings, Freedman, Furey, Goldberg, Green, Hoff, Huston, Keefe, Kraepelin, Lezak, Li, Light, McKeith, Purdon, Rogers, Vitiello
Y1  - 2003//
N2  - A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia. 15 subjects (mean age 43.1 yrs) who were on stable olanzapine treatment were entered into a 6-wk open-labeled trial of donepezil. Subjects received baseline and end-of-study P50 and neuropsychological assessments. Donepezil treatment resulted in significant improvement in manual dexterity. There were moderate improvements in verbal recall memory and visual memory and processing speed, with smaller changes in P50 and verbal recognition memory. There was no effect on an attention measure. There were no changes in either positive or negative symptoms, These results suggest that cholinergic tone modulation may enhance selective behavioral functions in patients with schizophrenia, but further study is required to delineate the full extent of the potential benefit of this approach. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Ability
KW  - *Drug Therapy
KW  - *Schizophrenia
KW  - Neuroleptic Drugs
M3  - Clinical Psychopharmacology [3340]
JF  - Schizophrenia Research
VL  - 59
IS  - 1
SP  - 29
EP  - 33
CY  - Netherlands
PB  - Elsevier Science
PB  - Netherlands
SN  - 0920-9964
AD  - Buchanan, Robert W.: U Maryland, Maryland Psychiatric Research Ctr, Dept of Psychiatry, P.O. Box 21247, Baltimore, MD, US, 21228, rbuchanan@mprc.umaryland.edu
AD  - Buchanan, Robert W.: rbuchanan@mprc.umaryland.edu
M1  - Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamato, H., Bickford, P., Leonard, S., & Freedman, R. 1998. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 24 (2), 189-202.1998-02576-001
M1  - Blyler, C. R., & Gold, J. M. 2000. Cognitive effects of typical antipsychotic treatment: another look. In: Sharma, T., Harvey, P. (Eds.), Cognition in Schizophrenia. Oxford Univ. Press, New York, pp. 241-265.
M1  - Broocks, A., Little, J. T., Martin, A., Minichiello, M. D., Mack, C., Tune, L., Murphy, D. L., & Sunderland, T. (1998). The influence of ondasetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Biol. Psychiatry, 43, 408-416. http://dx.doi.org/10.1016/S0006-3223(97)00388-0
M1  - Cohen, J. 1987. Statistical Power Analysis for the Behavioral Sciences, Revised Edition. Lawrence Erlbaum Associates, Publishers, Hillsdale, NJ.
M1  - Cummings, J. L. 2000. Cholinesterase inhibitors: a new class of psychotropic compounds. Am. J. Psychiatry 157, 4-15.2000-13126-001
M1  - Freedman, R., Adler, L. E., Myles-Worsley, M., Nagamoto, H. T., Miller, C., Kisley, M., McRae, K., Cawthra, E., & Waldo, M. 1996. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Arch. Gen. Psychiatry 53, 114-121.
M1  - Furey, M. L., Pietrini, P., & Haxby, J. V. (2000). Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science, 290, 2315-2319. http://dx.doi.org/10.1126/science.290.5500.2315
M1  - Goldberg, T. E., & Gold, J. M. 1995. Neurocognitive functioning in patients with schizophrenia: an overview. In: Bloom, F.E., Kupfer, D.J. (Eds.), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1245-1257.
M1  - Green, M. F. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321-330.1996-00417-002
M1  - Hoff, A. L., Faustman, W. O., Wieneke, M., Espinoza, S., Costa, M., Wolkowitz, O., & Csernansky, J. C. (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology, 15, 361-369. http://dx.doi.org/10.1016/0893-133X(95)00242-6
M1  - Huston, P. E., Shakow, D., & Riggs, L. A. 1937. Studies of motor function in schizophrenia. II: Reaction time. J. Gen. Psychol. 16, 39-82.1937-03274-001
M1  - Keefe, R. S., Silva, S. G., Perkins, D. O., & Lieberman, J. A. 1999. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25 (2), 201-222.1999-05588-003
M1  - Kraepelin, E. 1919. In: Barclay, R. Mary, Edinburgh, R.E., Livingston, E.S. (Eds.), Dementia Praecox and Paraphrenia (Translated and Edited).
M1  - Lezak, M. D. 1995. Neuropsychological Assessment, 3rd edn. Oxford Univ. Press, New York.
M1  - Li, X., Rainnie, D. G., McCarley, R. W., & Greene, R. W. 1998. Presynaptic nicotinic receptors facilitate monoaminergic transmission. J. Neurosci. 18, 1904-1912.
M1  - Light, G. A., Geyer, M. A., Clementz, B. A., Cadenhead, K. S., & Braff, D. L. (2000). Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry, 157, 767-771. http://dx.doi.org/10.1176/appi.ajp.157.5.767
M1  - McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356, 2031-2036.
M1  - Purdon, S. E., Jones, B. D., Stip, E., Labelle, A., Addington, D., David, S. R., Breier, A., & Tollefson, G. D. (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry, 57, 249-258. http://dx.doi.org/10.1001/archpsyc.57.3.249
M1  - Rogers, S. L., et al., & Donepezil Study Group. 1998. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. 158, 1021-1031.
M1  - Vitiello, B., Martin, A., Hill, J., Mack, C., Molchan, S. E., Martinez, R., Murphy, D. L., & Sunderland, T. (1997). Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropharmacology, 16, 15-24. http://dx.doi.org/10.1016/S0893-133X(96)00134-0
M2  - http://dx.doi.org/10.1016/S0920-9964%2801%2900387-5
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2002-11695-007
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2002-11695-007 

20. 
TY  - ELEC
ID  - 2002-18504-013
T1  - Donepezil for memory dysfunction in schizophrenia.
A1  - Howard, Andrew K
A1  - Thornton, Allen E
A1  - Altman, Siemion
A1  - Honer, William G
A2  - Court, Cuesta, de Vries, Friedman, Friedman, George, Green, Greenberg, Greene, Harvey, Heinrichs, Holt, Levin, Meltzer, Mihailescu, Powchik, Risch, Rogers, Sarter, Sumiyoshi, Tandon
Y1  - 2002//
N2  - A case is reported of a 54-year-old female patient with schizophrenia and cognitive impairment. Her memory dysfunction improved following the addition of donepezil to quetiapine. The possible implications for future studies are reviewed. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Ability
KW  - *Drug Therapy
KW  - *Memory Disorders
KW  - *Schizophrenia
M3  - Clinical Psychopharmacology [3340]
JF  - Journal of Psychopharmacology
VL  - 16
IS  - 3
SP  - 267
EP  - 270
CY  - US
PB  - Sage Publications
PB  - US
SN  - 0269-8811
AD  - Honer, William G.: Molecular Psychiatry & Therapeutics Lab, 211-828 West 10th Avenue, Vancouver, BC, Canada, V5Z 1L8, honer@interchange.ubc.ca
AD  - Honer, William G.: honer@interchange.ubc.ca
M1  - Court, J. A., Piggott, M. A., Lloyd, S., Cookson, N., Ballard, C. G., McKeith, I. G., et al. (2000) Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease and in relation to neuroleptic medications. Neuroscience 98: 79-87
M1  - Cuesta, M. J., Peralta, V., & Zarzuela, A. (1998). Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res, 33, 141-150. http://dx.doi.org/10.1016/S0920-9964(98)00068-1
M1  - de Vries, P. J., Honer, W. G., Kemp, P. M., & McKenna, P. J. (2001). Dementia as a complication of schizophrenia. J Neurol Neurosurg Psychiatry, 70, 588-596. http://dx.doi.org/10.1136/jnnp.70.5.588
M1  - Friedman, J. I., Adler, D. N., Howanitz, E., Temporini, H., Harvey, P. D., & Davis, K. L. (2001) Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia. Schizophr Res 49: 228
M1  - Friedman, J. I., Temporini, H., & Davis, K. L. (1999). Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry, 45, 1-16. http://dx.doi.org/10.1016/S0006-3223(98)00287-X
M1  - George, T. P., Vessicchio, J. C., Sahady, D. M., Head, C. A., Tamine, A., Bregartner, T. A., et al. (2001) Effects of smoking abstinence on cognitive function in schizophrenia. Biol Psychiatry 49: 5S
M1  - Green, M. F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-3301996-00417-002
M1  - Greenberg, S. M., Tennis, M. K., Brown, L. B., Gomez-Isla, T., Hayden, D. L., Schoenfeld, D. A., et al. (2000). Donepezil therapy in clinical practice. Arch Neurol, 57, 94-99. http://dx.doi.org/10.1001/archneur.57.1.94
M1  - Greene, Y. M., Tariot, P. N., Wishart, H., Cox, C., Holt, C. J., Schwid, S., & Noviasky, J. (2000). A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol, 20, 350-356. http://dx.doi.org/10.1097/00004714-200006000-00010
M1  - Harvey, P. D., Parrella, M., White, L., Mohs, R. C., Davidson, M., & Davis, K. L. (1999). Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res, 35, 77-84. http://dx.doi.org/10.1016/S0920-9964(98)00109-1
M1  - Heinrichs, R. W., & Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychologica, 12, 426-445. http://dx.doi.org/10.1037/0894-4105.12.3.426
M1  - Holt, D. J., Herman, M. M., Hyde, T. M., Kleinman, J. E., Sinton, C. M., German, D. C., et al. (1999) Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 94: 21-31
M1  - Levin, E. D., Wilson, W., Rose, J. E., & McEvoy, J. (1996). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15, 429-436. http://dx.doi.org/10.1016/S0893-133X(96)00018-8
M1  - Meltzer, H. Y., & McGurk, S. R. (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-2551999-05588-005
M1  - Mihailescu, S., & Drucker-Colin, R. (2000) Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 31: 131-144
M1  - Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, D. P., Perl, D. P., et al. (1998) Postmortem studies in schizophrenia. Schizophr Bull 24: 325-3411998-10644-002
M1  - Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., Molloy, M., et al. (2001). A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase, 7, 105-110. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136-145. http://dx.doi.org/10.1159/000023160
M1  - Sarter, M. (1994). Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?. Psychopharmacology, 114, 539-550. http://dx.doi.org/10.1007/BF02244983
M1  - Sumiyoshi, T., Matsui, M., Yamashita, I., Nohara, S., Kurachi, M., Vehara, T., et al. (2001). The effect of tandospirone, a serotonin 1A agonist, on memory function in schizophrenia. Biol Psychiatry, 49, 861-868. http://dx.doi.org/10.1016/S0006-3223(00)01025-8
M1  - Tandon, R., & Greden, J. (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. Am J Psychiatry 46: 745-753
M2  - http://dx.doi.org/10.1177/026988110201600313
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2002-18504-013
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2002-18504-013 

21. 
TY  - ELEC
ID  - 2002-02666-001
T1  - A double-blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
A1  - Friedman, Joseph I
A1  - Adler, David N
A1  - Howanitz, Evelyn
A1  - Harvey, Philip D
A1  - Brenner, Grant
A1  - Temporini, Humberto
A1  - White, Leonard
A1  - Parrella, Michael
A1  - Davis, Kenneth L
A2  - Adler, Adler, Aigner, Aleman, Alkondon, Andreasen, Benwell, Blozovski, Bodick, Breese, Bridge, Callahan, Caroff, Chouinard, Cornblatt, Crook, Davis, Davis, Delis, Drachman, Edelstein, el-Mallack, Fenster, Frazier, Freedman, Freedman, Grant, Green, Haroutunian, Haroutunian, Harvey, Hughes, Karson, Kay, Kirrane, Klein, Leonard, Levey, Levin, Levin, Luntz-Leybman, Maelicke, Maelicke, Maelicke, McAlonan, Modestin, Muir, Nelson, Nielsen, Nochi, Powchik, Reitstetter, Riley, Risch, Robbins, Rogers, Rogers, Rogers, Rupniak, Saykin, Schrattenholz, Siever, Spreen, Sugimoto, Wanibuchi, Weiner, Zarei
Y1  - 2002//
N2  - Despite the beneficial effects of atypical antipsychotics on cognition, these improvements will not return most schizophrenic patients to normative standards of cognitive functioning. Therefore, other treatments need to be considered. Subtle changes in cholinergic function in schizophrenic patients provide the rationale to test the effectiveness of cholinesterase inhibitors in treating cognitive impairment in schizophrenia. Given this, a 12-week, double-blind, placebo-controlled trial of donepezil (5 mg and 10 mg) as adjunctive treatment to risperidone was conducted in a total of 36 schizophrenic patients. Neither the 5-mg nor 10-mg dose of donepezil produced significant improvements in any cognitive measure compared with placebo. It is possible that nicotinic receptor desensitization produced by chronic tobacco use in these patients rendered their nicotinic receptors refractory to the effects of increased agonist activity produced by donepezil. An alternative treatment is the allosterically potentiating ligands, which enhance the activity of (sensitize) nicotinic receptors in the presence of acetylcholine. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Ability
KW  - *Drug Therapy
KW  - *Risperidone
KW  - *Schizophrenia
M3  - Clinical Psychopharmacology [3340]
JF  - Biological Psychiatry
VL  - 51
IS  - 5
SP  - 349
EP  - 357
CY  - Netherlands
PB  - Elsevier Science
PB  - Netherlands
SN  - 0006-3223
AD  - Friedman, Joseph I.: Mount Sinai Hosp, Dept of Psychiatry, One Gustave L. Levy Place, Box 1230, New York, NY, US, 10029
M1  - Adler, L. E., Hoffer, L. D., Wiser, A., & Freedman, R. (1993): Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861.1994-25605-001
M1  - Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., et al. (1998): Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24: 189-202.1998-02576-001
M1  - Aigner, T., & Mishkin, M. (1986). The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol, 45, 81-87. http://dx.doi.org/10.1016/S0163-1047(86)80008-5
M1  - Aleman, A., Hijman, R., de Haan, E. H., & Kahn, R. S. (1999): Memory impairment in schizophrenia: A meta-analysis. Am J Psychiatry 156: 1358-1366.1999-11374-007
M1  - Alkondon, M., Maelicka, A., & Albuquerque, E. (1996): Diversity of nicotinic acetylcholine receptors in rat brain: Bungarotoxinsensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release. J Pharmacol Exp Ther 278: 1460-1471.
M1  - Andreasen, N. C., Flaum, M., & Arndt, S. (1992): The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49 (8): 615-623.1993-00065-001
M1  - Benwell, M. E., Balfour, D. J., & Birrell, C. E. (1995): Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol 114: 454-460.
M1  - Blozovski, D., Cudennec, A., & Garrigou, D. (1977). Deficits in passive avoidance learning following atropine in the developing rat. Psychopharmacology, 54, 139-144. http://dx.doi.org/10.1007/BF00426769
M1  - Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., et al. (1997): Effects of xanomaline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54: 465-473.
M1  - Breese, C. R., Lee, M. J., Adams, C. E., Sullivan, B., Logel, J., Gillen, K. M., et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 234, 351-364. http://dx.doi.org/10.1016/S0893-133X(00)00121-4
M1  - Bridge, T. P., Kleinman, J. E., Karoum, F., & Wyatt, R. J. (1985): Postmortem central catecholamines and ante mortem cognitive impairment in elderly schizophrenics and controls. Biol Psychiatry 14: 57-61.
M1  - Callahan, M., Kinsora, J., Harbaugh, R., Reeder, T., & Davis, R. (1993). Continuous icv infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging, 14, 147-151. http://dx.doi.org/10.1016/0197-4580(93)90090-X
M1  - Caroff, S. N., Campbell, E. C., Havey, J. C., Sullivan, K. A., Katz, I. R., & Mann, S. C. (2001): Treatment of tardive dyskinesia with donepezil. J Clin Psychiatry 62 (2): 128-129.2001-14679-014
M1  - Chouinard, G., & Ross-Chouinard, A. (1979): Extrapyramidal Symptom Rating Scale -Manual. Montreal: Canada.
M1  - Cornblatt, B. A., Lenzenweger, M. F., & Erlenmeyer-Kimling, L. (1989). The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res, 29, 65-85. http://dx.doi.org/10.1016/0165-1781(89)90188-1
M1  - Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation. Biol Psychiatry, 48, 381-388. http://dx.doi.org/10.1016/S0006-3223(00)00918-5
M1  - Davis, K. L., & Berger, P. A. (1978): Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 13 (1): 23-49.1979-11395-001
M1  - Davis, K. L., Kahn, R. S., Ko, G., & Davidson, M. (1991): Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148: 11: 1474-1486.1992-09301-001
M1  - Delis, D. C., Kramer, J. H., Kaplan, E., & Ober, B. A. (1987): California Verbal Learning Test-Manual. San Antonio: Psychological Corp.
M1  - Drachman, D. (1977): Memory and cognitive function in man. Does the cholinergic system have a specific role? Neurology 27: 783-790.1978-20583-001
M1  - Edelstein, P., Schultz, J. R., Hirschowitz, J., Kanter, D. R., & Garver, D. L. (1981): Am J Psychiatry 138: 1078-1081.1981-30918-001
M1  - el-Mallack, R., Kirch, D., Shelton, R., Fan, K., Pezeshkpour, G., Kanhouwa, S., et al. (1991): The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatry Clin Neurosci 3: 383-386.1992-12743-001
M1  - Fenster, C. P., Whitworth, T. L., Sheffield, E. B., Quick, M. W., & Lester, R. A. (1999): Upregulation of surgace alpha4beta2 nicotine receptors initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 19: 4804-4818.1999-05650-001
M1  - Frazier, C. J., Rollins, Y. D., Breese, C. R., Leonard, S., Freedman, R., & Dunwiddie, T. V. (1998): Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18: 1187-1195.
M1  - Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., et al. (1997): Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587-592.
M1  - Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry, 38, 22-33. http://dx.doi.org/10.1016/0006-3223(94)00252-X
M1  - Grant, D. A., & Berg, E. A. (1948). A behavioral analysis of degree of impairment and ease of shifting to new responses in a Weigl-type card sorting problem. J Exp Psychol Gen, 39, 404-411. http://dx.doi.org/10.1037/h0059831
M1  - Green, M. F., Marshall, B. D., Jr.., Wirshing, W. C., Ames, D., Marder, S. R., McGurk, S., et al. (1997): Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am J Psychiatry 154: 799-804.1997-04662-010
M1  - Haroutunian, V., Davidson, M., Kanof, P. D., Perl, D. P., Powchik, P., Losonczy, M., et al. (1994). Cortical cholinergic markers in schizophrenia. Schizophr Res, 122, 137-144. http://dx.doi.org/10.1016/0920-9964(94)90071-X
M1  - Haroutunian, V., Powchik, P., Purohit, D. P., Perl, D. P., & Davis, K. L. (in press): Cognitive deficits without a cholinergic cause. Choline acetyltransferase activity in the parietal cortex of 95 elderly schizophrenics. Neurosci Lett.
M1  - Harvey, P. D., & Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry, 158, 176-184. http://dx.doi.org/10.1176/appi.ajp.158.2.176
M1  - Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dahlgren, L. A. (1986): Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993-997.1987-01309-001
M1  - Karson, C. N., Mrak, R. E., Husain, M. M., & Griffin, W. S. (1996): Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 29 (2-3): 181-191.
M1  - Kay, S. R. (1991): Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel.
M1  - Kirrane, R. M., Mitropoulou, V., Nunn, M., Silverman, J., & Siever, L. J. (2001). Physostigmine and cognition in schizotypal personality disorder. Schizophr Res, 48, 1-5. http://dx.doi.org/10.1016/S0920-9964(00)00059-1
M1  - Klein, C., & Andersen, B. (1991): On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls. J Psychophysiol 5: 361-369.1992-23683-001
M1  - Leonard, S., Adams, C., Breese, C. R., Adler, L. E., Bickford, P., Byerley, W., et al. (1996): Nicotinic receptor function in schizophrenia. Schizophr Bull 22: 431-445.1996-06147-004
M1  - Levey, A. I., Edmunds, S. M., Koliatsos, V., Wiley, R. G., & Heilman, C. J. (1995): Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 15: 4077-4092.
M1  - Levin, E. D., Kim, P., & Meray, R. (1996). Chronic nicotine effects on working and reference memory in the 16-arm radial maze: Interactions with D1 agonist and antagonist drugs. Psychopharmacology, 127, 25-30. http://dx.doi.org/10.1007/BF02805971
M1  - Levin, E. D., & Rezvani, A. H. (2000): Development of nicotinic drug therapy for cognitive disorders. Eur J Phamacol 393: 141-146.
M1  - Luntz-Leybman, V., Bickford, P. C., & Freedman, R. (1992). Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res, 587, 130-136. http://dx.doi.org/10.1016/0006-8993(92)91437-J
M1  - Maelicke, A., & Albuquerque, E. X. (1996): New approach to drug therapy in Alzheimer's disease. Drug Discov Today 1: 53-59.
M1  - Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwid, J., Albuquerque, E. X., et al. (2001). Allosteric sensitization of nicotinic receptors by galantamine, and new treatment strategy for Alzheimer's disease. Biol Psychiatry, 49, 279-288. http://dx.doi.org/10.1016/S0006-3223(00)01109-4
M1  - Maelicke, A., Schrattenholz, A., Storch, A., Schroder, B., Gutrod, O., Methfessel, C., et al. (1995): Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. J Recept Signal Transduct Res 15 (1-4): 333-353.
M1  - McAlonan, G. M., Dawson, G. R., Wilkinson, L. O., Robbins, T. W., & Everitt, B. J. (1995). The effects of AMPA-induced lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on spatial delayed non-matching to sample and spatial learning in the water maze. Eur J Neurosci, 7, 1034-1049. http://dx.doi.org/10.1111/j.1460-9568.1995.tb01091.x
M1  - Modestin, J., Schwartz, R. B., & Hunger, J. (1973): Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl). Pharmakopsychiatr Neuropsychopharmakol 6 (6): 300-304.
M1  - Muir, J., Dunnett, S., Robbins, T., & Everitt, B. (1992): Attentional functions of the forebrain cholinergic systems: Effects of intraventricular hemicholinium, physostigmine, basal cortical lesions and intracortical grafts on a multiple choice serial reaction time task. Exp Brain Res 89: 611-622.
M1  - Nelson, M. D., Saykin, A. J., Flashman, L. A., & Riordan, J. H. (1998). Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study. Arch Gen Psychiatry, 55, 433-440. http://dx.doi.org/10.1001/archpsyc.55.5.433
M1  - Nielsen, J., Mena, A., Williams, I., Nocerini, M., & Liston, D. (1989): Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 173: 53-64.
M1  - Nochi, S., Asakawa, N., & Sato, T. (1995): Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm Bull 18: 1145-1147.
M1  - Powchik, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, D. P., Perl, D. P., et al. (1998): Postmortem studies in schizophrenia. Schizophr Bull 24 (3): 325-341.1998-10644-002
M1  - Reitstetter, R., Lukas, R. J., & Gruener, R. (1999): Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther 289: 656-660.
M1  - Riley, B. P., Makoff, A. M., Mogudi-Carter, M., Jenkins, T. J., Williamson, R., Collier, D. A., et al. (2000): High marker-density analyses of the alpha7-nicotine cholinergic receptor subunit (CHRNA7) gene region on chromosome 15q13-q14 and 5' RACE cloning of fragments specific to CHRNA7 or its partial duplication. Schizophr Res 41: 93.
M1  - Risch, S. C., McGurk, S., Horner, M. D., Nahas, Z., Owens, S. D., Molloy, M., et al. (2001). A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates. Neurocase, 72, 105-110. http://dx.doi.org/10.1093/neucas/7.2.105
M1  - Robbins, T., Everitt, B., Marston, H., Wilkinson, J., Jones, G., & Page, K. (1989). Comparative effects of ibotenic acid and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: Further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res, 35, 221-240. http://dx.doi.org/10.1016/S0166-4328(89)80143-3
M1  - Rogers, S. L., Doody, R. S., Mohs, R. C., & Friedhoff, L. T. (1998c): Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Donepezil study group. Arch Intern Med 158: 1021-1031.
M1  - Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil study group. Neurology, 50, 136-145. http://dx.doi.org/10.1159/000023160
M1  - Rogers, S. L., & Friedhoff, L. T. (1998a): Pharmacokinetic and pharmacodynamic profile of donepezil HCI following single oral doses. Br J Clin Pharmacol 46 (suppl 1): 1-6.
M1  - Rupniak, N., Spencer, T., & Field, M. (1997). Enhanced performance of spatial and visual memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology, 131, 406-410. http://dx.doi.org/10.1007/s002130050310
M1  - Saykin, A. J., Shtasel, D. L., Gur, R. E., Kester, D. B., Mozley, L. H., Stafiniak, P., et al. (1994): Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-131.1994-25655-001
M1  - Schrattenholz, A., Pereira, E. F., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996): Agonist responses of neuronal nicotinic are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49: 1-6.
M1  - Siever, L. J., Kalus, O. F., & Keefe, R. S. (1993): The boundaries of schizophrenia. Psychiatr Clin North Am 16 (2): 217-244.1994-01941-001
M1  - Spreen, O., & Strauss, E. (1998): A Compendium of Neuropsychological Tests and Norms. 2nd ed. New York: Oxford University Press.
M1  - Sugimoto, H., Iimura, Y., Yamanishi, Y., et al. (1992): Synthesis and Anti-Acetylcholinesterase Activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020) and Related Compounds. Bioorganic Med Chem Lett 2 (8): 871-876.
M1  - Wanibuchi, F., Nishida, T., Yamashita, H., Hikada, K., Koshiya, K., Tsukamoto, S., et al. (1994): Characterization of a novel muscarinic receptor agonist, YM796: Comparison with cholinesterase inhibitors in in-vivo pharmacological studies. Eur J Pharmacol 265: 151-158.
M1  - Weiner, M. F., Martin-Cook, K., Foster, B. M., Saine, K., Fontaine, C. S., & Svetlik, D. A. (2000): Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 61 (7): 487-492.2000-08995-004
M1  - Wisconsin Card Sorting Test: Computer Version 2. Psychological Resources Assessment Inc., Odessa, FL.
M1  - Zarei, M., Radcliffe, K. A., Chen, D., Patrick, J. W., & Dani, J. A. (1999): Distribution of nicotinic acetylcholine receptor alpha7 and beta2 submits on cultured hippocampal neurons. Neuroscience 88: 755-764.
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2002-02666-001
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2002-02666-001 

22. 
TY  - ELEC
ID  - 2002-01846-012
T1  - "A double-blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia":Erratum.
A1  - Friedman, Joseph I
A1  - Adler, David N
A1  - Evelyn, Howanitz
A1  - Harvey, Philip D
A1  - Brenner, Grant
A1  - Temporini, Humberto
A1  - White, Leonard
A1  - Parrella, Michael
A1  - Davis, Kenneth L
Y1  - 2002//
N2  - Reports an error in the original article by Friedman et al (Biological Psychiatry, 2002[Mar], Vol 51[5], 349-357). The published acknowledgment for the article is incorrect. The correct acknowledgment is provided. (The following abstract of this article originally appeared in record 2002-02666-001.): Despite the beneficial effects of atypical antipsychotics on cognition, these improvements will not return most schizophrenic patients to normative standards of cognitive functioning. Therefore, other treatments need to be considered. Subtle changes in cholinergic function in schizophrenic patients provide the rationale to test the effectiveness of cholinesterase inhibitors in treating cognitive impairment in schizophrenia. Given this, a 12-week, double-blind, placebo-controlled trial of donepezil (5 mg and 10 mg) as adjunctive treatment to risperidone was conducted in a total of 36 schizophrenic patients. Neither the 5-mg nor 10-mg dose of donepezil produced significant improvements in any cognitive measure compared with placebo. It is possible that nicotinic receptor desensitization produced by chronic tobacco use in these patients rendered their nicotinic receptors refractory to the effects of increased agonist activity produced by donepezil.... (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Ability
KW  - *Drug Therapy
KW  - *Risperidone
KW  - *Schizophrenia
M3  - Clinical Psychopharmacology [3340]
JF  - Biological Psychiatry
VL  - 51
IS  - 12
SP  - P
CY  - Netherlands
PB  - Elsevier Science
PB  - Netherlands
SN  - 0006-3223
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc4&NEWS=N&AN=2002-01846-012
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc4&AN=2002-01846-012 

23. 
TY  - ELEC
ID  - 2000-03467-015
T1  - New drugs and the NHS: Square pegs and a round hole.
T3  - The Psychiatric Bulletin, The Psychiatrist
A1  - Taylor, David
Y1  - 1998//
N2  - The most important constraint on the use of new drugs is the absence or inadequacy of National Health Service funding. This has perhaps been most clearly demonstrated by the National Schizophrenia Fellowship survey which showed that 55% of 719 psychiatrists felt that cost in some way inhibited their use of clozapine. This survey was completed in 1995, before the introduction of sertindole, olanzapine, quetiapine, amisulpride, reboxetine, mirtazapine, donepezil, and acamprosate. It seems likely that restrictions on prescribing and, indeed, frank rationing are now much more common and widespread.If we are to accept that at least some of the new drugs are an important step forward and that their use is currently inadequately funded, then it is clear that 'the system' has failed us and, sadly, failed those suffering from mental illness. (PsycINFO Database Record (c) 2014 APA, all rights reserved)
KW  - *Costs and Cost Analysis
KW  - *Drug Therapy
KW  - *Mental Disorders
KW  - *Mental Health Services
KW  - Psychopharmacology
M3  - Clinical Psychopharmacology [3340]
JF  - Psychiatric Bulletin
VL  - 22
IS  - 11
SP  - 709
EP  - 710
CY  - United Kingdom
PB  - Royal College of Psychiatrists
PB  - United Kingdom
SN  - 0955-6036
M2  - http://dx.doi.org/10.1192/pb.22.11.709
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=2000-03467-015
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc3&AN=2000-03467-015 

24. 
TY  - ELEC
ID  - 2001-14679-014
T1  - Treatment of tardive dyskinesia with donepezil.
T3  - Diseases of the Nervous System
A1  - Caroff, Stanley N
A1  - Campbell, E. Cabrina
A1  - Havey, Joan C
A1  - Sullivan, Kenneth A
A1  - Katz, Ira R
A1  - Mann, Stephan C
A2  - Egan, Guy, Ingram, Lieberman, Mayeux, Miller, Tracy
Y1  - 2001//
N2  - Examined the response to treatment with donepezil in 3 male patients (aged 66, 45, and 39 yrs) with schizoaffective disorder or schizophrenia who developed tardive dyskinesia (TD). Measurements were taken at 2-wk intervals after donepezil was initiated using the Abnormal Involuntary Movement Scale. Following 6 wks of treatment, the TD appeared to diminish by 22%, 74%, and 78% in the 3 Ss. Although changes in the 1st S were modest, compared with the others, this S also had a mood disorder, was older, and had more severe TD for a longer period of time. With donepezil, response may depend on the degree of cholinergic cell loss or damage, which may correlate with age of duration of symptoms. (PsycINFO Database Record (c) 2013 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Drug Therapy
KW  - *Tardive Dyskinesia
KW  - Schizoaffective Disorder
KW  - Schizophrenia
M3  - Schizophrenia & Psychotic States [3213]
JF  - Journal of Clinical Psychiatry
VL  - 62
IS  - 2
SP  - 128
EP  - 129
CY  - US
PB  - Physicians Postgraduate Press
PB  - US
SN  - 0160-6689
M1  - American Psychiatric Association Task Force on Tardive Dyskinesia. (1992). Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Press; 1992
M1  - Egan, M. F., Apud, J., & Wyatt, R. J. (1997). Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-6091997-43749-003
M1  - Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976: 534-537
M1  - Ingram, N. A., & Newgreen, D. B. (1983). The use of tacrine for tardive dyskinesia. Am J Psychiatry 1983; 140: 1629-1631
M1  - Lieberman, J., Pollack, S., Lesser, M., et al. (1988). Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol, 8, 254-260. http://dx.doi.org/10.1097/00004714-198808000-00004
M1  - Mayeux, R., & Sano, M. (1999). Treatment of Alzheimer's disease. New Engl J Med, 341, 1670-1679. http://dx.doi.org/10.1056/NEJM199911253412207
M1  - Miller, R., & Chouinard, G. (1993). Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry, 34, 713-738. http://dx.doi.org/10.1016/0006-3223(93)90044-E
M1  - Tracy, K., Adler, L. A., Rotrosen, J., et al. (1997). Interrater reliability issues in multicenter trials, pt 1: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 1997; 33: 53-571997-03978-007
M2  - http://dx.doi.org/10.4088/JCP.v62n0210e
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=2001-14679-014
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc3&AN=2001-14679-014 

25. 
TY  - ELEC
ID  - 2001-05581-003
T1  - Treatment of tardive dyskinesia with donepezil: A pilot study.
T3  - Diseases of the Nervous System
A1  - Caroff, Stanley N
A1  - Campbell, E. Cabrina
A1  - Havey, Joan
A1  - Sullivan, Kenneth A
A1  - Mann, Stephan C
A1  - Gallop, Robert
A2  - Barnes, Byrk, Caroff, Casey, Davis, Difiglia, Egan, Fann, Folstein, Gerlach, Goldsteir, Ingram, Jeste, Jeste, Klawans, Lieberman, Lieberman, Lindcboom, Littell, Mahadik, Mayeux, Miller, Moore, Nasrallah, Overall, Simpson, Tarsy, Tracy, Weiss
Y1  - 2001//
N1  - 52nd Institute on Psychiatric Services.. Oct, 2000. Philadelphia. PA, US. This research was presented at the aforementioned conference.
N2  - Tardive dyskinesia (TD) remains a significant clinical problem for which there is no uniformly effective treatment. Earlier trials with acetylcholine precursors have been disappointing due to underlying damage to striatal cholinergic neurons in patients with TD. In contrast, new cholinesterase inhibitors, developed for the treatment of dementia, may improve TD by directly increasing cholinergic synaptic transmission. An 8-wk trial of donepezil in the treatment of TD was conducted. 10 male Ss (aged 37-77 yrs) with schizophrenia or schizoaffective disorder who received stable doses of antipsychotics and met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for TD were treated with donepezil, 5-10 mg/day, for 6 wks after a 2-wk baseline period. Changes in total Abnormal Involuntary Movement Scale (AIMS) scores measured every 2 wks were assessed. Ss were also assessed using the Brief Psychiatric Rating Scale, the Mini-Mental State Examination, the Barnes Akathisia Scale, and the Simpson-Angus Scale. Total AIMS scores decreased significantly, with no changes in other measures. Nine Ss showed a positive response. Improvement was greatest in orofacial and upper extremity movements. No significant interactions were noted between the total AIMS scores and age, duration of TD, or duration of antipsychotic treatment. (PsycINFO Database Record (c) 2013 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Drug Therapy
KW  - *Tardive Dyskinesia
M3  - Clinical Psychopharmacology [3340]
JF  - Journal of Clinical Psychiatry
VL  - 62
IS  - 10
SP  - 772
EP  - 775
CY  - US
PB  - Physicians Postgraduate Press
PB  - US
SN  - 0160-6689
AD  - Caroff, Stanley N.: Behavioral Health Service, 7 East-116A, VA Medical Center, University Ave., Philadelphia, PA, US, 19104
M1  - American Psychiatric Association Task Force on Tardive Dyskinesia. (1992). Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Press: 1992
M1  - Barnes, T. R. (1989). A rating scale for drug-induced akathisia. Br J Psychiatry, 154, 672-676. http://dx.doi.org/10.1192/bjp.154.5.672
M1  - Byrk, A., & Raudenbush, S. (1996). Hierarchical Linear Modeling: Applications and Data Analysis Methods. Newbury Park, Calif: Sage Publishing; 1996
M1  - Caroff, S. N., Campbell, E. C., Havey, J., et al. (2001). Treatment of tardive dyskinesia with donepezil [letter]. J Clin Psychiatry 2001; 62: 128-1292001-14679-014
M1  - Casey, D. E., & Denney, D. (1977). Pharmacological characterization of tardive dyskinesia. Psychopharmacology (Berl), 54, 1-8. http://dx.doi.org/10.1007/BF00426532
M1  - Davis, K. L., Hollister, L. E., Barchas, J. D., et al. (1976). Choline in tardive dyskinesia and Huntington's disease. Life Sci, 19, 1507-1516. http://dx.doi.org/10.1016/0024-3205(76)90095-3
M1  - Difiglia, M. (1987). Synaptic organization of cholinergic neurons in the monkey neostriatum. J Comp Neurology 1987; 255: 245-258
M1  - Egan, M. F., Apud, J., & Wyatt, R. J. (1997). Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-6091997-43749-003
M1  - Fann, W. E., Lake, C. R., Gerber, C. J., et al. (1974). Cholinergic suppression of tardive dyskinesia. Psychopharmacologia 1974; 37: 101-1071975-03646-001
M1  - Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res, 12, 189-198. http://dx.doi.org/10.1016/0022-3956(75)90026-6
M1  - Gerlach, J., Reisby, N., & Randrup, A. (1974). Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia, 34, 21-35. http://dx.doi.org/10.1007/BF00421217
M1  - Goldsteir, H. (1987). Models in Educational and Social Research. New York, NY: Oxford University Press; 1987
M1  - Ingram, N. A., & Newgreen, D. B. (1983). The use of tacrine for tardive dyskinesia. Am J Psychiatry 1983; 140: 1629-1631
M1  - Jeste, D. V., Lohr, J. B., & Clark, K. (1988). Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988; 8: 38S-48S
M1  - Jeste, D. V., Lohr, J. B., & Manley, M. (1992). Study of neuropathologic changes in the striatum following 4, 8, and 12 months of treatment with fluphenazine in rats. Psychopharmacology (Berl), 106, 154-160. http://dx.doi.org/10.1007/BF02801966
M1  - Klawans, H. L., & Rubovits, R. (1974). Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry, 37, 941-947. http://dx.doi.org/10.1136/jnnp.37.8.941
M1  - Lieberman, J., Lesser, M., Johns, C., et al. (1988). Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 1988; 8: 57S-63S
M1  - Lieberman, J., Pollack, S., Lesser, M., et al. (1988). Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol, 8, 254-260. http://dx.doi.org/10.1097/00004714-198808000-00004
M1  - Lindcboom, S. F., & Lakke, J. P. (1978). Deanol and physostigmine in the treatment of L-dopa--induced dyskinesias. Acta Neurol Scand 1978; 58: 134-138
M1  - Littell, R. C., Milliken, G. A., Stroup, W. W., et al. (1996). SAS System for Mixed Models. Cary, NC: SAS Institute Inc; 1996
M1  - Mahadik, S. P., & Mukherjee, S. (1995). Monosialoganglioside cotreatment prevents haloperidol treatment-associated loss of cholinergic enzymes in rat brain. Biol Psychiatry, 38, 246-254. http://dx.doi.org/10.1016/0006-3223(94)00304-L
M1  - Mayeux, R., & Sano, M. (1999). Treatment of Alzheimer's disease. N Engl J Med, 341, 1670-1679. http://dx.doi.org/10.1056/NEJM199911253412207
M1  - Miller, R., & Chouinard, G. (1993). Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry, 34, 713-738. http://dx.doi.org/10.1016/0006-3223(93)90044-E
M1  - Moore, D. C., & Bowers, M. B., Jr. (1980). Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes. Am J Psychiatry 1980; 137: 1202-12051980-32806-001
M1  - Nasrallah, H. A., Pappas, N. J., & Crowe, R. R. (1980). Oculogyric dystonia in tardive dyskinesia. Am J Psychiatry 1980; 137: 850-851
M1  - Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-8121963-05043-001
M1  - Pharmacology Research Branch. (1976). National Institute of Mental Health, Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised, US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976; 534-537
M1  - Simpson, G. M., & Angus, J. W. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 45 (suppl 212): 11-19
M1  - Tarsy, D., Leopold, N., & Sax, D. S. (1974). Physostigmine in choreiform movement disorders. Neurology 1974; 24: 28-331974-21483-001
M1  - Tracy, K., Adler, L. A., Rotrosen, J., et al. (1997). Interrater reliability issues in multicenter trials, pt 1: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 1997; 33: 53-571997-03978-007
M1  - Weiss, K. J., Ciraulo, D. A., & Shader, R. I. (1980). Physostigmine test in the rabbit syndrome and tardive dyskinesia. Am J Psychiatry 1980; 137: 627-628
M2  - http://dx.doi.org/10.4088/JCP.v62n1004
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=2001-05581-003
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc3&AN=2001-05581-003 

26. 
TY  - ELEC
ID  - 2002-15544-009
T1  - Pharmacotherapy of cognitive impairment in schizophrenia: Variant approaches.
A1  - Waddington, John L
A2  - Friedman, Green, Harvey, MacEwan, Waddington
Y1  - 2001//
N2  - Comments on the G. W. MacEwan study et al (see record 2002-15544-008) which examined the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable 36-yr-old male outpatient with paranoid-type schizophrenia. The author notes that while the limitations of the MacEwan et al case study are readily apparent, their findings from an ABAB design present a challenge to surpass those limitations. However, it is argued that although the MacEwan et al results are provocative, any relevant enthusiasm must be tempered by uncertainties as to not only the reproducibility, specificity and generality of any such effect to similar patients, but also the extent to which the cognitive deficits of older, more chronically ill patients, or of younger, first-episode patients, might be less, more or not malleable under similar conditions. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Acetylcholinesterase
KW  - *Cholinergic Drugs
KW  - *Drug Therapy
KW  - *Paranoid Schizophrenia
KW  - *Risperidone
KW  - Cognitive Ability
KW  - Psychiatric Symptoms
KW  - Side Effects (Drug)
M3  - Clinical Psychopharmacology [3340]
JF  - Acta Psychiatrica Scandinavica
VL  - 104
IS  - 6
SP  - 471
EP  - 472
CY  - United Kingdom
PB  - Blackwell Publishing
PB  - United Kingdom
SN  - 0001-690X
M1  - Friedman, J. I., Alder, D. N., Howanitz, E., Temporini, H., Harvey, P. D., & Davis, K. L. (2001). Effects of donepezil on cognition, symptoms and movement disorders in patients with chronic schizophrenia. Schizophr Res 2001; 49: 228.
M1  - Green, M. F., & Braff, D. L. (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry, 49, 374-384. http://dx.doi.org/10.1016/S0006-3223(00)01027-1
M1  - Harvey, P. D., & Keefe, R. S. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry, 158, 176-184. http://dx.doi.org/10.1176/appi.ajp.158.2.176
M1  - MacEwan, G. W., Ehmann, T. S., Khanbhai, I., & Wrixon, C. (2001). Donepezil in schizophrenia -- is it helpful? An experimental design case study. Acta Psychiatr Scand 2001; 104: 00-00.2002-15544-008
M1  - Waddington, J. L., & Morgan, M. G. (2001). Pathobiology of schizophrenia: implications for clinical management and treatment. In: Lieberman JA, Murray RM, eds. Comprehensive care of schizophrenia. London: Martin Dunitz, 2001: 27-35.
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=2002-15544-009
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc3&AN=2002-15544-009 

27. 
TY  - ELEC
ID  - 2002-15544-008
T1  - Donepezil in schizophrenia--is it helpful? An experimental design case study.
A1  - MacEwan, G. W
A1  - Ehmann, T. S
A1  - Khanbhai, I
A1  - Wrixon, C
A2  - Burt, Davis, Friedman, Furey, Green, Janowsky, Kertzman, Meltzer, Sarter, Sarter, Tandon, Telford
Y1  - 2001//
N2  - Examined the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable 36-yr-old male outpatient with paranoid-type schizophrenia. Assessments were completed objectively by standardized neuropsychological tests and clinical rating scales and subjectively with visual analogue scales. Strong improvements attributable to donepezil were found for verbal fluency and the patient's subjective response. No adverse changes were noted in psychiatric symptoms or side effects. It is concluded that cholinergic enhancement as an adjunctive treatment in schizophrenia should be explored in larger controlled trials. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Acetylcholinesterase
KW  - *Cholinergic Drugs
KW  - *Drug Therapy
KW  - *Paranoid Schizophrenia
KW  - *Risperidone
KW  - Cognitive Ability
KW  - Psychiatric Symptoms
KW  - Side Effects (Drug)
M3  - Clinical Psychopharmacology [3340]
JF  - Acta Psychiatrica Scandinavica
VL  - 104
IS  - 6
SP  - 469
EP  - 471
CY  - United Kingdom
PB  - Blackwell Publishing
PB  - United Kingdom
SN  - 0001-690X
M1  - Burt, T., Sachs, G. S., & Demopulos, C. (1999). Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry, 45, 959-964. http://dx.doi.org/10.1016/S0006-3223(98)00320-5
M1  - Davis, K., Hollister, L., Overall, J., Johnson, A., & Train, K. (1976). Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology, 51, 23-27. http://dx.doi.org/10.1007/BF00426316
M1  - Friedman, J., Temporini, H., & Davies, K. (1999). Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry, 45, 1-16. http://dx.doi.org/10.1016/S0006-3223(98)00287-X
M1  - Furey, M., Pietrini, P., Haxby, J., Alexander, G., Lee, H., & Meter, J. V. (1997). Cholinergic stimulation alters performance and task specific regional cerebral blood flow during working memory. Proc Natl Acad Sci USA 1997; 94: 6512-6516.
M1  - Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring 'the right stuff'? Schizophr Bull 2000; 26: 119-136.2000-08139-007
M1  - Janowsky, D. S., El-Yousef, M. K., Davis, J. M., & Sekerke, H. J. (1973). Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 1973; 130: 1370-1376.1974-11629-001
M1  - Kertzman, C., Robinson, D., & Litvan, I. (1990). Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990; 47: 1346-1350.1991-16271-001
M1  - Meltzer, H., & McGurk, S. (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-255.1999-05588-005
M1  - Sarter, M., & Bruno, J. (1997). Cognitive functions of acetylcholine: toward a unifying hypothesis. Brain Res Rev, 23, 28-46. http://dx.doi.org/10.1016/S0165-0173(96)00009-4
M1  - Sarter, M., & Bruno, J. P. (1998). Cortical acetylcholine, reality distortion, schizophrenia and lewy body dementia: too much or too little cortical acetylcholine?. Brain Cogn, 38, 297-316. http://dx.doi.org/10.1006/brcg.1998.1035
M1  - Tandon, R., Greden, J., & Haskett, R. (1993). Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls. Schizophr Res, 9, 19-23. http://dx.doi.org/10.1016/0920-9964(93)90004-3
M1  - Telford, R., & Worrall, E. (1978). Cognitive function in manic depressives: effects of lithium and physostigmine. Br J Psychiatry, 133, 424-428. http://dx.doi.org/10.1192/bjp.133.5.424
M2  - http://dx.doi.org/10.1046/j.0001-690X.2001.acp1c008d.x
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=2002-15544-008
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc3&AN=2002-15544-008 

28. 
TY  - ELEC
ID  - 2001-17379-002
T1  - A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates.
T2  - Special Issue: Frontotemporal dementia: Part II.
A1  - Risch, S. Craig
A1  - McGurk, Susan
A1  - Horner, Michael D
A1  - Nahas, Ziad
A1  - Owens, Susan D
A1  - Molloy, Monica
A1  - Gilliard, Cynthia
A1  - Christie, Scott
A1  - Markowitz, John S
A1  - DeVane, C. Lindsay
A1  - Mintzer, Jacobo
A1  - George, Mark S
A2  - Benton, Cassens, Cleghorn, Cummings, Davidson, Friston, Frith, Fujii, Gold, Gold, Goldberg, Goldman, Green, Green, Green, Hagger, Heaton, Hoff, Hoff, Keefe, Kern, Lysaker, McGurk, Meltzer, Palmer, Park, Paulsen, Powchick, Saykin, Schlosser, Stone, Zahn
Y1  - 2001//
N2  - Cognitive impairment in multiple domains is common in patients with schizophrenia and may be a powerful determinant of poor functional ability and quality of life. A double-blind, placebo-controlled, cross-over study of donepezil augmentation in a 38 yr old schizoaffective disorder patient stabilized on olanzapine pharmacotherapy is reported. The patient showed significant improvements in several cognitive measures and increased activation of prefrontal cortex and basal ganglia on functional MRI during the donepezil augmentation. In addition, the donepezil augmentation resulted in a reduction of depressive symptoms and in significant improvements in functional abilities and quality of life. Further studies of donepezil augmentation of neuroleptics in schizophrenia are warranted. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
KW  - *Cholinesterase Inhibitors
KW  - *Cognitive Ability
KW  - *Drug Interactions
KW  - *Neuroleptic Drugs
KW  - *Schizoaffective Disorder
KW  - Drug Therapy
M3  - Clinical Psychopharmacology [3340]
JF  - Neurocase
VL  - 7
IS  - 2,Pt2
SP  - 105
EP  - 110
CY  - United Kingdom
PB  - Taylor & Francis
PB  - United Kingdom
SN  - 1355-4794
M1  - Benton, A. L., Hamsher, K., & Sivan, A. B. (1994). Multilingual aphasia examination. 3rd ed. Iowa City, IA: AJA Associates, 1994.
M1  - Cassens, G., Inglis, A. K., Appelbaum, P. S., & Gutheil, T. G. (1990). Neuroleptics: effects of neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin 1990; 16: 477-99.2005-09758-014
M1  - Cleghorn, J. M., Kaplan, R. D., Szechtman, B., Szechtman, H., & Brown, G. M. (1990). Neuroleptic drug effects on cognitive function in schizophrenia. Schizophrenia Research, 3, 211-9. http://dx.doi.org/10.1016/0920-9964(90)90038-9
M1  - Cummings, J. L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry 2000; 157: 4-15.2000-13126-001
M1  - Davidson, M., Harvey, P., Welsh, K. A., Powchik, P., Putnam, K. M., & Mohs, R. C. (1996). Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenics patients and patients with Alzheimer's disease. American Journal of Psychiatry 1996; 153: 1274-9.1996-00484-004
M1  - Friston, K. J., Frith, C. D., & Liddle, P. F. (1991). Investigating a network model of word generation with positron emission tomography. Proceedings of the Royal Society of London Series B: Biological Science 1991; 244: 101-6.
M1  - Frith, C. D., Friston, K. J., Liddle, P. F., & Frackowiak, R. S. (1991). A PET study of word finding. Neuropsychologia, 29, 1137-48. http://dx.doi.org/10.1016/0028-3932(91)90029-8
M1  - Fujii, D. E., Ahmed, I., Jokumsen, M., & Comptom, J. M. (1997). The effects of clozapine on cognitive function in treatment-resistant schizophrenic patients. Journal of Neuropsychiatry and Clinical Neuroscience 1997; 9: 240-5.1997-04045-006
M1  - Gold, J. M., Carpenter, C., Randolph, C., Goldberg, T. E., & Weinberger, D. R. (1997). Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Archives of General Psychiatry 1997; 54: 159-65.1997-06506-005
M1  - Gold, J. M., & Harvey, P. D. (1995). Cognitive deficits in schizophrenia. Psychiatric Clinics of North America 1995; 16: 295-312.1994-01911-001
M1  - Goldberg, T. E., Weinberger, D. R., Berman, K. E., Piskin, N. H., & Podd, M. H. (1987). Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Archives of General Psychiatry 1987; 44: 1008-14.1988-10810-001
M1  - Goldman, R. S., Axelrod, B. N., Tandon, R., Ribeiro, S. C., Craig, K., & Berent, S. (1993). Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993; 26: 122-6.1994-22604-001
M1  - Green, M. F., Marshall, B. D., Jr.., Wirshing, W. C., Ames, D., Marder, S. R., McGurk, S., et al. (1997). Does risperidone improve verbal working memory in treatment resistant schizophrenia? American Journal of Psychiatry 1997; 154: 799-804.1997-04662-010
M1  - Green, M. F. (1998). Schizophrenia from a neurocognitive perspective. Boston, MA, USA: Allyn and Bacon 1998: 1-190.
M1  - Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 1996; 153: 321-30.1996-00417-002
M1  - Hagger, C., Buckley, P., Kenny, J. T., Friedman, I., Ubogy, D., & Meltzer, H. Y. (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702-12. http://dx.doi.org/10.1016/0006-3223(93)90043-D
M1  - Heaton, R., Paulsen, J. S., McAdams, L. A., Kuck, J., Zisook, S., Braff, D., et al. (1994). Neuropsychological deficits in schizophrenics: relationship to age, chronicity and dementia. Archives of General Psychiatry 1994; 51: 469-76.1994-41323-001
M1  - Hoff, A. L., Faustman, W. O., Wieneke, M., Espinoza, S., Costa, M., Wolkowitz, O., et al. (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic patients. Neuropsychopharmacology, 15, 361-9. http://dx.doi.org/10.1016/0893-133X(95)00242-6
M1  - Hoff, A. L., Riordan, H., O'Donnell, D. W., Morris, L., & DeLisi, C. E. (1992). Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry 1992; 149: 898-903.1992-43257-001
M1  - Keefe, R. S., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999). The effects of atypical antipsychotics on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 1999; 25: 201-22.1999-05588-003
M1  - Kern, R. S., Green, M. F., Marshall, B. D., Jr.., Wirshing, W. C., Wirshing, D., McGurk, S., et al. (1998). Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenic patients. Biological Psychiatry, 44, 726-32. http://dx.doi.org/10.1016/S0006-3223(98)00088-2
M1  - Lysaker, P., Bell, M., & Beam-Goulet, J. (1995). Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatric Research, 56, 45-51. http://dx.doi.org/10.1016/0165-1781(94)02641-U
M1  - McGurk, S. R., Green, M. F., Wirshing, W. C., Ames, D., Marshall, B. D., Marder, S. R., et al. (1997). The effects of risperidone vs. haloperidol on cognitive functioning in treatment resistant schizophrenia: The Trail Making Test. CNS Spectrums 1997; 2: 60-4.
M1  - Meltzer, H. Y., & McGurk, S. (1999). The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999; 25: 223-55.1999-05588-005
M1  - Palmer, B. W., Heaton, R. K., & Paulsen, I. S. (1997). Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology, 11, 437-46. http://dx.doi.org/10.1037/0894-4105.11.3.437
M1  - Park, S., & Holzman, P. S. (1992). Schizophrenics show spatial working memory deficits. Archives of General Psychiatry 1992; 49: 975-82.1993-17718-001
M1  - Paulsen, J. S., Heaton, R. K., Sadek, J. R., Perry, W., Delis, D. D., Braff, D., et al. (1995). The nature of learning and memory impairments in schizophrenia. Journal of the International Neuropsychological Society, 1, 88-99. http://dx.doi.org/10.1017/S135561770000014X
M1  - Powchick, P., Davidson, M., Haroutunian, V., Gabriel, S. M., Purohit, P., Perl, D. P., et al. (1998). Postmortem studies in schizophrenia. Schizophrenia Bulletin 1998; 24: 325-41.1998-10644-002
M1  - Saykin, A., Shtasel, D. I., Gur, R. E., Kester, D. B., Moxley, L. H., Stafaniak, P., et al. (1994). Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 1994; 51: 124-31.1994-25655-001
M1  - Schlosser, R., Hutchinson, M., Joseffer, S., Rusinek, H., Saarimaki, A., Stevenson, J., et al. (1998). Functional magnetic resonance imaging of human brain activity in a verbal fluency task. Journal of Neurology, Neurosurgery and Psychiatry, 64, 492-8. http://dx.doi.org/10.1136/jnnp.64.4.492
M1  - Stone, M., Gabrieli, J. D., Stebbins, G. T., & Sullivan, E. V. (1998). Working and strategic memory deficits in schizophrenia. Neuropsychology, 12, 278-88. http://dx.doi.org/10.1037/0894-4105.12.2.278
M1  - Zahn, T. P., Pickar, D., & Haier, R. J. (1994). Effects of clozapine, fluphenazine and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 15, 133-44. http://dx.doi.org/10.1016/0920-9964(94)90094-9
M2  - http://dx.doi.org/10.1093/neucas/7.2.105
L2  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=2001-17379-002
ER  -  

Link to the Ovid Full Text or citation: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=psyc3&AN=2001-17379-002 


